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Abstract
The INTRABEAM® Photon Radiotherapy System for the
adjuvant treatment of early breast cancer: a systematic
review and economic evaluation
Jo Picot,* Vicky Copley, Jill L Colquitt, Neelam Kalita, Debbie Hartwell
and Jackie Bryant
Southampton Health Technology Assessments Centre (SHTAC), University of Southampton,
Southampton, UK
*Corresponding author j.picot@soton.ac.uk
Background: Initial treatment for early breast cancer is usually either breast-conserving surgery (BCS) or
mastectomy. After BCS, whole-breast external beam radiotherapy (WB-EBRT) is the standard of care.
A potential alternative to post-operative WB-EBRT is intraoperative radiation therapy delivered by the
INTRABEAM® Photon Radiotherapy System (Carl Zeiss, Oberkochen, Germany) to the tissue adjacent to the
resection cavity at the time of surgery.
Objective: To assess the clinical effectiveness and cost-effectiveness of INTRABEAM for the adjuvant
treatment of early breast cancer during surgical removal of the tumour.
Data sources: Electronic bibliographic databases, including MEDLINE, EMBASE and The Cochrane Library,
were searched from inception to March 2014 for English-language articles. Bibliographies of articles,
systematic reviews, clinical guidelines and the manufacturer’s submission were also searched. The advisory
group was contacted to identify additional evidence.
Methods: Systematic reviews of clinical effectiveness, health-related quality of life and cost-effectiveness
were conducted. Two reviewers independently screened titles and abstracts for eligibility. Inclusion criteria
were applied to full texts of retrieved papers by one reviewer and checked by a second reviewer. Data
extraction and quality assessment were undertaken by one reviewer and checked by a second reviewer,
and differences in opinion were resolved through discussion at each stage. Clinical effectiveness studies
were included if they were carried out in patients with early operable breast cancer. The intervention was
the INTRABEAM system, which was compared with WB-EBRT, and study designs were randomised
controlled trials (RCTs). Controlled clinical trials could be considered if data from available RCTs were
incomplete (e.g. absence of data on outcomes of interest). A cost–utility decision-analytic model was
developed to estimate the costs, benefits and cost-effectiveness of INTRABEAM compared with WB-EBRT
for early operable breast cancer.
Results: One non-inferiority RCT, TARGeted Intraoperative radioTherapy Alone (TARGIT-A), met the
inclusion criteria for the review. The review found that local recurrence was slightly higher following
INTRABEAM than WB-EBRT, but the difference did not exceed the 2.5% non-inferiority margin providing
INTRABEAM was given at the same time as BCS. Overall survival was similar with both treatments.
Statistically significant differences in complications were found for the occurrence of wound seroma
requiring more than three aspirations (more frequent in the INTRABEAM group) and for a Radiation
Therapy Oncology Group toxicity score of grade 3 or 4 (less frequent in the INTRABEAM group).
Cost-effectiveness base-case analysis indicates that INTRABEAM is less expensive but also less effective
than WB-EBRT because it is associated with lower total costs but fewer total quality-adjusted life-years
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gained. However, sensitivity analyses identified four model parameters that can cause a switch in the
treatment option that is considered cost-effective.
Limitations: The base-case result from the model is subject to uncertainty because the disease progression
parameters are largely drawn from the single available RCT. The RCT median follow-up of 2 years
5 months may be inadequate, particularly as the number of participants with local recurrence is low.
The model is particularly sensitive to this parameter.
Conclusions and implications: A significant investment in INTRABEAM equipment and staff training
(clinical and non-clinical) would be required to make this technology available across the NHS. Longer-term
follow-up data from the TARGIT-A trial and analysis of registry data are required as results are currently
based on a small number of events and economic modelling results are uncertain.
Study registration: This study is registered as PROSPERO CRD42013006720.
Funding: The National Institute for Health Research Health Technology Assessment programme. Note that
the economic model associated with this document is protected by intellectual property rights, which are
owned by the University of Southampton. Anyone wishing to modify, adapt, translate, reverse engineer,
decompile, dismantle or create derivative work based on the economic model must first seek the
agreement of the property owners.
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Plain English summary
B reast cancer is the most common cancer in women in England. In early-stage breast cancer, thetumour has not spread beyond the breast or armpit lymph glands on the same side as the affected
breast. Initial treatment may be breast-conserving surgery (BCS) (removal of the tumour but keeping an
intact breast) or mastectomy (total removal of the breast). After BCS, a 3-week course of whole-breast
external beam radiotherapy (WB-EBRT) reduces the risk of breast cancer returning in the affected breast
(local recurrence). A new radiotherapy approach is single-treatment radiotherapy delivered using the
INTRABEAM® Photon Radiotherapy System (Carl Zeiss, Oberkochen, Germany). We used standard
systematic methods to identify all the current evidence comparing WB-EBRT with INTRABEAM and one
study, the TARGeted Intraoperative radioTherapy-A trial, was included. Local recurrence was slightly higher
following INTRABEAM than after WB-EBRT providing that INTRABEAM was given at the same time as BCS,
but the likelihood of dying from breast cancer was similar with both treatments. INTRABEAM patients
more frequently experienced fluid pockets that were drained more than three times, but radiation therapy
toxicity was less frequent than with WB-EBRT. In our economic model, INTRABEAM was less expensive
but also less effective than WB-EBRT. The results from the model changed, showing INTRABEAM to be
cost-effective compared with WB-EBRT, when different estimates for treatment effects (e.g. local recurrence,
probability of death from breast cancer) were tested. The longer-term effects of INTRABEAM are not known
and further research on this is needed.
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Scientific summary
Background
Breast cancer is the most common cancer in women in England, with 41,523 new diagnoses in 2011.
Earlier detection and improved treatment for breast cancer in women have led to a rise in survival, with
3-year net survival in early breast cancer now 99.3% for patients with tumour node metastasis (TNM)
stage I disease and 92.4% for patients with TNM stage 2 disease.
The focus of this assessment is the treatment of early breast cancer. Definitions vary, but for the purposes
of this assessment early breast cancer includes early invasive cancer for which the tumour has not spread
beyond the breast or the lymph nodes (which remain mobile) in the armpit on the same side as the
affected breast. The first treatment option for early breast cancer is usually surgery, which may be wide
local excision (WLE) of the tumour [breast-conserving surgery (BCS)] instead of mastectomy. Post-operative
whole-breast external beam radiotherapy (WB-EBRT) is the standard of care for all patients with early
invasive breast cancer after BCS, because it substantially reduces the risk of recurrence and moderately
reduces the risk of breast cancer death.
A potential alternative to post-operative WB-EBRT is treatment with the INTRABEAM® Photon Radiotherapy
System (Carl Zeiss, Oberkochen, Germany). The INTRABEAM device can be used to deliver intraoperative
radiation therapy to the tissue adjacent to the resection cavity in an ordinary operating theatre at the time
of surgery.
Objectives
To assess the clinical effectiveness and cost-effectiveness of INTRABEAM for the adjuvant treatment of
early breast cancer during surgical removal of the tumour.
Methods
Data sources
Electronic resources including MEDLINE, EMBASE, The Cochrane Library and Web of Science were
searched for published studies and ongoing research from inception to March 2014 for English-language
articles. Bibliographies of included articles, systematic reviews, clinical guidelines and the manufacturer’s
submission to National Institute for Health and Care Excellence were also searched for additional studies.
An advisory group was contacted to identify additional published and unpublished evidence.
Study selection
Titles and abstracts were screened for eligibility by two reviewers independently. Inclusion criteria were
applied to full texts by one reviewer and checked by a second reviewer. Inclusion criteria were as follows:
l Intervention – INTRABEAM device with or without post-operative WB-EBRT.
l Comparator – WB-EBRT delivered by linear accelerator.
l Population – people with early operable breast cancer; people with a local recurrence were excluded.
For the systematic review of health-related quality of life (HRQoL), the population was not limited to
early-stage breast cancer.
l Outcomes – overall survival, disease-free survival, ipsilateral local recurrence, adverse effects of
treatment, HRQoL, cost-effectiveness [expressed in units such as life-years gained or quality-adjusted
life-years (QALYs) gained or in monetary units].
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l Study design – randomised controlled trials (RCTs) [good-quality controlled clinical trials could be
considered if the data from RCTs were incomplete (e.g. absence of data on outcomes of interest)] for
the review of clinical effectiveness; full cost-effectiveness analyses, cost–utility analyses and cost–benefit
analyses for the systematic review of cost-effectiveness; primary research studies based in the UK,
Europe, North America and Australasia for the systematic review of quality of life (QoL).
Abstracts or conference presentations were eligible for inclusion only if sufficient details were presented.
Data extraction and quality assessment
Data extraction and quality assessment were undertaken by one reviewer and checked by a second
reviewer. Differences in opinion were resolved by discussion at each stage.
Data synthesis
Data were synthesised through narrative reviews with full tabulation of the results of included studies.
Economic model
A cost–utility decision-analytic model was developed to estimate the costs, benefits and cost-effectiveness
of INTRABEAM compared with WB-EBRT for early operable breast cancer. The intervention effects and
characteristics of the modelled patient population were obtained from RCT data identified by the clinical
effectiveness systematic review. The perspective of the analysis was that of the NHS and Personal Social
Services in the UK. A lifetime (40-year) horizon was used to estimate costs and benefits from each
treatment. Future costs and benefits were discounted at 3.5% per annum and the outcomes were
reported as the cost saved per QALY lost.
Results
Systematic review of clinical effectiveness
From 655 records screened, 44 references were retrieved for consideration. One non-inferiority RCT,
the TARGeted Intraoperative radioTherapy Alone (TARGIT-A) trial, which evaluated whether or not
INTRABEAM treatment was no worse than WB-EBRT, met the inclusion criteria. The trial was judged to be
at a low risk of bias. Results were reported for the whole trial population (n= 3451) and separately for the
pre-pathology stratum (n= 2298 randomisation to INTRABEAM or WB-EBRT prior to WLE of the primary
tumour) and the post-pathology stratum (n= 1153 randomisation after initial surgery to either INTRABEAM
as a second procedure or WB-EBRT). Median follow-up was 2 years 5 months, with 35% of participants
achieving median follow-up of 5 years.
Local recurrence
Local recurrence in the conserved breast (primary outcome) for the whole trial population was higher in
the INTRABEAM group than in the WB-EBRT group (3.3% vs. 1.3%); however, the absolute difference in
5-year risk of local recurrence did not exceed the 2.5% non-inferiority margin. A similar result was
observed for the pre-pathology stratum. In the post-pathology stratum, the non-inferiority margin was
exceeded and non-inferiority was not established.
Overall survival
Overall survival (secondary outcome) for the whole trial population did not differ statistically significantly
between INTRABEAM and WB-EBRT arms (3.9% vs. 5.3%; p= 0.099). Rates of breast cancer deaths were
similar but there were significantly fewer non-breast cancer deaths in the INTRABEAM group than in the
WB-EBRT group. In the pre-pathology stratum, lower overall mortality was observed in the INTRABEAM group
because there were significantly fewer non-breast cancer deaths. In the post-pathology stratum, overall
mortality, breast cancer mortality and non-breast cancer mortality were similar between treatment groups.
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Complications
Wound seroma requiring more than three aspirations occurred more frequently in the INTRABEAM group
(2.1% vs. 0.8%; p= 0.012), whereas a Radiation Therapy Oncology Group toxicity score of grade 3 or 4
was less frequent in the INTRABEAM group (0.5% vs. 2.1%; p= 0.002). These were the only statistically
significant differences in complications.
Health-related quality-of-life substudy
One small single-centre substudy (n= 88) did not identify any statistically significant differences in QoL
measures between the study arms.
Systematic review of cost-effectiveness
From 184 citations screened, 10 references were retrieved for consideration. Three publications were
included, two on the same economic model. Outcomes from both models suggested that INTRABEAM was
a cost-effective option when compared with WB-EBRT. In one model, the incremental cost-effectiveness
ratio (ICER) showed that INTRABEAM dominated WB-EBRT by being both cheaper and more clinically
effective. In the other model, the costs per QALY for WB-EBRT compared with INTRABEAM ranged from
$89,234 to $108,735 depending on the difference in whole-breast irradiation rates.
Systematic review of health-related quality of life
From 939 records screened, 65 studies were retrieved for consideration. Nine studies were included which
provided European Quality of Life–5 Dimensions data for five out of seven health states potentially relevant
for the independent model.
Manufacturer’s economic evaluation
The manufacturer’s submitted model indicates that INTRABEAM is associated with higher QALY gains
and lower costs, with the incremental analysis showing dominance of INTRABEAM over WB-EBRT.
A probabilistic sensitivity analysis (PSA) found that INTRABEAM had a 100% probability of being
cost-effective, at both the £20,000 and £30,000 thresholds.
Independent economic evaluation
The assessment group’s model finds INTRABEAM to be less expensive but also less effective than WB-EBRT
because it is associated with lower total costs but fewer total QALYs gained. The base-case ICER to replace
WB-EBRT with intraoperative radiation therapy is £1596 saved per QALY lost. INTRABEAM is therefore
not cost-effective compared with WB-EBRT at a willingness-to-pay (WTP) threshold of £20,000 per QALY.
The PSA indicates that WB-EBRT has a greater probability than INTRABEAM of being cost-effective at
the £20,000 and £30,000 per QALY WTP thresholds. INTRABEAM has a higher probability of being
cost-effective than WB-EBRT at thresholds of around £5000 per QALY or less. Deterministic sensitivity
analysis finds four parameters for which the difference between upper and lower values causes a switch
in the treatment option, which is considered cost-effective at the £20,000 per QALY threshold. The
parameters to which the model is most sensitive are the probability of any other recurrence assumed for
WB-EBRT and INTRABEAM, the beta coefficient for the time to local recurrence (INTRABEAM) and the
probability of death from breast cancer (INTRABEAM).
Discussion
Systematic reviews and an economic evaluation have been carried out independent of any vested interest.
A de novo economic model was developed following recognised guidelines and systematic searches were
conducted to identify data inputs for the model.
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Limitations
The base-case result is subject to uncertainty because the disease progression parameters are largely drawn
from the single available RCT. This RCT has a median follow-up of 2 years 5 months, which may be
inadequate, particularly as numbers of participants experiencing a local recurrence in the pre-pathology
stratum are small. The model is particularly sensitive to this parameter.
Conclusions
A significant investment in INTRABEAM equipment and staff training (clinical and non-clinical) would be
required to make this technology available across the NHS. Longer-term follow-up data from the TARGIT-A
trial and analysis of registry data are required as results are currently based on a small number of events
and economic modelling results are uncertain.
Study registration
This study is registered as PROSPERO CRD42013006720.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. Note that the economic model associated with this document is protected
by intellectual property rights, which are owned by the University of Southampton. Anyone wishing to
modify, adapt, translate, reverse engineer, decompile, dismantle or create derivative work based on the
economic model must first seek the agreement of the property owners.
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Chapter 1 Background
Description of underlying health problem
Breast cancer is the most common cancer in women in England, with 41,523 new diagnoses in 2011.1
It accounts for about one-third of all cancers in women2 but is rare in men, accounting for < 0.25% of
cancers in 2011 (303 new diagnoses in England in 2011).1 Consequently, the primary focus of this report is
breast cancer in women and, when data are presented for men, this is clearly indicated.
Breast cancer aetiology
Breast cancer, in common with all other cancers, is caused by deoxyribonucleic acid (DNA) mutations that
disrupt the normal maintenance of cellular identity, growth and differentiation.3 The majority of breast and
other cancers develop from somatic mutations3,4 resulting from errors in processes such as DNA replication,
DNA modification or DNA repair,4,5 which in turn may be influenced by environmental and/or dietary
factors.6 A small proportion of cancer types arise from inheritable single-gene disorders,3 for example BRCA1
(breast cancer 1) and BRCA2 (breast cancer 2) are genes associated with inheritable breast cancer.4,7–9
There are two main forms of breast cancer: non-invasive, in which the cancer cells have not spread; and
invasive, in which the breast cancer cells can potentially spread to the surrounding breast tissue or beyond.
Approximately 10% of newly diagnosed breast cancer cases are non-invasive, the majority (approximately
90%) being ductal carcinoma in situ (DCIS).10 In DCIS, cancer cells have developed inside milk ducts but
have not yet developed the ability to spread beyond the ducts. DCIS is usually identified by mammography
as it rarely presents as a lump. The remaining 90% of newly diagnosed breast cancer cases are various
types of invasive breast cancer.
When breast cancer is diagnosed, information is gathered to describe and classify it according to a variety
of characteristics. Much of the information required can be obtained only from samples taken during
surgical removal of the primary tumour. Key aspects include:11
l histological type (e.g. invasive ductal carcinoma, invasive lobular carcinoma)
l histological grade, ranging from low (generally slow growing) to high (generally fast growing)
l stage, based on the tumour node metastasis (TNM) classification (Tables 1 and 2)
l oestrogen receptor (ER) alpha status
l human epidermal growth factor receptor-2 (HER-2) status
l DNA profile.
This information is essential for deciding what local and systemic treatments may be required and provides
information about prognosis. The focus of this assessment is the treatment of early breast cancer;
however, it should be noted that there is no internationally agreed single definition of early breast cancer
(e.g. in terms of TNM stage). Typically, however, early breast cancer would be classified as TNM stage I or II
(either IIa or IIb), with potentially some stage III tumours (those for which treatment could be curative).
The aim of treatment for early breast cancer is to provide a cure. As already stated, there are two major
categories of early breast cancer: non-invasive (in situ) disease (predominantly in the form of DCIS) and
invasive cancer.11 For invasive cancer to be categorised as early breast cancer, the tumour should not have
spread beyond the breast or the lymph nodes (which remain mobile) in the armpit ipsilateral to (on the
same side as) the affected breast.13 Once an invasive cancer has spread to distant sites (which may occur
after initial treatment with curative intent), it is no longer curable, but can be treated to control symptoms.
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Breast cancer epidemiology
In England, in 2011, the age-standardised rates of breast cancer incidence per 100,000 of the population
were 124.8 for women and 0.9 for men.1 For the period 2008–10 the age-standardised rate for women in
England was 125.7 [95% confidence interval (CI) 125.0 to 126.4].14 The strongest risk factor for breast
cancer is increasing age and, consequently, over 80% of new diagnoses of breast cancer in England are
in women aged > 50 years1 and in men aged > 60 years.1 Other important risk factors include obesity,
alcohol consumption and lack of physical activity, which are estimated to be linked to about 18.5% of UK
female breast cancer cases.15
There were 9702 deaths of women and 64 deaths of men from breast cancer in England in 2011.16 The
UK age-standardised mortality rate from breast cancer per 100,000 women in 2008–10 was 25.3 (95% CI
25.0 to 25.6 per 100,000 women).14 For women diagnosed with breast cancer during 2004–6 and
followed up to 2011, the age-standardised 1-year survival rate for all breast cancers was 94.7% and the
5-year survival was 83.3%.17 Between 2002 and 2006, a statistically significant annual increase in 1-year
survival of 0.3% and in 5-year survival of 0.9% was observed.17 The rise in survival estimates has been due
to earlier detection and improved treatment of breast cancer in women.2 An analysis of survival by stage
at diagnosis for women in the UK diagnosed with invasive breast cancer (DCIS was excluded) during
2000–718 reported 1-year and 3-year net survival as shown in Table 3.
TABLE 1 Stage of breast cancer using the TNM classification12,13
STAGE TNM (see Table 2)
Stage 0 Tisa N0 M0
Stage I T1 N0 M0
Stage IIa T1 N1 M0 or T2 N0 M0
Stage IIb T2 N1 M0 or T3 N0 M0
Stage IIIa T2 N2 M0 or T3 N1 M0 or T3 N2 M0
Stage IIIb T4 N0 M0 or T4 N1 M0 or T4 N2 M0
Stage IIIc Any T N3 M0
Stage IV Any T any N M1
M, metastases; N, node; T, tumour.
a DCIS.
TABLE 2 Tumour node metastasis classification scheme12,13
Tumour stage Nodal stage Distant metastasis
Tisa Tumour in situ N0 No regional lymph
node metastasis
M0 No distant metastasis
T1 Tumour < 2 cm in diameter N1 Mobile regional lymph
node metastasis
M1 Distant metastasis
T2 Tumour 2–5 cm in diameter N2 Fixed regional lymph
node metastasis
T3 Tumour > 5 cm in diameter N3 Supraclavicular lymph
node metastasis
T4 Tumour fixed to skin/chest wall or
inflammatory cancer
M, metastases; N, node; T, tumour.
a DCIS.
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Breast cancer diagnosis
In England, the main routes to diagnosis for the majority of breast cancer cases are via the NHS Breast
Cancer Screening Programme or urgent (2-week wait) referrals from a general practitioner (GP) due to a
suspicion of cancer. The Breast Cancer Screening Programme targets women aged 50–69 years (with
extension from 47 years to 73 years ongoing, and expected to be completed after 2016). In 2006–8, just
over 50% of breast cancer cases in the 50–69 years age group were diagnosed through screening,
whereas, in other age groups (< 50 years and ≥ 70 years), over 50% of cases were diagnosed through the
urgent GP referral route.19 Breast cancer screening aims to detect cancers at an early stage when they are
too small to cause changes to the breast that can be observed or felt. In England in 2011–12, 40.7%
(6403) of all the breast cancers detected by screening were invasive but small (< 15mm in diameter).20
In the case of breast cancers detected via routes other than screening, there are no regularly published
data on stage of breast cancer at diagnosis;21 however, evidence suggests that the majority (at least 80%)
of women are diagnosed with early disease (stage I or stage II) whatever their route to diagnosis.22
The 2009 National Institute for Health and Care Excellence (NICE) guideline Early and Locally Advanced
Breast Cancer: Diagnosis and Treatment11 provides recommendations for breast cancer diagnosis. Diagnosis
is made after triple assessment consisting of a clinical assessment, mammography and/or ultrasound
imaging, and core biopsy and/or fine-needle aspiration cytology.11 A multidisciplinary team should review
and discuss the test results and, if a cancer diagnosis is pathologically confirmed, suggest a treatment plan.
Breast cancer natural history and prognosis
The natural history of breast cancer is variable and incompletely understood.23 If left untreated, a typical
invasive breast cancer might progress in the following manner. Initially, the breast cancer cells multiply,
thereby increasing the size of the tumour;24 as the tumour proliferates, the risk that metastatic cells will be
generated increases.25 A key route for metastatic spread of breast cancer cells is via the lymphatic system.
If a breast cancer spreads, the first place it spreads to is often the first lymph node (or nodes) receiving
direct lymphatic drainage from the tumour;24,25 this lymph node is called the sentinel lymph node.26 The
tumour can also spread to more distant lymph nodes and to systemic sites via the bloodstream (e.g. bone,
lung, liver, brain). It is also possible for tumour cells to metastasise via the vascular system directly to
systemic sites;25 however, not all breast cancers metastasise. Evidence from screening studies suggests that
some screen-detected breast cancers may regress spontaneously27 and natural history may vary according
to a variety of factors, for example genotype,28 hormone receptor status29 and race.30
The heterogeneous nature of breast cancer natural history has an impact when trying to provide a
prognosis and tools have been developed which aim to predict invasive breast cancer outcome. For
example, the Nottingham Prognostic Index (NPI)31 (Table 4) is a tool that combines information on the size
of the tumour, the number of lymph nodes involved and the histological grade to produce an overall
score, with a higher score indicating a worse prognosis. Other models have been developed which aim to
TABLE 3 Age-standardised survival in the UKa by invasive breast cancer stage at diagnosis
TNM stage 1-year net survival (%) (95% CI) 3-year net survival (%) (95% CI)
TNM stage 1 100 (100 to 100) 99.3 (99.2 to 99.4)
TNM stage 2 99.2 (99.2 to 99.3) 92.4 (92.2 to 92.7)
TNM stage 3 90.9 (90.5 to 91.4) 70.7 (69.9 to 71.5)
TNM stage 4 53.0 (52.0 to 54.0) 27.9 (26.9 to 28.9)
a Data for these analyses (which excluded DCIS) came from five of the eight regional cancer registries because these had
stage data for at least 50% of registered patients: Northern Ireland; Wales and the Northern and Yorkshire Cancer
Registry and Information Service; Eastern Cancer Registration and Information Centre; Oxford Cancer Intelligence
Unit; and the West Midlands Cancer Intelligence Unit. The study defined net survival as the survival of cancer patients,
after controlling for other causes of death.
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more accurately predict outcome by including alternative indicators and/or more explanatory factors, for
example Predict33 and the Galway Index of Survival.34 The program Adjuvant! enables prognostic estimates
of outcome either with or without therapy to be produced based on estimates of individual patient
prognosis and data on the efficacy of a range of adjuvant therapy options and is available online
(www.adjuvantonline.com/index.jsp).35
Impact of breast cancer
Psychological distress, chiefly in the form of anxiety, may be experienced by women from the initial
diagnostic procedures for a suspected breast cancer36 through all stages of treatment and beyond.37,38
In addition to psychological aspects, women may experience a range of physical problems, for example
arm and breast symptoms and/or lymphoedema39,40 and fatigue.40
An analysis of patients’ free-text comments from the Cancer Patient-Reported Outcome Measures (PROMs)
Survey in England41 identified a range of issues that may affect patients diagnosed with breast cancer.
These included poor body image following breast surgery, ongoing problems following surgery such as
pain and lymphoedema and problems associated with other non-surgical treatments, for example hot
flushes related to hormone treatments, burns following radiotherapy and neuropathy during and following
chemotherapy. In addition, some patients found that existing comorbidities such as arthritis and
osteoporosis were exacerbated by their treatment. Some survey respondents highlighted that, during
and/or following treatment, a lack of energy affected their everyday life, and some found that they had
cognitive problems and memory loss. Both during and after treatment some patients suffered from feelings
of depression, loneliness and isolation. A continuing fear of recurrence was also an issue for some. Other
problems highlighted by the survey were social and financial issues, for example relating to employment
and obtaining insurance.
The impact of breast cancer for the NHS is likely to increase across all facets of the breast cancer care
pathway in the future. This is because the population of England is growing in both size and age, which
will lead to increasing rates of breast cancer given that the strongest risk factor for breast cancer is age.
TABLE 4 The NPI32
NPI= (T × 0.2)+ L+G
Score Prognostic group 10-year survivala
2.08–2.4 Excellent 96%
2.42 to≤ 3.4 Good 93%
3.42 to≤ 4.4 Moderate I 81%
4.42 to≤ 5.4 Moderate II 74%
5.42 to≤ 6.4 Poor 50%
6.5 to 6.8 Very poor 38%
G, histological grade, either 1, 2, or 3; L, lymph node stage, either 1 (0 lymph nodes involved), 2 (1–3 nodes),
or 3 (> 3 nodes); T, tumour size in cm.
a The 10-year breast cancer-specific survivals are based on data from 2238 patients treated for breast cancer in
1990–9, inclusive.32
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Current service provision
Surgery is usually the first treatment option for early breast cancer (DCIS and invasive breast cancer).
Pre-operative assessment of the breast and axilla determines the size of the primary tumour relevant to the
volume of breast and this information is used to decide whether or not wide local excision (WLE) of the
tumour (‘lumpectomy’) is possible, allowing breast-conserving surgery (BCS) instead of mastectomy
(removal of the breast). Patients who have a mastectomy can have immediate breast reconstruction
(carried out at the same time as the mastectomy) or delayed breast reconstruction.
Pre-operative assessment of the axilla includes ultrasound to determine whether or not morphologically
abnormal lymph nodes are present. If abnormal lymph nodes are identified, ultrasound-guided needle
biopsy is offered to obtain a tissue sample for testing. If there is no evidence of lymph node involvement
on ultrasound, or the ultrasound-guided needle biopsy outcome is negative, lymph node clearance is
not performed during BCS. The NICE guideline Early and Locally Advanced Breast Cancer: Diagnosis
and Treatment11 recommends, instead, sentinel lymph node biopsy (SLNB) as the preferred technique
(SLNB was undertaken for 84% of invasive breast cancers identified during breast cancer screening between
April 2011 and March 201242). The tissue from SLNB has typically been analysed using post-operative
histopathology with a 5–15-day wait for results. If macrometastases (tumour deposits with at least one
dimension over 2mm) are identified, a second operation takes place to remove the remaining axillary lymph
nodes (axillary lymph node dissection).43 In August 2013, NICE recommended whole lymph node analysis
using the RD-100i one-step nucleic acid amplification (OSNA) system as an option for detecting sentinel lymph
node metastases. This analysis is carried out during breast surgery, takes approximately 30 to 45 minutes and
means that, if the result is positive for metastases (cytokeratin-19 gene expression identified which is a marker
associated with breast cancer), axillary lymph node dissection can be completed during the initial surgery,
removing the need for a second operation.43 The advisory group for this assessment indicated that there are
22 RD-100i OSNA systems currently in use in the UK and use is increasing.
After surgical removal of the primary tumour (and axillary lymph nodes if indicated), the information on
prognostic and predictive factors obtained by histological examination, the outcome of tests for ER and
HER-2 status, and other patient and tumour characteristics are used by the breast cancer multidisciplinary
team to consider options for adjuvant therapy for all patients with early breast cancer. Decisions regarding
adjuvant therapy are made following discussion with the patient.44 Adjuvant chemotherapy or radiotherapy
should start as soon as clinically possibly and within 31 days of being ‘fit to treat’ after surgery.45,46
Data from the NHS Breast Screening Programme Audit 2011–1242 indicate that, in practice, some trusts are
struggling to meet this 31-day standard for radiotherapy. Overall, 57% of women received radiotherapy
within 60 days and 92% within 90 days of their final surgery.42 Advice from the advisory group for this
assessment suggested that the figures for symptomatic cancer (i.e. not screen detected) were likely to be
similar and that meeting the 31-day goal for adjuvant chemotherapy may also be difficult.
The range of recommended breast cancer treatment options described by the 2009 NICE guideline Early
and Locally Advanced Breast Cancer: Diagnosis and Treatment11 are summarised in Table 5.
After BCS, whole-breast external beam radiotherapy (WB-EBRT) substantially reduces the risk of recurrence
(15.7% absolute reduction in 10-year risk of any first recurrence) and moderately reduces the risk of breast
cancer death (3.8% absolute reduction in 15-year risk of breast cancer death) for patients with early
invasive breast cancer.47 Therefore, post-operative WB-EBRT is the standard of care for all patients with
early invasive breast cancer after breast-conserving therapy (as per the 2009 NICE guideline11). WB-EBRT
works by directing a beam, or multiple beams, of radiation through the skin directly at the tumour and
surrounding cancer cells to destroy them. The radiation beam is generated by an instrument, known as a
linear accelerator, which is capable of producing high-energy X-rays or electrons. The most common types
of external radiotherapy use photon beams (as X-rays).48 From the patient’s perspective, external
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radiotherapy is similar to having an X-ray, only the radiation is more intense. In the UK, a hypofractionated
regimen is standard practice, with NICE guidelines recommending that patients with early invasive breast
cancer who have undergone BCS receive 40 Gy in 15 fractions.11 The 15 fractions are typically delivered to
patients by hospital radiotherapy departments at short (10–15-minute) treatment sessions each day,
Monday to Friday, with a rest at the weekends. The course is usually given for 3 weeks, but may last
longer. This course of radiotherapy can be followed by a ‘boost’ dose (e.g. 12 Gy in four fractions, 10 Gy
in five fractions or 16 Gy in eight fractions) to the tumour bed over a further 1–2 weeks in patients
considered to be at a higher risk of local recurrence (e.g. aged < 40 years, grade 3 disease and lymph
node positive).11 In many other parts of the world standard practice for whole-breast radiotherapy is 50 Gy
in 25 fractions given daily (Monday to Friday) over 5 weeks.49 For patients with apparently localised DCIS
treated with BCS, there is a 25% risk of a local recurrence over 10 years if there is no further therapy and
half of the recurrences will be of invasive cancer.11 Unfortunately, there is no reliable way to identify the
patients who will not be at risk of local recurrence.50 Therefore, adjuvant radiotherapy should be offered to
all patients with DCIS following BCS alongside a discussion of the potential benefits and risks.11
The treatment schedule described above can be difficult for some women to undertake (e.g. if they live a
long way from their nearest treatment centre, if they have caring responsibilities, if they are elderly and/or
disabled). Whole-breast radiotherapy may also be associated with short-term adverse effects (e.g. skin
soreness/redness, tiredness, nausea) as well as long-term adverse effects (e.g. changes to breast size and
texture/feel, lung or heart problems), and can be impossible to deliver effectively in patients who are
unable to lie flat or in those unable to raise the shoulder on the side receiving treatment.
When chemotherapy is indicated, WB-EBRT is nearly always given when chemotherapy has been
completed and after a gap of 2–3 weeks that minimises overlapping and/or enhancing toxicities. For
patients who require biological therapy or endocrine therapy, this is typically administered concurrently
with WB-EBRT.
Radiotherapy is viewed as a cost-effective treatment. The total spend on radiotherapy (not limited to
breast cancer) has been estimated to constitute just 5% of the estimated total NHS spend on cancer care.45
TABLE 5 Non-surgical treatment options for early breast cancer
Adjuvant treatment Treatment options Comments
Radiotherapy Whole-breast radiotherapy
following BCS
Post-mastectomy radiotherapy to
chest wall
For example, if at high risk of local recurrence
Boost to tumour bed following BCS For example, if at high risk of local recurrence
Radiotherapy to nodal areas For example, if four or more involved axillary
lymph nodes
Systemic therapy for
metastatic disease
Endocrine therapy For example, tamoxifen or aromatase inhibitor for
ER-positive tumours only
Chemotherapy For example, anthracycline-containing regimens,
docetaxel
Biological therapy For example, trastuzumab (Herceptin®, Roche)
May need assessment and treatment for bone loss
Primary systemic therapy
Chemotherapy Before surgery, e.g. to shrink tumour before surgery, to observe response in the primary
tumour before its surgical removalEndocrine therapy
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Description of technology under assessment
The INTRABEAM® Photon Radiotherapy System (Carl Zeiss, Oberkochen, Germany) has a miniature,
electronic, high-dose-rate, and low-energy X-ray source (XRS) which is used to deposit high-dose radiation
directly to a tumour or tumour bed.51 In the USA, INTRABEAM gained US Food and Drug Administration
approval in 1997, and in Europe it was awarded Conformité Européenne (CE) certification in 1999.52
As INTRABEAM uses a low-energy XRS, the system does not have to be contained within the kind of
specially designed room that is required for high-energy radiation sources (e.g. linear accelerators).51
This means that INTRABEAM can be used to deliver intraoperative radiation therapy (IORT) in an ordinary
operating theatre at the same time as surgery. In addition, the system is mobile so it can be moved with care
between different operating theatres.
The XRS component of the device has a 10-cm-long probe51 and one of a variety of applicators of different
shapes and sizes can be attached to this depending on the anatomical site being treated. For breast cancer,
a set of eight reusable spherical applicators is available with diameters from 1.5 to 5.0 cm.52 An applicator
is chosen for irradiating the tumour bed after lumpectomy depending on the size of the resection cavity. The
INTRABEAM technical specifications state that the dose is usually entered by one person (usually a physicist)
and must be checked by a doctor, who verifies the dose planning and confirms it by entering a password.52
The tissue adjacent to the resection cavity is then irradiated by the INTRABEAM device for typically
20–30 minutes.51 A characteristic of the low-energy X-rays produced by the INTRABEAM device is that the
maximum dose of radiotherapy is delivered to the tissues at the surface of the cavity, but, because the dose
attenuates steeply as tissue depth increases, peripheral healthy tissue is spared.53 As a result, the surface of
the tumour bed typically receives 20Gy in this single-fraction treatment.53 After this treatment the incision is
closed. The design of the INTRABEAM equipment ensures that the tissue most at risk of developing a local
recurrence, that is, comprising the wall of the resection cavity adjacent to the resected tumour, receives the
largest dose of irradiation.
The INTRABEAM device has been used in patients with early breast cancer to deliver IORT to the cavity wall
resulting from lumpectomy for treatment of the primary tumour. Patients at low risk of recurrence do not
receive any further local treatment. Patients with a higher risk of recurrence (e.g. histopathology showing
invasive lobular carcinoma, extensive intraductal component, grade 3, node involvement, close margins)
may go on to receive an additional course of WB-EBRT to the whole breast but without a tumour bed
boost because the INTRABEAM device has already delivered therapy directly to the tumour bed. Other
adjuvant treatments, for example endocrine therapy, chemotherapy, biological therapy, will also be given
if indicated.
Six centres in the UK (four in London, one in Winchester and one in Dundee) are known to have used the
INTRABEAM device to treat breast cancer but in the absence of NICE guidance, the equipment has not
entered into routine use. In addition to these six centres, information received from the advisory group for
this assessment suggests that Liverpool and Harlow have purchased the equipment for neurosurgical and
breast use, respectively. Ten other NHS trusts have expressed an interest in purchasing the device and
private providers may also have or be intending to purchase the INTRABEAM device.
The device manufacturer has indicated that the cost of the INTRABEAM device in the UK is £435,000. This
cost includes a set of spherical applicators, each of which would need to be replaced, at a cost of £3170
per applicator, after 100 treatments. A fully inclusive service contract for maintenance of the device would
cost £35,000 annually. Additionally, there are associated consumable costs, for example radiation
protection shields (pack of 10 costs £1041, sufficient for five treatments), and sterile plastic drapes (pack of
five £95.00, sufficient for five treatments).
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Chapter 2 Definition of the decision problem
Decision problem
In line with the scope54 of the NICE appraisal, this assessment will consider the intraoperative use of the
INTRABEAM Radiotherapy System as an alternative to post-operative WB-EBRT to the whole breast, and
as a boost during BCS before WB-EBRT is provided. Its use for local recurrence will not be considered.
The comparator for this review is WB-EBRT delivered by linear accelerator. As already noted, post-operative
WB-EBRT is the standard of care for all patients with early invasive breast cancer after breast-conserving
therapy (as per the 2009 NICE guideline11).
The population of patients included within this assessment is people with early operable breast cancer who
are eligible for WLE of the tumour followed by whole-breast radiotherapy. If the cancer has spread to the
regional lymph nodes, the metastasis remains mobile (not fixed to other structures). Although there is no
single definition of early breast cancer, a common definition is disease that is confined to the breast and
draining nodes for which treatment could be curative. The majority of people with early breast cancer are,
therefore, likely to have tumours classified as TNM stage I or II (either IIa or IIb) but some with stage III
tumours could also be considered to have early breast cancer using this definition. People with a local
recurrence are excluded from the assessment. The NICE scope that underpins this assessment did not
identify any relevant subgroups for consideration.
As specified in the NICE scope,54 the following outcome measures are included in the decision problem:
l overall survival
l disease-free survival
l ipsilateral local recurrence
l adverse effects of treatment
l health-related quality of life (HRQoL).
Overall aims and objectives of assessment
The aim of this assessment is to assess the clinical effectiveness and cost-effectiveness of the INTRABEAM
Photon Radiotherapy System for the adjuvant treatment of early breast cancer during surgical removal of
the tumour.
Other intraoperative techniques were not included as comparators in the NICE scope because they are not
currently in use in clinical practice. These techniques were also not included as interventions alongside the
INTRABEAM Photon Radiotherapy System because their use was not considered sufficiently comparable.
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Chapter 3 Methods
The a priori methods for systematically reviewing the evidence of clinical effectiveness andcost-effectiveness are described in the research protocol, which was sent to our expert advisory group
for comment. None of the comments we received identified specific problems with the methods of the
review which has been undertaken following the general principles outlined in Systematic Reviews: CRD’s
Guidance For Undertaking Reviews In Health Care.55 The methods outlined in the protocol are briefly
summarised below.
Identification of studies
The search strategies were developed and tested by an experienced information scientist. The strategies
were designed to identify all relevant clinical effectiveness studies of the INTRABEAM Photon Radiotherapy
System for people with early operable breast cancer. Separate searches were conducted for the economic
evaluation to identify studies of cost-effectiveness and HRQoL.
The following databases were searched for published studies and ongoing research from inception to
March 2014: The Cochrane Library [including the Cochrane Database of Systematic Reviews (CDSR), the
Cochrane Central Register of Controlled Trials, Centre for Reviews and Dissemination (CRD) (University of
York) Database of Abstracts of Reviews of Effectiveness (DARE), the NHS Economic Evaluation Database
(NHS EED), the Health Technology Assessment (HTA) database], MEDLINE (via Ovid), EMBASE (via Ovid),
MEDLINE In-Process & Other Non-Indexed Citations (via Ovid), Web of Science with Conference
Proceedings, Science Citation Index Expanded (SCIE) and Conference Proceedings Citation Index (CPCI) –
Science (ISI Web of Knowledge), Bioscience Information Service (BIOSIS) Previews (ISI Web of Knowledge),
Zetoc (Mimas), National Institute for Health Research (NIHR) – Clinical Research Network Portfolio,
ClinicalTrials.gov, Current Controlled Trials, and World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP). Searches were limited to randomised controlled trials (RCTs) and controlled
clinical trials (CCTs) for the assessment of clinical effectiveness. Although searches were not restricted by
language, only full texts of English-language articles were retrieved during the study selection process.
Bibliographies of included articles, systematic reviews and clinical guidelines were also searched. The
manufacturer’s submission (MS) to NICE was searched for any additional studies that met the inclusion
criteria. Members of our advisory group were asked to identify additional published and unpublished
evidence. Further details including search dates for each database and an example search strategy can be
found in Appendix 1.
Inclusion and exclusion criteria
The inclusion and exclusion criteria were derived from the final scope54 issued by NICE.
Study design
l For the systematic review of clinical effectiveness, RCTs were eligible for inclusion. If the data from
available RCTs were incomplete (e.g. absence of data on outcomes of interest), evidence from
good-quality CCTs was eligible for consideration.
l For the systematic review of cost-effectiveness, full economic evaluations (cost-effectiveness, cost–utility
or cost–benefit analyses) reporting on measures of both costs and consequences were eligible
for inclusion.
l For the systematic review of HRQoL, primary research studies based in the UK, Europe, North America
and Australasia were eligible for inclusion.
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l Abstracts or conference presentations of studies were eligible for inclusion only if sufficient details were
presented to allow an appraisal of the methodology and the assessment of results to be undertaken.
l Case series, case studies, narrative reviews, editorials and opinions were excluded, as were
non-English-language studies. Systematic reviews and clinical guidelines were used only as a source
of references.
Intervention(s)
l INTRABEAM Photon Radiotherapy System with or without post-operative WB-EBRT.
Comparator(s)
l External beam radiotherapy delivered by a linear accelerator.
Population
l For the systematic review of clinical effectiveness, people with early operable breast cancer (as defined
by the trials).
l For the systematic review of HRQoL, people with breast cancer (not limited to early-stage
breast cancer).
l People with a local recurrence were excluded.
Outcomes
Studies were included if they reported on one or more of the following outcomes:
l overall survival
l disease-free survival
l ipsilateral local recurrence
l adverse effects of treatment
l HRQoL
l cost-effectiveness [expressed in natural units such as life-years gained (cost-effectiveness analysis),
quality-adjusted life-years (QALYs) (cost–utility analysis), or in monetary units (cost–benefit analysis)].
Inclusion screening process
Studies were selected for inclusion through a two-stage process. Literature search results (titles and, if present,
abstracts) identified by the search strategy were screened independently by two reviewers to identify
all citations that potentially met the inclusion/exclusion criteria detailed above. Full manuscripts of selected
citations that appeared potentially relevant were obtained. These were assessed by one reviewer against the
inclusion/exclusion criteria using a flow chart and checked independently by a second reviewer before a final
decision regarding inclusion was agreed. At each stage any disagreements were resolved by discussion,
with the involvement of a third reviewer when necessary.
Data extraction process
Data were extracted by one reviewer using a standardised data extraction form and each data extraction
was checked for accuracy by a second reviewer. Discrepancies in the extracted data were resolved by
discussion, with involvement of a third reviewer when necessary.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Critical appraisal strategy
The risk of bias of the included clinical effectiveness studies was assessed using criteria devised by the
Cochrane Collaboration.56 Criteria were applied by one reviewer and checked by a second reviewer with
any disagreements resolved by consensus and involvement of a third reviewer where necessary. The
methodological quality of included cost-effectiveness studies was assessed using criteria adapted by the
review authors from checklists for appraising economic evaluations by Drummond et al.57 The economic
evaluation included in the MS [Multiple Technology Appraisal (MTA) INTRABEAM Photon Radiosurgery
System for the Adjuvant Treatment of Early Breast Cancer. Carl Zeiss, UK. 2014] to NICE was assessed
using criteria adapted by the review authors from checklists for appraising economic evaluations by
Drummond et al.,57 supplemented with additional criteria for critical appraisal of model-based evaluations
by Philips et al.58 For the systematic review of HRQoL, the included studies were assessed against a critical
appraisal checklist adapted by the review authors from common themes found in other published
assessment forms for HRQoL studies.59–62
Method of data synthesis
Clinical effectiveness, cost-effectiveness and HRQoL data were synthesised through narrative reviews that
included critical appraisal of study methods, critical assessment of data used in any economic models and
tabulation of the results of included studies.
DOI: 10.3310/hta19690 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 69
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Picot et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
13

Chapter 4 Clinical effectiveness
Results
Quantity and quality of research available
Titles and, where available, abstracts of a total of 655 citations were screened and full copies of 44 references
were obtained. Of these, 38 were excluded after inspection of the full article (see Appendix 2). The most
common primary reason for exclusion was that the reference was an abstract containing insufficient details
to allow appraisal of methodology and/or results (n= 25); a further eight records were excluded chiefly
because the outcome was not relevant to the review, three records were excluded chiefly because of an
incorrect intervention, one record was excluded on the basis of study design and one record was excluded
because it related to an ongoing study (see Chapter 4, Ongoing studies). One RCT, the TARGeted
Intraoperative radioTherapy Alone (TARGIT-A) trial, met the inclusion criteria for the review (Figure 1).
The primary and secondary outcomes for the whole trial population were described by two full papers and
three linked abstracts. Five substudies of the TARGIT-A trial which report outcome data from participants
at just one or two centres were identified. Four of these substudies were excluded from this systematic
review on the grounds of outcome (see Appendix 2). One substudy has been included which reports data
on HRQoL from patients at one TARGIT-A trial centre.63 Table 6 provides a summary description of the
TARGIT-A study publications included in the clinical effectiveness systematic review.
References for retrieval and screening
(n= 44)
Titles and abstracts inspected
(n= 655)
Total identified from searching
(after deduplication)
(n= 655)
Excluded
(n= 611)
Full papers excluded
(n= 38)
Reasons for exclusion
• Abstract, n= 25
• Outcomes, n= 8
• Intervention, n= 3
• Design, n= 1
• Ongoing study, n= 1a
(Note: only the primary reason 
for exclusion is listed) 
Studies included in our review
(n= 1)
(Six records: whole trial described by two full
papers and three included linked abstracts;
one substudy described by one full paper)  
FIGURE 1 Flow chart for the identification of studies. a, See Chapter 4, Ongoing studies.
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Overview of the TARGIT-A trial
The key characteristics of the TARGIT-A trial64,65 are shown in Table 7 with further details in the data extraction
form (see Appendix 3). The TARGIT-A trial is the pivotal trial evaluating the concept of delivering a single
dose of targeted IORT at the time of surgery using the mobile INTRABEAM Photon Radiotherapy System.
Design
The TARGIT-A trial is an international, multicentre, non-inferiority RCT that recruited participants in
33 centres in 11 countries including the UK (six centres), Europe (17 centres in six countries), the USA
(seven centres), Canada (one centre) and Australia (two centres). The trial evaluated IORT using the
INTRABEAM device compared with conventional WB-EBRT. The planned follow-up for trial participants was
at least 10 years.69 Median follow-up achieved for the most recent 2014 publication65 is 2 years 5 months.
As a non-inferiority trial, the RCT sought to determine whether or not INTRABEAM treatment was no
worse than WB-EBRT. The pre-stated non-inferiority margin was an absolute difference of 2.5% in the
primary end point (local recurrence) between groups. The 2.5% non-inferiority margin was chosen at
the trial outset because it seemed clinically acceptable to both clinicians and patients.64 However, it should
be noted that, when the non-inferiority margin was chosen, the estimated local recurrence rate (LRR)
(based on the literature available in 1999)70,71 was 6%, and since then recurrence rates have fallen. Two
patient preference studies72,73 suggest that patients would be willing to accept an increase in the risk of
local recurrence for the convenience of INTRABEAM treatment but it should be noted that these studies
were conducted in countries in which WB-EBRT is typically delivered over 5–6 weeks and it is not known
whether or not patient preference would be similar in England where WB-EBRT is typically delivered over
3 weeks.
The trial randomised participants in three strata: pre pathology, post pathology and contralateral breast
cancer. In the initial 2010 publication,64 pre-pathology entry accounted for two-thirds of patients,
post pathology approximately 30% and contralateral breast cancer patients < 4%. It is not clear if
these proportions were maintained in the additional patient numbers reported in the updated 2014
publication.65 The baseline stratification data show differences between centres in the number of patients
entering the trial according to the three timings of delivery strata, particularly pre and post pathology
(see Appendix 3 for further details). Patients who entered the trial in the pre-pathology stratum were
randomised to either INTRABEAM or WB-EBRT prior to WLE of the primary tumour (Figure 2a). The trial
was pragmatic in that if participants randomised to INTRABEAM were subsequently found to have
unfavourable pathological features (unexpected lobular carcinoma, extensive intraductal component,
positive margins at first excision), and hence were at high risk of recurrence elsewhere in the breast, they
received WB-EBRT in addition (i.e. INTRABEAM+WB-EBRT, approximately 15% of INTRABEAM patients).
The protocol also allowed for post-pathology entry of patients whereby patients underwent initial surgery
and then, providing no unfavourable pathological features were identified, were randomised in a second
stratum to receive INTRABEAM delivered as a second procedure or WB-EBRT (Figure 2b). Post-pathology
TABLE 6 Publications included in the clinical effectiveness review
Author Study Details
Vaidya et al., 201064 TARGIT-A trial Initial results of local recurrence and complications,
n= 2232
Vaidya et al., 201465 TARGIT-A trial Updated longer-term results of local recurrence,
complications and survival, n= 3451
Welzel et al., 201363 TARGIT-A trial substudy,
one centre (Germany)
QoL outcome, n= 88
QoL, quality of life.
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WLE plus INTRABEAM
(a)
Randomisation
Breast cancer patient meets trial eligibility criteria
WLE
Histopathology
No adverse criteria
Histopathology
high risk of recurrence
WB-EBRT
WB-EBRT
(b)
Breast cancer patient received WLE, initial tumour pathology
shows no unfavourable features, meets trial eligibility criteria
Randomisation
Second procedure INTRABEAM WB-EBRT
Final histopathology
high risk of recurrence
Final histopathology
No adverse criteria
WB-EBRT
FIGURE 2 Flow diagram for the two main trial strata. (a) Pre pathology; and (b) post pathology.
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entrants to the trial were randomised within 30 days after lumpectomy and the median time between
initial lumpectomy and post-pathology INTRABEAM treatment was 37 days. The timing of INTRABEAM
delivery was not specified in the intervention description within the NICE scope and, therefore, the
post-pathology participants are included in this systematic review. Additionally, patients with a history of
previous contralateral breast cancer were also included and randomised in a third stratum. Treatment
for breast cancer in the contralateral breast is not an exclusion criterion for this review and, therefore,
these participants are also judged to meet the criteria for inclusion.
Participants
The TARGIT-A trial was a moderately large trial, recruiting 3451 women with early breast cancer eligible
for BCS (2298 to the pre-pathology stratum, 1153 to the post-pathology stratum, as noted above final
proportion of contralateral breast cancer patients not reported).65 Participants had to be ≥ 45 years of age
and have invasive ductal carcinoma that was unifocal on conventional examination and imaging. The trial
protocol specifically defined early invasive breast cancer as T1 and small T2, N0–1, M0.69 The initial
trial publication64 stipulated the pre-operative diagnosis of lobular carcinoma as a single exclusion criterion,
although the trial protocol specified additional exclusion criteria.69 Furthermore, because the trial was
pragmatic, each participating centre had the option to predefine more restrictive entry criteria than in the
core protocol (e.g. age, tumour size, grade, node) and to stipulate local policy for the delivery of WB-EBRT.
The majority of women (77%) were aged between 51 and 70 years. Approximately one-third of participants
had a grade 1 tumour and around half had grade 2 tumour, while only 15% had a grade 3 tumour.
The publications64,65 did not specify the grading system used, but it is likely to have been the standard
Bloom–Richardson system74 or the Nottingham system,75 which is modification of the Bloom–Richardson
system. In the majority of women, tumour sizes were small (87% < 2 cm) and were associated with a good
prognosis – nodes were uninvolved (84%) and ER status and progesterone receptor (PgR) status were
positive (93% and 82%, respectively).65 Two-thirds of women were receiving hormone therapy as adjuvant
systemic treatment, while around 12% were receiving chemotherapy.64
Intervention
The INTRABEAM patients received a typical dose of 20 Gy to the surface of the tumour bed (attenuating to
5–7 Gy at a 1 cm depth).
Comparator
External beam radiotherapy patients received a typical dose of 40–56Gy with/without an additional boost
to the tumour bed of 10–16 Gy. Trial centres were allowed to stipulate local policy for the delivery of
WB-EBRT and, therefore, there would have been some differences between WB-EBRT delivered at different
centres. It is presumed that, in UK centres, 40 Gy in 15 fractions would have been the likely treatment
schedule, whereas in some other centres local policy was an alternative schedule, for example 56 Gy in
28 fractions.63
Outcomes
The primary outcome of the trial was pathologically confirmed local recurrence in the conserved breast. In
the initial 2010 paper,64 survival free of recurrence (i.e. disease-free survival) was reported, but, in the
201465 paper, the data on recurrence are not presented in that format. Secondary outcomes were rates of
local toxicity or morbidity, which were assessed using a complications form that contained a pre-specified
checklist. The timing of the data collection for complications was unclear in the trial publications, being
described as ‘early’ in the 2010 paper64 and ‘arising 6 months after randomisation’ in the 2014 paper.65
Complications recorded on the pre-specified checklist were haematoma, seroma, wound infection, skin
breakdown, delayed wound healing and Radiation Therapy Oncology Group (RTOG) toxicity grade 3 or 4
(for dermatitis, telangiectasia, pain in irradiated field, or other). Overall survival was reported as a
secondary outcome measure in the 2014 updated publication.65 No data on HRQoL have been published
for the whole trial population; however, one small substudy63 is included in this systematic review which
reports on HRQoL for 88 participants enrolled at one centre in Mannheim, Germany. HRQoL was assessed
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by two validated questionnaires of the European Organisation for Research and Treatment of Cancer
(EORTC), the quality of life (QoL) questionnaire – C30 (QLQ-C30, version 3; European Organization for
Research and Treatment of Cancer, Brussels, Belgium) and the QoL questionnaire – Breast Cancer Module
(QLQ-BR23). Data presented in the initial TARGIT-A trial publication64 suggest that all the participants
enrolled at this centre were randomised to the pre-pathology stratum.
For most outcomes, analyses were by intention to treat (ITT), one exception being local recurrence in the
conserved breast which, because of the nature of the outcome, could not include women who had
undergone a mastectomy (approximately 2%). For a superiority trial, the Consolidated Standards of
Reporting Trials (CONSORT) statement76 states that analysis should be by ITT. However, the TARGIT-A trial
is a non-inferiority trial. An extension to the CONSORT statement77 for non-inferiority trials indicates that
non-ITT analyses might be desirable and that there would be greater confidence in the results if these
were consistent between ITT and non-ITT analyses. Therefore, an analysis by treatment received in addition
to the ITT analyses presented for the TARGIT-A trial would have been welcome. Outcomes of local
recurrence and overall survival were reported for the whole trial population and separately for the pre- and
post-pathology strata. Data from participants who received INTRABEAM only and from those who received
INTRABEAM with WB-EBRT in addition were analysed together for most outcomes. Median length of
follow-up for participants in the initial 2010 publication was not reported, although it was stated that
maximum follow-up was 10 years.64 The more recent 2014 publication65 reported an overall median
follow-up of 2 years 5 months, with 2020 (59%) participants reaching a median 4 years and 1222 (35%)
reaching a median 5 years.
Funding
The trial64,65 was funded primarily by the NIHR HTA programme in addition to funding from a number of
academic centres and government bodies.
Quality assessment of TARGIT-A trial
Overall, the methodological quality of the TARGIT-A trial was judged to be good with a low risk of bias.
Table 8 shows the judgements of risk of bias in the various domains. For the HRQoL substudy, the
assessment of selection bias and reporting bias for the main trial was judged to apply. For the remaining
criteria it was judged that the HRQoL substudy could potentially differ from the main trial and, therefore,
separate assessments were conducted (see Table 8). Overall, the substudy was judged to be at a high risk
of bias owing to the lack of blinding and it is not clear how representative the results are for the total trial
population because the substudy represents only about 2.5% of the overall trial population. Therefore,
the substudy results should be interpreted with caution.
Randomisation schedules that were generated by computer and held securely in two centres, with requests
for randomisation made by telephone or fax, meant that the risk of selection bias was low.
Owing to the nature of the interventions, it was not feasible to blind the patients or investigators in the
trial, which could potentially introduce performance bias. However, given that the main trial outcomes
(recurrence and survival) were objective measures, it was deemed unlikely that patients or investigators
were influenced by the lack of blinding and thus performance bias was judged to be low. Similarly, for the
main trial, although not all outcome assessors were blinded, the risk of detection bias was judged to be
low because the main trial outcomes (recurrence and survival) were objective measures. For the substudy,63
the lack of patient and investigator blinding led to a judgement of a high risk of performance bias, and
detection bias was judged as unclear owing to a lack of information.
The risk of attrition bias (differences between groups in withdrawals from the study) was deemed to be
low in the TARGIT-A trial. There was a low proportion of withdrawals, and the rate appeared similar
between treatment groups (0.5% INTRABEAM, 1.6% WB-EBRT).65 Similar numbers of patients in the
two treatment groups received their allocated treatment (91% INTRABEAM, 92% WB-EBRT)65 and all
randomised patients were included in an ITT analysis for most outcomes. However, as noted above
(see Overview of the TARGIT-A trial, Outcomes), an additional analysis by treatment received would have
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been desirable. The substudy63 was deemed to be at low risk of attrition bias because only one patient was
reported as lost to follow-up.
The risk of bias due to selective reporting was deemed low as all outcomes specified in the trial protocol69
were reported in either the original or updated publication.64,65 No other sources of bias in the total trial
population were identified. The substudy63 used a retrospective questionnaire without reporting baseline
measurements and was therefore deemed to be at unclear risk of other sources of bias.
Assessment of clinical effectiveness
The majority of the results presented in the following section are the most recent data for the TARGIT-A
trial reported in the updated publication by Vaidya et al.65 Results are presented for ipsilateral local
recurrence, overall survival, and morbidity and toxicity. The main trial outcome data are supplemented with
some morbidity data from the initial trial publication (see Vaidya et al.64). The TARGIT-A trial presented
TABLE 8 Assessment of risk of bias
Cochrane criteria for assessment
of risk of bias in RCTs56 Judgementa Support for judgement
Selection bias
Random sequence generation Low risk Computer-generated randomisation schedules
Allocation concealment Low risk Central allocation
Performance bias
Blinding of participants and
personnel in the TARGIT-A trial
Low risk Neither patients nor investigators were blinded. However,
outcomes of mortality and recurrence were unlikely to be
influenced by lack of blinding
Blinding of participants and
personnel in the HRQoL substudy
High risk As part of the TARGIT-A trial neither patients nor
investigators were blinded and the outcome could
potentially be influenced by the lack of blinding
Detection bias
Blinding of outcome assessment in
the TARGIT-A trial
Low risk Some investigators and teams were not blinded and it is
not clear whether or not all the analyses were performed
unblinded. However, outcomes of mortality and
recurrence are objective measures and hence unlikely to
be influenced by lack of blinding
Blinding of outcome assessment in
the HRQoL substudy
Unclear risk No information reported for this substudy
Attrition bias
Incomplete outcome data
addressed in the TARGIT-A trial
Low risk Low proportion of withdrawals and participants not
receiving allocated treatment (reasons similar between
groups). Analyses by ITT
HRQoL sub-study Low risk Reason for loss of one participant given
Reporting bias
Selective reporting Low risk The protocol is available online (www.nets.nihr.ac.uk/__data/
assets/pdf_file/0007/51892/PRO-07-60-49.pdf)69 and
specifies all outcomes including relapse-free survival and
overall survival (as secondary outcomes)
Other bias
Other sources of bias in the
TARGIT-A trial
Low risk None evident
Other sources of bias in the
HRQoL substudy
Unclear risk Retrospective questionnaire with no baseline
QoL measurement
a ’Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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outcomes of recurrence and survival for the whole trial population, and separately for the pre- and
post-pathology strata. The separate analysis of these two strata was pre-specified. No data were presented
from the third stratum (participants with a history of previous contralateral breast cancer) and no data on
HRQoL have been published for the whole trial population. However, limited data on the secondary
outcome of QoL are provided by a substudy at one trial centre.63
Ipsilateral local recurrence
Local recurrence in the conserved breast was the primary outcome in the TARGIT-A trial. Recurrence was
defined as a recurrent tumour in the ipsilateral breast and was confirmed pathologically by clinical
examination and cytology or biopsy.69 The most recent data from the 201465 publication are shown, which
were not expressed in terms of disease-free survival. Results are presented in Tables 9 and 10 and show
data for the whole cohort and for the two pre-specified randomisation strata (pre pathology and post
pathology) representing the different timings in delivery of INTRABEAM therapy. The trial authors also
report results separately for the mature cohort (participants previously reported in the initial publication in
201064) and the earliest cohort (which excludes participants enrolled in the last 4 years of the study) in
order to ‘assess stability over time’65 (see Table 10). However, there has been criticism of this approach78
because all patients included in the earliest cohort are also included in, and account for, just over half of
the mature cohort and are included again in the whole cohort representing approximately one-third of
this. The assessment team and the advisory group for this assessment also have concerns about the
approach taken. For the INTRABEAM arm, data from participants who received INTRABEAM only and from
those who received INTRABEAM and WB-EBRT were analysed together.
By nature of the outcome, the recurrence data do not include women who underwent mastectomy
(n= 76). Statistical significance levels were set at p< 0.01 for recurrence. The rationale for setting p< 0.01
for recurrence but p< 0.05 for survival (see Overall survival) is not provided.
As can be seen in Table 9, the 5-year risk of local recurrence in the conserved breast in the whole cohort of
patients was higher in patients receiving INTRABEAM than in those treated with WB-EBRT, but the absolute
difference did not exceed the pre-stated non-inferiority margin of 2.5% (3.3% vs. 1.3%, respectively; absolute
difference 2.0%; p= 0.042). With the statistical significance level set at p< 0.01 for recurrence, the difference
between groups was not statistically significant. Similarly, in the pre-pathology stratum (INTRABEAM delivered
at the time of BCS), the absolute difference in recurrence did not exceed the 2.5% non-inferiority margin
(2.1% INTRABEAM vs. 1.1% WB-EBRT, absolute difference 1.0%; p= 0.31) and the difference between
groups was not statistically significant. However, in the post-pathology stratum (INTRABEAM delivered after
BCS as a secondary procedure), although the difference between groups was not statistically significant
(and the analysis may not have been powered to detect a difference), the 5-year local recurrence was higher in
INTRABEAM patients, with the difference being larger than the pre-defined non-inferiority margin of 2.5%
(5.4% INTRABEAM vs. 1.7% WB-EBRT, absolute difference 3.7%; p= 0.069). Therefore, INTRABEAM has
been shown to be non-inferior to WB-EBRT for the whole group and for the pre-pathology stratum but not for
participants in the post-pathology stratum (based on a non-inferiority margin of 2.5%).
TABLE 9 Ipsilateral local recurrence at 5 years
Local recurrence
INTRABEAM events/n;
5-year cumulative
risk (%) (95% CI)65
WB-EBRT events/n;
5-year cumulative
risk (%) (95% CI)65
Absolute difference in
Kaplan–Meier estimate
at 5 years; p-value
Whole group (n= 3375)a 23/1679; 3.3 (2.1 to 5.1) 11/1696; 1.3 (0.7 to 2.5) 12 (2.0%); p= 0.042
Pre-pathology stratum
(n= 2234)a
10/1107; 2.1 (1.1 to 4.2) 6/1127; 1.1 (0.5 to 2.5) 4 (1.0%); p= 0.31
Post-pathology stratum
(n= 1141)a
13/572; 5.4 (3.0 to 9.7) 5/569; 1.7 (0.6 to 4.9) 8 (3.7%); p= 0.069
a Patients who had undergone a mastectomy were not included in the analysis of local recurrence (n= 76 mastectomies in
the whole group, n= 64 in the pre-pathology stratum, n= 12 in the post-pathology stratum).
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The data on recurrence were used to generate a non-inferiority statistic (pnon-inferiority) for the absolute
difference in the binomial proportions of ipsilateral local recurrence (see Table 10). INTRABEAM was shown
to be non-inferior to WB-EBRT for the whole cohort (absolute difference in binomial proportions 0.72%,
90% CI 0.2% to 1.3%; pnon-inferiority< 0.0001) and for all pre-pathology patients (absolute difference in
binomial proportions 0.37%, 90% CI –0.2% to 1.0%; pnon-inferiority< 0.0001). However, non-inferiority was
not established for the post-pathology patients (absolute difference in binomial proportions 1.39%,
90% CI 0.0% to 2.8%; pnon-inferiority= 0.0664).
The non-inferiority statistic was also reported separately for two cohorts of participants within the trial that
had longer follow-up. As already noted, the stated aim of these analyses was to ‘assess stability over time’,65
but participants in the earliest cohort are also included in the mature cohort and whole trial population and
there are concerns about this approach; therefore, the results should be interpreted cautiously. For the
mature cohort, which comprised participants previously reported on in 2010,64 and the earliest cohort, which
had a median follow-up of 5 years, results reflect those of the ‘all-patients’ analyses. It is worth noting that
the number of local recurrence events in the earliest cohort (median follow-up 5 years) was 23 events for the
whole trial, just nine of which occurred in pre-pathology participants.
The absolute differences in the 5-year Kaplan–Meier estimates of percentage with local recurrence in the
conserved breast were calculated and presented as a figure in the trial publication65 for the pre-pathology
stratum only. Data were estimated from the figure using Engauge digitising software (version 4.1,
© Mark Mitchell) (see Appendix 3). The Kaplan–Meier estimates were consistent across the three cohorts
with increasing median follow-up, with absolute differences in percentage with local recurrence in the
conserved breast of 1.1 (whole cohort), 1.1 (mature cohort) and 1.0 (earliest cohort).
TABLE 10 pnon-inferiority for ipsilateral local recurrence
Local recurrence65 Median follow-up Events, n
Absolute difference (%)
(90% CI) in the binomial
proportionsa of ipsilateral
local recurrence
(INTRABEAM minus
WB-EBRT) z-value pnon-inferiority
Whole trial
All patients 2 years 5 months 34 0.72 (0.2 to 1.3) –5.168 < 0.0001
Mature cohortb 3 years 7 months 32 1.13 (0.3 to 2.0) –2.652 0.0040
Earliest cohortc 5 years 23 1.14 (–0.1 to 2.4) –1.750 0.0400
Pre pathology
All patients 2 years 4 months 16 0.37 (–0.2 to 1.0) –5.954 < 0.0001
Mature cohortb 3 years 8 months 14 0.60 (–0.3 to 1.5) –3.552 0.0002
Earliest cohortc 5 years 9 0.76 (–0.4 to 2.0) –2.360 0.0091
Post pathology
All patients 2 years 4 months 18 1.39 (0.2 to 2.6) –1.503 0.0664
Mature cohortb 3 years 7 months 18 2.04 (0.3 to 3.8) –0.429 0.3339
Earliest cohortc 5 years 14 1.80 (–1.2 to 4.8) –0.382 0.3511
a Binomial proportion= number of recurrences/number of patients.
b Mature cohort= 2232 participants previously reported on in 201064 (pre pathology n= 1450, post pathology n= 782).
Numbers of participants in the mature cohort who received mastectomy and who are therefore excluded from the
analysis of local recurrence were not reported.
c Earliest cohort n= 1222 excludes participants enrolled in the last four years of the study (pre pathology n= 817, post
pathology n= 405). Numbers of participants in the earliest cohort who received mastectomy and who are therefore
excluded from the analysis of local recurrence were not reported.
The pre-specified non-inferiority margin was 2.5% and the significance level was set at p< 0.01.
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Overall survival
Overall survival was a secondary outcome in the TARGIT-A trial and was reported in the more recent 2014
publication.65 Overall survival was defined as the time interval between randomisation and death69 and
included breast cancer deaths and non-breast cancer deaths. Statistical significance levels were set at
p< 0.05 for survival. As already noted, the rationale for setting p< 0.05 for survival but p< 0.01 for
recurrence was not provided.
There were no statistically significant differences in overall mortality between women who received
INTRABEAM compared with those who received WB-EBRT (3.9% vs. 5.3%, respectively; difference –1.4%;
p= 0.099) (Table 11). When mortality was split into breast cancer and non-breast cancer deaths, rates of
breast cancer death were similar between the two treatments (2.6% vs. 1.9%; p= 0.56), but there were
significantly fewer non-breast cancer deaths in the INTRABEAM group than in the WB-EBRT group
(1.4% vs. 3.5%, respectively; p= 0.0086).
In the pre-pathology stratum (INTRABEAM delivered at the time of BCS), overall mortality was slightly
lower in the INTRABEAM group (4.6% vs. 6.9% for INTRABEAM and WB-EBRT, respectively; difference
–2.3%; no p-value reported). When split into causes of death, the same pattern was observed as for the
whole cohort for which deaths attributable to breast cancer were similar between the two treatments
(3.3% vs. 2.7% for INTRABEAM and WB-EBRT, respectively; p= 0.72), but there were significantly fewer
non-breast cancer deaths in the INTRABEAM group (1.3%) than in the WB-EBRT group (4.4%; p= 0.016).
When INTRABEAM was delivered after BCS as a delayed procedure (post-pathology stratum), rates of
overall mortality, breast cancer and non-breast cancer mortality were similar between treatment groups
(see Table 11).
TABLE 11 Breast cancer and non-breast cancer deaths at 5 years
Mortality65
INTRABEAM events/n; 5-year
cumulative risk (%) (95% CI)65
WB-EBRT events/n; 5-year
cumulative risk (%) (95% CI)65
Absolute
difference;
p-value
Overall mortality
All patients (n= 3451) 37/1721; 3.9 (2.7 to 5.8) 51/1730; 5.3 (3.9 to 7.3) –14 (–1.4%);
p= 0.099
Pre-pathology stratum
(n= 2298)
29/1140; 4.6 (1.8 to 6.0) 42/1158; 6.9 (4.3 to 9.6) –13 (–2.3%);
p=NR
Post-pathology stratum
(n= 1153)
8/581; 2.8 (1.3 to 5.9) 9/572; 2.3 (1.0 to 5.2) –1 (0.5%);
p=NR
Breast cancer mortality
All patients (n= 3451) 20/1721; 2.6 (1.5 to 4.3) 16/1730; 1.9 (1.1 to 3.2) p= 0.56
Pre-pathology stratum
(n= 2298)
17/1140; 3.3 (1.9 to 5.8) 15/1158; 2.7 (1.5 to 4.6) p= 0.72
Post-pathology stratum
(n= 1153)
3/581; 1.2 (0.4 to 4.2) 1/572; 0.5 (0.1 to 3.5) p= 0.35
Non-breast cancer mortality
All patients (n= 3451) 17/1721; 1.4 (0.8 to 2.5) 35/1730; 3.5 (2.3 to 5.2) p= 0.0086
Pre-pathology stratum
(n= 2298)
12/1140; 1.3 (0.7 to 2.8) 27/1158; 4.4 (2.8 to 6.9) p= 0.016
Post-pathology stratum
(n= 1153)
5/581; 1.58 (0.62 to 3.97) 8/572; 1.76 (0.7 to 4.4) p= 0.32
NR, not reported.
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For non-breast cancer mortality, which was statistically significantly different between the INTRABEAM and
WB-EBRT groups, Vaidya et al.65 detailed the causes of death. These included other types of cancer,
cardiovascular causes and other causes. Details can be found in the data extraction form in Appendix 3.
The absolute differences in the 5-year Kaplan–Meier estimates of percentage overall mortality were
calculated and presented in the published paper65 for the pre-pathology stratum only (as with local
recurrence, see Ipsilateral local recurrence) for the three cohorts with increasing median follow-up. As noted
in section Ipsilateral local recurrence, there are concerns about the approach taken and, therefore, the
results should be interpreted cautiously. The Kaplan–Meier estimates were similar across the three cohorts,
with absolute differences in percentage mortality of –2.3 (whole cohort), –2.6 (mature cohort) and –2.2
(earliest cohort) (the data extracted from the published figure are available in Appendix 3). These data and
the absolute differences in the 5-year Kaplan–Meier estimates of percentage with local recurrence in the
conserved breast (see Ipsilateral local recurrence) were presented together in the 2014 trial publication65
to demonstrate the relationship between local recurrence and mortality whereby women receiving
INTRABEAM experience more local recurrences but fewer deaths than those receiving WB-EBRT.
Morbidity and toxicity
Complications, in the form of local toxicity and morbidity, were reported as secondary outcomes. The
initial publication by Vaidya et al. 201064 reported early complications but did not specifically define ‘early’,
although the trial protocol69 stipulated that the period of serious adverse event observation extended from
the time of registration onto the trial until 90 days after the completion of randomised treatment. The
more recent TARGIT-A publication65 reported complications arising 6 months after randomisation.
As can be seen in Table 12, the incidence of any early complication was similar in the two treatment
groups. Clinically significant complications were also similar between groups with the exception of two.
Wound seroma requiring more than three aspirations occurred more frequently in women receiving
INTRABEAM than in those receiving WB-EBRT (2.1% vs. 0.8%, respectively; p= 0.012), while, conversely,
a RTOG toxicity score of grade 3 or 4 was less frequent in the INTRABEAM group than in the WB-EBRT
group (0.5% vs. 2.1%; p= 0.002).64 Separate data were not reported for the categories of dermatitis,
telangiectasia, pain in irradiated field, or other that contributed to the RTOG toxicity grade 3 or 4 outcome.
A member of the advisory group for this assessment indicated that the clinical impact for patients with
grade 3 or 4 toxicity is much greater than for those with a seroma requiring several aspirations.
The incidence of complications arising 6 months after randomisation (reported by the 2014 publication65)
was lower in both treatment groups, although it is not clear whether or not these complications occurred
in any of the same patients who were reported in the 2010 publication64 as having clinically significant
complications. There appeared to be no differences between treatment groups in any single defined
wound-related complication (see Table 12) (p-values not reported), or in total complications (1.1%
INTRABEAM vs. 0.9% WB-EBRT; p= 0.599). The incidence of radiotherapy-related complications (RTOG
toxicity score of grade 3 or 4) remained higher in women receiving WB-EBRT (0.8%) than in those
receiving INTRABEAM (0.2%), but the difference between the groups was no longer statistically
significant (p= 0.29).
Substudy reporting quality of life for participants at one trial centre
No data on HRQoL have been published for the whole trial population; however, Welzel et al.63 have
assessed QoL retrospectively in one small substudy of 88 participants enrolled at one centre in Mannheim,
Germany. The initial TARGIT-A trial publication64 indicates that all the participants enrolled at this centre
were randomised to the pre-pathology stratum. QoL was assessed by using two validated questionnaires of
the EORTC: the QLQ-C30 (version 3) and the QLQ-BR23. Participants (n= 88) were asked to report on their
situation in the last week and these participants represent 2.5% of the total TARGIT-A trial population.
The results of both an ITT analysis and an as-treated analysis (with a threshold for significance of p< 0.01
in both cases) are presented in Table 13. The as-treated analysis removes five participants from the
INTRABEAM group and moves four of them to the WB-EBRT group because this was the treatment
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TABLE 12 Toxicity and morbidity
Earlya complications INTRABEAM (n= 1113) WB-EBRT (n= 1119) p-value
Number of complications per patient64
0 917/1113 (82.4%) 946/1119 (84.5%) NR
1 151/1113 (13.6%) 139/1119 (12.4%) NR
2 29/1113 (2.6%) 27/1119 (2.4%) NR
3 11/1113 (1.0%) 5/1119 (0.4%) NR
4 3/1113 (0.3%) 0/1119 NR
5 2/1113 (0.2%) 0/1119 NR
6 0/1113 3/1119 (0.3%) NR
Any complicationa 196/1113 (17.6%) 174/1119 (15.5%) χ2 1.74; p= 0.19b
aClinically significant complications64
Haematoma needing surgical evacuation 11/1113 (1.0%) 7/1119 (0.6%) 0.338
Seroma needing > 3 aspirations 23/1113 (2.1%) 9/1119 (0.8%) 0.012
Infection needing i.v. antibiotics or
surgical intervention
20/1113 (1.8%) 14/1119 (1.3%) 0.292
Skin breakdown or delayed wound healingc 31/1113 (2.8%) 21/1119 (1.9%) 0.155
RTOG toxicity grade 3 or 4d 6/1113 (0.5%) 23/1119 (2.1%) 0.002
Major toxicitye 37/1113 (3.3%) 44/1119 (3.9%) 0.443
Wound-related complications arising
6 months after randomisation65 INTRABEAM (n = 1721) WB-EBRT (n = 1730) p-value
Haematoma/seroma needing > 3 aspirations 4/1721 (0.2%)f 2/1730 (0.1%)f NR
Infection needing i.v. antibiotics or surgery 12/1721 (0.7%)f 9/1730 (0.5%)f NR
Skin breakdown or delayed wound healing 3/1721 (0.2%)f 5/1730 (0.3%)f NR
Total 19/1721 (1.1%) 16/1730 (0.9%) 0.599
Radiotherapy-related complications65
RTOG toxicity grade 3 or 4 4/1721 (0.2%) 13/1730 (0.8%) 0.029
i.v., intravenous; NR, not reported.
a Clinical significance is not defined and the 2010 paper64 does not indicate the time period over which these
complications arose, but the 201465 paper describes them as ‘early complications’.
b TARGIT-A vs. WB-EBRT for no complications vs. any number of complications, degree of freedom= 1.
c Some patients in first three rows could be included in the fourth row.
d No patient had grade 4 toxicity.
e Defined as skin breakdown or delayed wound healing and RTOG toxicity grade of 3 or 4.
f Percentages calculated by reviewer.
Data are number of patients (%).
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TABLE 13 The QoL outcomes
ITT analysis, QoL
outcome, mean (SD)
INTRABEAM (N= 46; IORT n= 30,
INTRABEAM+WB-EBRT n= 16) WB-EBRT (n= 42) p-valuea
Global health statusb 61.6 (21.7), n= 46 54.8 (19.9), n= 40 0.183
Restrictions in daily
activitiesb
72.8 (32.3), n= 46 61.8 (29.2), n= 41 0.055
General painc 29.3 (32.8), n= 46 42.5 (33.0), n= 42 0.048
Breast symptomsc 17.0 (20.8), n= 45 18.1 (20.2), n= 42 0.629
Arm symptomsc 24.4 (26.7), n= 45 31.1 (27.9), n= 40 0.279
As-treated analysis,
QoL outcome,
mean (SD) INTRABEAM (n= 25)
INTRABEAM+
WB-EBRT (n= 16) WB-EBRT (n= 46) p-value
Global health statusb 63.6 (24.2) 60.9 (19.9) 52.4 (22.1) > 0.01
Restrictions in daily
activitiesb
78.7 (35.2) NR 60.5 (29.5) 0.007d
General painc,e 21.3 (95% CI NRf
to 54.4)
43.7 (95% CI 11.6 to 75.9) 40.9 (95% CI 8.6
to 73.2)
0.007d
0.018
g
Breast symptomsc,e 7.2 (95% CI NRf
to 20.9)
29.7 (95% CI 6.8 to 52.5) 19.0 (95% CI NRf
to 39.2)
0.001d
< 0.001g
0.021h
Arm symptomsc,e 15.2 (95% CI NRf
to 37.2)
32.6 (95% CI 6.8 to 58.4) 32.8 (95% CI 4.2
to 61.5)
0.009d
0.011f
As-treated analysis,
frequency breast/arm
symptomsi
INTRABEAM (n= 25),
% moderate/severe
INTRABEAM+WB-EBRT
(n= 16), % moderate/severe
WB-EBRT (n= 46),
% moderate/severe p-value
Pain in area of affected
breast
4/0 25/13 11/4 > 0.01
Swelling in area of
affected breast
0/0 7/7 4/2
Oversensitivity in area of
affected breast
4/0 20/7 9/7
Skin problems on or in
area of affected breast
4/4 13/6 9/4
Pain in arm or shoulder 8/8 33/20 18/23 > 0.01
Swelling in arm or hand 8/4 6/6 9/7
Difficulty in raising or
moving arm sideways
20/0 13/7 24/12 > 0.01
NR, not reported; SD, standard deviation.
a Statistical significance was set at 0.01.
b Higher scores are equal to good functioning/good QoL.
c Higher scores are equal to severe symptoms/worse QoL.
d IORT vs. WB-EBRT.
e Values are estimated from figure 463 by reviewer using Engauge digitising software.
f Lower CI not specified on bar chart.
g IORT vs. IORT-WB-EBRT.
h WB-EBRT vs. iort-WB-EBRT.
i Reported by patients.
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received, with the fifth (who refused WB-EBRT) not contributing data. The ITT analysis did not identify any
statistically significant differences in QoL measures (global health status, restrictions in daily activities, general
pain, breast or arm symptoms) reported by the INTRABEAM arm in comparison with the WB-EBRT arm. The
as-treated analyses were not presented in the same way as the ITT analysis. For the as-treated analyses, the
results for the INTRABEAM arm were reported separately for those who received INTRABEAM therapy only
and those who received INTRABEAM+WB-EBRT with statistical comparisons of INTRABEAM only versus
WB-EBRT, INTRAEAM only versus INTRABEAM+WB-EBRT, and WB-EBRT versus INTRABEAM+WB-EBRT
being reported. Thus, a statistical comparison between the original randomised groups is not reported. For the
comparison of the INTRABEAM-only group with the WB-EBRT-treated group the as-treated analyses showed a
statistically significant benefit of INTRABEAM for restrictions in daily activities, general pain, breast symptoms
and arm symptoms, but there was no statistically significant difference in the global health status subscale.
When comparing the INTRABEAM-only group with the INTRABEAM+WB-EBRT group, the only statistically
significant difference in the reported QoL measures was for breast symptoms. No statistically significant
differences were reported for comparisons of QoL measures between the INTRABEAM+WB-EBRT and the
WB-EBRT groups. These data should be interpreted cautiously owing to their non-randomised nature and the
small numbers involved. The breast and arm symptoms most commonly reported by participants were
moderate or severe pain in the arm or shoulder, difficulty in raising/moving arm sideways and pain in area of
affected breast. No statistically significant differences between groups were reported for the as-treated
analysis of frequency of symptoms.
Summary of clinical effectiveness
l One RCT64,65 met the inclusion criteria for the systematic review. It evaluated IORT using the
INTRABEAM device compared with conventional WB-EBRT. In addition to the main trial,64,65 one
substudy reported on participants from an individual trial centre for the outcome of QoL.63 Other
publications from TARGIT-A were not included.
l The RCT was a non-inferiority trial that sought to determine whether or not INTRABEAM treatment
was no worse than WB-EBRT. The pre-stated non-inferiority margin was an absolute difference
of 2.5% in the primary end point (local recurrence) between groups. However, the choice of
non-inferiority margin was based on an estimated 5-year LRR of 6%, but since then trial recurrence
rates have reduced.
l The RCT had two randomisation strata. Participants in the pre-pathology stratum were randomised to
INTRABEAM or WB-EBRT prior to surgery to remove the tumour. Any participants in the INTRABEAM
arm who were subsequently found to have unfavourable pathological features received WB-EBRT in
addition (i.e. INTRABEAM+WB-EBRT). Participants in the post-pathology stratum received surgery to
remove the tumour and were entered into the trial providing initial histopathology showed no adverse
criteria. Participants in the INTRABEAM arm found to have unfavourable pathological features on final
histopathology received INTRABEAM+WB-EBRT.
l The quality of the RCT was judged to be good with a low risk of bias.
l Local recurrence in the conserved breast was the primary outcome of the RCT, with the pre-stated
non-inferiority margin being an absolute difference of 2.5% between groups. Overall survival was a
secondary outcome. The median follow-up was 2 years 5 months, with 2020 (59%) of the total study
population reaching a median follow-up of 4 years and 1222 (35%) reaching a median follow-up of
5 years. Results were presented for the whole trial population, the pre-pathology stratum and the
post-pathology stratum.
Whole trial population
¢ Local recurrence for the whole trial population was higher in the INTRABEAM group, but the
absolute difference in 5-year risk of local recurrence did not exceed the 2.5% non-inferiority
margin. Analysis of the non-inferiority statistic for local recurrence indicated that INTRABEAM was
non-inferior to WB-EBRT.
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¢ The difference in overall survival for the whole trial population between women who received
INTRABEAM and those who received WB-EBRT was not statistically significant. Analysis of breast
cancer and non-breast cancer deaths showed that rates of breast cancer death were similar
between the two treatments but there were significantly fewer non-breast cancer deaths in the
INTRABEAM group than in the WB-EBRT group.
¢ When considering these results for differences in 5-year risks it should be remembered that median
follow-up was just under 2.5 years and 1222 participants had completed 5 years of follow-up.
The initial sample size calculation required 2232 participants be enrolled; however, this was based
on a background 5-year recurrence rate of 6% whereas the observed recurrence rate in the trial to
date is lower than 6% so a smaller sample size could achieve the same statistical power.
Pre-pathology stratum
¢ Local recurrence for the pre-pathology stratum was higher in the INTRABEAM group but the
absolute difference in 5-year risk of local recurrence did not exceed the 2.5% non-inferiority
margin. Analysis of the non-inferiority statistic for local recurrence indicated that INTRABEAM was
non-inferior to WB-EBRT.
¢ Overall, mortality was slightly lower in the INTRABEAM group because, although breast cancer
deaths were similar between the two treatments, there were significantly fewer non-breast cancer
deaths in the INTRABEAM group.
¢ Participants in the pre-pathology stratum treated with INTRABEAM experienced a 1% increase in
local recurrence but this was counterbalanced with a potential 2.3% decrease in overall mortality.
¢ When considering these results, the same issues regarding median length of follow-up apply to the
pre-pathology stratum as have already been noted for the whole trial population. It should also be
remembered that 2298 participants were randomised to the pre-pathology stratum.
Post-pathology stratum
¢ Local recurrence in the post-pathology stratum was higher in the INTRABEAM arm and the
absolute difference in the 5-year local recurrence exceeded the pre-defined non-inferiority margin
of 2.5%. Analysis of the non-inferiority statistic indicated that non-inferiority was not established
for the post-pathology patients.
¢ Overall mortality, breast cancer mortality and non-breast cancer mortality were similar between
treatment groups.
¢ When considering these results, the same issues regarding median length of follow-up apply as
noted for the whole trial population. In addition, it should be remembered that 1153 participants
were randomised to the post-pathology stratum
l Numbers of early complications reported were similar in the two treatment groups. Clinically significant
complications were also similar, except for wound seroma requiring more than three aspirations, which
occurred more frequently in the INTRABEAM group, whereas an RTOG toxicity score of grade 3 or 4
was less frequent in the INTRABEAM group. Complications arising 6 months after randomisation
appeared similar between the groups and, although RTOG toxicity of grade 3 or 4 remained more
common among WB-EBRT arm participants, the difference between groups was no longer
statistically significant.
l One substudy reported QoL for participants at one trial centre:
¢ The outcomes from this substudy should be treated with some caution because of the risks of bias
identified and the small proportion of the overall trial population involved.
¢ ITT analysis did not identify any statistically significant differences in QoL measures between the
study arms.
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The Southampton Health Technology Assessments Centre’s
review of clinical effectiveness in the manufacturer’s submission
to the National Institute for Health and Care Excellence
Carl Zeiss, UK, (INTRABEAM manufacturer) submitted a report and economic model to NICE. The clinical
effectiveness evidence has been briefly appraised (see Appendix 4) and a review of the economic model
and cost-effectiveness results included in the MS can be found in Chapter 5 (see Review of evidence
submission from Carl Zeiss, UK, to National Institute for Health and Care Excellence).
The manufacturer did not conduct a formal systematic review of the clinical effectiveness evidence.
Although the databases searched and the dates of searches were specified, no information is provided to
indicate how the results of this search were screened to identify relevant studies, no detailed inclusion
or exclusion criteria were presented and there is no quality assessment of the included studies. The
manufacturer did not report searching for any ongoing studies but information is included from
conference proceedings.
The MS contains a narrative summary of the single key RCT, the TARGIT-A trial, which is also included in
the Southampton Health Technology Assessments Centre (SHTAC)’s systematic review. However, there are
two differences in the evidence presented. First, the MS excludes evidence from the initial TARGIT-A
trial publication from 2010,64 reasoning that the 2010 results are expected to be included in the more
recent (201465) publication but, in contrast, the SHTAC’s systematic review includes evidence on early
complications from the 2010 TARGIT-A trial publication64 as these are not reported by the more recent
2014 trial paper.65 The second difference in the TARGIT-A trial evidence presented is that the MS includes
a cohort study79 reporting on post-operative complications within the first week following surgery at the
TARGIT-A trial centre in Mannheim, Germany. This cohort study is excluded from SHTAC’s systematic
review because it is likely that the data reported are either partially or wholly contained within the early
complications reported by the initial TARGIT-A trial publication64 and, furthermore, Tuschy et al.79 report
no comparable data for the WB-EBRT group.
In addition to evidence from the TARGIT-A RCT, the MS also provides a narrative summary of evidence
from a further 22 studies72,79,80–99 (six reported as conference abstracts) that did not meet the inclusion
criteria of the SHTAC’s review, chiefly on the grounds of study design.
The MS Interpretation of clinical evidence subsections a, b, and c (MS pp. 42–46) focuses on the TARGIT-A
trial data and, consequently, with just one included trial there is no discrepancy for the key outcomes of
recurrence and overall survival between the MS and the SHTAC’s systematic review.
Ongoing studies
The clinical effectiveness search and the search for ongoing studies identified one ongoing RCT
(TARGIT-B),100,101 one prospective single-arm study (TARGIT-E)102 and three registry database studies
(TARGIT-R,103 TARGIT-BQR104 and TARGIT-US).105 A brief description of each study is provided in Table 14.
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TABLE 14 Ongoing studies
Title, database
identifier(s)
Study type (country),
estimated enrolment
Summary description
of study aims Start date
End date
(primary
end date)
Funding
and/or
sponsor
TARGIT-B,100,101
NCT01792726,
HTA 10\104\07
RCT multicentre,
multinational, n= 1796
To evaluate whether or
not a tumour bed boost
in the form of a single
fraction of radiotherapy
given intraoperatively and
targeted to the tissues at
the highest risk of local
recurrence is superior
(in terms of local tumour
control) to standard
post-operative WB-EBRT
boost after BCS in
women undergoing
breast-conserving therapy
who have a higher risk of
local recurrence
March
2013
April 2022
(January 2022)
HTA
TARGIT-E,102
NCT01299987
Prospective multicentre
single-arm, Phase II,
n= 265
To investigate the efficacy
of a single intraoperative
radiotherapy treatment
(based on the protocol of
TARGIT-A) within elderly
low-risk patients which is
followed by WB-EBRT only
when risk factors are
present. In presence of risk
factors, post-operative
WB-EBRT will be added
according to international
guidelines
January
2011
November 2025
(November 2015)
Sponsor:
University
Hospital
Mannheim
TARGIT-R,103
ISRCTN91179875
Registry database
multicentre,
multinational,
n not provided
To monitor the long-term
effectiveness and safety
of TARGIT treatment in
women who receive
TARGIT outside of a
clinical trial. Recruitment
start mid-2013 continuing
to at least mid-2015
July 2013 July 2023 Royal Free
Charity (UK)
TARGIT-BQR,104
NCT01440010
Registry database
(Germany), n= 1000
A quality control registry
collecting data on LRR,
toxicity and overall
survival. For women with
breast cancer receiving
TARGIT with the
INTRABEAM system as an
advanced boost followed
by shortened WB-EBRT
September
2011
Not provided Sponsor:
University
Hospital
Mannheim
TARGIT-US,105
NCT01570998
Registry trial
(USA), n= 755
A pragmatic registry trial
(modelled on TARGIT-A)
to continue the use
of intraoperative
radiotherapy for a select
population of women,
and to follow outcomes
of local and regional
control, toxicity
and morbidity
May 2012 Not provided
(January 2015)
Sponsor:
University of
California,
San Francisco
TARGIT, TARGeted Intraoperative radioTherapy.
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Chapter 5 Economic analysis
The aim of this section is to assess the cost-effectiveness of the INTRABEAM Photon RadiotherapySystem for the adjuvant treatment of early operable breast cancer.
The economic analysis comprises:
l a systematic review of the literature on the cost-effectiveness of the INTRABEAM Photon Radiotherapy
System for the adjuvant treatment of early operable breast cancer
l a systematic review of studies of the HRQoL of patients with breast cancer
l a review of the INTRABEAM MS to NICE
l an independent economic model and cost-effectiveness evaluation (the SHTAC’s model).
Systematic review of existing cost-effectiveness evidence
The methods and inclusion criteria considered for this review of economic evaluations are presented in
Chapter 2, Decision problem, and details of the search strategy are documented in Appendix 1.
A total of 184 citations were identified through the systematic searches. Following examination of titles
and abstracts, 10 potentially relevant papers were retrieved for a more detailed inspection. Of these, seven
papers were excluded, some for more than one reason. The primary reasons for exclusion were as folows:
full economic evaluation was not conducted (four studies), publications were abstracts with insufficient
details to allow an appraisal of the methodology and results (two studies ) and the intervention was not
INTRABEAM (one study) (for details, see list of excluded studies in Appendix 5). A summary of the selection
process and the reasons for exclusion is presented in Figure 3.
References for retrieval
and screening
(n = 10)
Titles and abstracts
inspected
(n = 184) 
Total identified from
searching (after
deduplication)
(n = 184)
Excluded
(n = 174)
Excluded
(n = 7) 
• Design, n = 4
• Abstract with insufficient information, n = 2
• Intervention, n = 1 
Studies included
(n = 2)
(reported in three publications) 
FIGURE 3 Flow chart of identification of studies for inclusion in the review of cost-effectiveness.
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Three publications were eligible for inclusion, two of which reported the same economic model: Alvarado
et al.106 reported a full economic evaluation based on the trial results of TARGIT-A; and Esserman et al.107
assessed the level of confidence of the TARGIT-A trial results and the impact of early and late adoption
of the trial results. The remaining study by Shah et al.108 conducted an economic evaluation based on
TARGIT-A and the Electron Intraoperative Radiotherapy (ELIOT) trial; however, the analysis based on the
ELIOT trial is not relevant to this systematic review. Characteristics of the included studies106–108 are shown
in Table 15 and discussed in more detail subsequently. The full data extraction forms are shown in
Appendix 6.
TABLE 15 Characteristics of included economic evaluations
Characteristic Alvarado et al.106,107 Shah et al.108
Publication year 2013, 2014 2014
Country USA USA
Funding source Not stated Not stated
Study type Cost–utility analysis Cost–utility analysis; cost minimisation analysis
Perspective Societal Societal
Study population Women with early breast cancer included in
TARGIT-A trial
Women with early breast cancer as included in
TARGIT-A trial
Intervention(s) INTRABEAM INTRABEAM
Comparator(s) 6-week WB-EBRT with a standard
33 fractions
Whole-breast irradiation (WB-EBRT)
Intervention effect Kaplan–Meier estimate of local recurrence
in the conserved breast at 4 years: 1.2%
(95% CI 0.53 to 2.71) for INTRABEAM and
0.95% (95% CI 0.39 to 2.31) for WB-EBRT
(TARGIT-A trial)
LRRs 3.3% for INTRABEAM and 1.3% for
WB-EBRT (TARGIT-A trial)
Currency base US$ 2011 US$ (price year not stated)
Model type,
health states
A Markov decision-analytic model with six
health states based on the TARGIT-A trial
Not reported explicitly, analyses were based on
reimbursement models
Time horizon 10 years Not clearly stated, assumed to be 10 years
Baseline cohort Women aged ≥ 55 years with early breast
cancer defined as stage I-IIA ER+
TARGIT-A trial: women with early-stage ductal
breast cancer who were ≥ 45 years
Base-case results Costs: INTRABEAM $28,879; 6-week
WB-EBRT $34,070
Reimbursement costs ranges:a INTRABEAM
$3094 to $10,179; WB-EBRT $11,726
to $13,743
LY: INTRABEAM 8.38240; 6-week
WB-EBRT 8.38257
QALY: INTRABEAM 9.04; WB-EBRT 9.08
QALY: INTRABEAM 7.66020; 6-week
WB-EBRT 7.65994
ICERs for local recurrence: range $1782 to
$2172 for WB-EBRT based on difference in
whole-breast irradiation rates (15–21%)
ICER: 6-week WB-EBRT dominated Costs per QALY for WB-EBRT compared with
INTRABEAM: range $89,234/QALY to
$108,735/QALY depending on the difference in
whole-breast irradiation rates
ER+, ER positive; ICER, incremental cost-effectiveness ratio; LY, life-years; TARGIT, targeted intraoperative radiotherapy.
a Cost ranges encompass the findings from four reimbursement models the costs for each of these are presented in
Table 17. These reimbursement costs are not directly comparable with the costs reported by Alvarado et al.106
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Critical appraisal of the economic evaluations
The included cost-effectiveness studies were assessed against a critical appraisal checklist (Table 16), which
appraised the quality of the studies and their generalisability to the UK. Any concerns identified by the
assessment group (AG) are described below.
Both studies clearly defined the decision problem and used the relevant intervention and comparator for
the purpose of this review, although the number of fractions used in the comparator arm of WB-EBRT was
not relevant to UK practice (a standard of 33 fractions was used by Alvarado et al.,106 whereas standard UK
practice is 15 fractions over 3 weeks; the number of fractions was not reported by Shah et al.108). The
patient groups of interest as well as the perspective of the studies (societal) were stated; however, as
the studies were based in the USA, they are not generalisable to the UK NHS setting. It is to be noted that
the TARGIT-A trial, on which both the economic evaluations were based, included pre- and post-pathology
patients. The study type and modelling methodology adopted by Alvarado et al.106 are appropriate for the
decision problem in this review. Shah et al.,108 on the other hand, do not describe the methodology but do
state that the methodologies are described elsewhere.
The study by Alvarado et al.106,107 was transparent with respect to the information on model inputs and the
assumptions used. Health state-specific costs109–118 and utilities119 were populated from published literature,
although it was unclear if systematic reviews were conducted to inform these parameters. Both direct and
indirect costs were reported.106,107 The utilities associated with the health states in the base-case model
were obtained via standard gamble technique in the source study119 and health outcomes were reported in
terms of QALYs and life-years gained. A 10-year time horizon was used; this is considered inappropriate as
risk of local recurrence continues over a lifetime. A series of one-way and two-way sensitivity analyses
were conducted to assess uncertainty. In addition, scenario analysis of the 3-week accelerated WB-EBRT
schedule of 16 fractions was performed. Although the results of the one-way sensitivity analyses favoured
INTRABEAM over WB-EBRT in the treatment of patients with early-stage breast cancer, the robustness of
the results still remains questionable as a probabilistic sensitivity analysis (PSA) was not conducted. The
external validity of the economic model was assessed by comparing the findings with the published results
of TARGIT-A, as well as against an online tool for adjuvant therapy and published cost-effectiveness
evidence in the disease area using WB-EBRT as one of the comparator arms. The results of the base-case
model were comparable with these sources.
TABLE 16 Critical appraisal checklist for economic evaluations (based on Drummond et al.57)
Item Alvarado et al.106,107 Shah et al.108
1. Is the decision problem (including interventions compared and patient group)
relevant to the UK?
Yes Yes
2. Is the setting comparable to the UK? No No
3. Is the analytical and modelling methodology appropriate? Yes Yes
4. Are all the relevant costs and consequences for each alternative identified? Yes Yes
5. Are the data inputs for the model described and justified? Yes Yes
6. Are health outcomes measured in QALYs? Yes Yes
7. Is the time horizon considered appropriate? No ?
8. Are costs and outcomes discounted? Yes No
9. Is an incremental analysis performed? Yes No
10. Is uncertainty assessed? Yes No
?, unclear.
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Shah et al.108 reported that all assumptions and methodology adopted in the analyses were based on, and
consistent with, previously published articles, references of which were obtained and examined by the AG.
The methodologies adopted to estimate reimbursement costs as well as the assumptions used in cost
estimations were adequately described in the references provided. The study reported health outcomes in
terms of QALYs. The time horizon for the analysis was not clearly stated but based on the estimation of
mean utility by reimbursement technique it was assumed to be 10 years. No sensitivity or validation checks
were reported, thus raising questions about the robustness of the results presented.
Description and results of the published economic evaluations
Alvarado et al.106
Modelling approach
Alvarado et al.106 developed a Markov decision-analytic model in TreeAge Pro 11 software (TreeAge
Software, Inc., Williamstown, MA, USA) to assess the cost-effectiveness of INTRABEAM compared with
WB-EBRT, based on the results of the TARGIT-A trial. The analysis was conducted over a 10-year time
horizon with annual model cycles. Patients’ transition through the model was clearly stated. The six health
states were:
l disease-free status post BCS
l disease free following local recurrence+ salvage mastectomy
l disease free following local recurrence+ salvage lumpectomy
l metastases
l death due to other causes
l death due to metastatic breast cancer.
All patients entering the model were assumed to be in a healthy state without evidence of the disease,
having initially undergone BCS and allocated radiation treatment. Patients with local recurrence who
initially received WB-EBRT were treated with salvage mastectomy followed by immediate reconstruction;
however, patients with local recurrence who had initially received INTRABEAM also had the option of
salvage lumpectomy followed by WB-EBRT. Patients could die from any other causes at any time in the
model, although death resulting from breast cancer was possible only for those women who had
metastatic breast cancer. A total of 14.1% of women with INTRABEAM received an additional 5 weeks
(28 fractions) of WB-EBRT. Costs and benefits were discounted at 3% per annum. Costs were expressed in
US$ and the price year was 2011.
Assumptions
Alvarado et al.106 incorporated the following assumptions to inform the cost–utility model:
l It was assumed that LRRs progressed linearly over 10 years. This is a strong assumption and should be
treated with caution.
l For women treated with INTRABEAM followed by WB-EBRT, it was assumed that they incurred the
same LRRs as those who had INTRABEAM alone.
Estimation of effectiveness
Alvarado et al.106 sourced inputs for rates and probabilities from published literature.64,109,120–122 Data for the
4-year LRRs from the TARGIT-A trial64 were converted to annual transitional probabilities and projected
over a 10-year period. The Kaplan–Meier estimate of local recurrence in the conserved breast at 4 years
was estimated to be 1.20% (95% CI 0.53 to 2.71) for the INTRABEAM arm and 0.95% (95% CI 0.39 to
2.31) in the WB-EBRT arm.
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Estimation of quality-adjusted life-years
Alvarado et al.106 stated that, where possible, health state utilities were obtained via standard gamble
preferences. These were sourced from a 1998 publication which evaluated HRQoL in breast cancer
patients treated with lumpectomy and radiotherapy.119 The utilities for INTRABEAM, 6-week WB-EBRT and
INTRABEAM followed by 5-week WB-EBRT were assumed to be the same, at 0.92. The utility associated
with salvage mastectomy was valued at 0.82 and that associated with salvage mastectomy followed by
WB-EBRT at 0.87. Patients with metastatic breast cancer were assigned a value of 0.70.
Estimation of costs
A societal perspective was adopted for the analyses, including both direct and indirect costs (resource use
was not reported). Direct costs included by Alvarado et al.106 were costs of the physician, facility fees for
various surgical and radiotherapy therapy treatments and costs of the metastatic health state. Surgical
and treatment costs were estimated using Medicare reimbursements and the costs associated with the
metastatic states were sourced from published literature. The intervention costs were reported as follows:
INTRABEAM, US$5547; 6-week WB-EBRT, US$10,464; INTRABEAM followed by 5-week WB-EBRT,
US$13,640; and 3-week WB-EBRT, US$6,640.
Indirect costs were derived from published data and were estimated as follows: INTRABEAM followed by
5-week WB-EBRT, US$1244; 6-week WB-EBRT, US$1467; and 3-week WB-EBRT, US$667.
Cost-effectiveness results
For the base-case analysis, Alvarado et al.106 found that INTRABEAM resulted in a QALY gain of 0.00026 and cost
US$5191 less than 6-weekWB-EBRT. Therefore, the incremental cost-effectiveness ratio (ICER) of INTRABEAM
dominated 6-weekWB-EBRT as it was cheaper andmore effective. One-way and two-way sensitivity analyses,
conducted to check uncertainty in the base-casemodel prediction, further supported the base-case results.
External validity of the model was assessed and the predicted 4-year recurrence rate of INTRABEAM in the model
was similar to that in TARGIT-A trial as well as the predicted 10-year overall survival in the model comparedwith
the results of an online tool of an adjuvant therapy and a published cost-effectiveness model.
Summary of key issues
l The study Alvarado et al.106 was based on the US health-care system; hence it is not generalisable to
the UK setting. Further, a societal perspective was adopted which differed from the UK NHS and
Personal Social Services (PSS) perspectives.
l The model included results from both pre-pathology and post-pathology patients.
l The number of fractions of WB-EBRT was not relevant to UK practice. The study used the assumption
of using WB-EBRT with a standard 33 fractions whereas the current standard UK practice is
15 fractions. (The impact of variations in WB-EBRT fractions is explored in the AG’s Independent
Economic Evaluation with results presented in Results of independent economic analysis and Table 39.)
l Uncertainty around the base-case results was not fully explored, a very limited number of one-way and
two-way sensitivity analyses were conducted, and PSA was not performed.
l The economic analysis was conducted for a time horizon of 10 years, which is inappropriate given that
risk of local recurrence continues over a lifetime.
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Shah et al.108
Modelling approach
Shah et al.108 analysed the cost-effectiveness of IORT compared with WB-EBRT and accelerated partial
breast irradiation (APBI) through reimbursement models based on the results of two trials, TARGIT-A and
ELIOT. The results based on the ELIOT trial were not extracted as the intervention was not eligible for
inclusion in this systematic review. The study estimated reimbursement models in four ways:
l reimbursement only (professional and facility)
l reimbursement incorporating additional medical costs (e.g. increased operative time with IORT, fraction
of IORT patients requiring additional radiation)
l reimbursement requiring non-medical costs
l reimbursement incorporating costs associated with recurrences.
A cost minimisation analysis was also conducted based on the absolute difference in reimbursements by
techniques. The ICER analysis provided the increased reimbursement required to use WB-EBRT or APBI
compared with IORT per percentage point of improvement in local recurrence. The study, in general, did
not adhere to the prescribed modelling techniques advocated by NICE. Price year and discount rates were
not reported.
Assumptions
Shah et al.108 refer to other publications for details about assumptions.80,123–125
Estimation of effectiveness
Shah et al.108 obtained LRRs for both the INTRABEAM and WB-EBRT arms (3.3% for INTRABEAM vs. 1.3%
for WB-EBRT) from the TARGIT-A trial.
Estimation of quality-adjusted life-years
The utility values used by Shah et al.108 were obtained from the same source119 as Alvarado et al.,106
as outlined above. A utility of 0.92 was assigned to the ‘no recurrence’ health state, 0.779 to ‘local
recurrence’, and 0.685 to the ‘other recurrence’ health state.
Estimation of costs
A societal perspective was adopted for the analyses, including both direct and indirect costs. Details of the
costs (direct and indirect) used in the analysis by Shah et al.108 are described elsewhere.80,123–125 A detailed
overview of the methods to estimate non-medical costs, follow-up costs and costs of local recurrence or
other recurrence (including salvage mastectomy) was presented. Reimbursement costs for INTRABEAM
and WB-EBRT were reported as outlined in Table 17. Non-medical costs were reported as US$44.96 and
US$89.92 per day for once-daily and twice-daily treatment schedules, respectively. Non-medical costs were
estimated as follows (Shah et al.,108 p. 143):
l Average round trip travel was 40 miles to the radiation centre (36 cents per mile).
l The time involved was 2 hours per treatment, including travel, of which 30 minutes was spent receiving
treatment (US$14.78 per hour).
l Patients receiving twice daily treatment returned to work during the interfraction period.
Cost-effectiveness results
Based on the TARGIT-A trial results, Shah et al.108 reported that the ICERs for local recurrence ranged from
US$1782 to US$2172 for WB-EBRT, based on the difference in whole-breast irradiation rates (15–21%),
when all associated costs were incorporated. The costs per QALY for WB-EBRT compared with INTRABEAM
ranged from US$89,234/QALY to US$108,735/QALY depending on the difference in whole-breast
irradiation rates. Results from the cost minimisation analysis indicated that the use of INTRABEAM was
associated with cost savings of US$3.6–4.3M when compared with WB-EBRT.
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Summary of key issues
Shah et al.108 reported the results of cost-effectiveness analysis based on reimbursement models. This study
also had a number of limitations:
l The study was based in the USA and adopted a societal perspective, which is not generalisable to the
UK NHS and PSS setting.
l Limited information was reported on the model approach and assumptions in the included paper;
however, details on model structure and assumptions were reported elsewhere.
l The time horizon for the analysis was not clearly stated.
l Although the techniques adopted to estimate costs associated with non-medical, follow-up, local
recurrence or other recurrence (including salvage mastectomy) were mentioned, the costs were not
reported, except for non-medical costs.
l Sensitivity analysis was not conducted as part of the analysis, thereby raising questions on the
robustness of the model predictions.
Summary of cost-effectiveness studies
l Two cost-effectiveness studies, reported in three publications,106–108 were identified.
l Both studies were based on the findings of the TARGIT-A trial.
l Cost–utility analyses were performed to evaluate QALYs, costs and ICERs of INTRABEAM compared
with WB-EBRT.
l The analyses were conducted for a time horizon of 10 years in one study;106,107 for the other study108
it is assumed that a similar time horizon was adopted, although this was not clearly stated.
l The quality of utility data used in both the studies is questionable. The source study by Hayman et al.119
was an old publication and more recent data would have been appropriate, such as those identified in
Southampton Health Technology Assessments Centre’s systematic review of health-related quality-of-life
studies. It was also not clear whether or not a systematic approach was adopted to identify this source.
l The perspectives, settings and comparators of both studies were not generalisable to the UK setting.
l Alvarado et al.106 found INTRABEAM to be a more valuable strategy with less cost and greater QALYs
than WB-EBRT. Shah et al.108 concluded that although INTRABEAM represented a potential cost-saving
alternative compared with WB-EBRT, the latter represented a cost-effective modality compared with
INTRABEAM when additional medical and non-medical costs were factored in.
TABLE 17 Reimbursement costs for INTRABEAM and WB-EBRT reported by Shah et al.108
Reimbursement type INTRABEAM WB-EBRT
Total reimbursement US$3094 US$11,726
Reimbursement including additional medical costsa US$8003–8706 US$11,726
Reimbursement including medical and non-medical costsa US$8192–8971 US$12,985
Reimbursement including medical, non-medical and recurrence costs (TARGIT)a US$9399–10,179 US$13,743
a Range based on differences in WB-EBRT rates (15–21%).
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Southampton Health Technology Assessments Centre’s
systematic review of health-related quality-of-life studies
A systematic review of HRQoL was undertaken, which aimed to identify utility data to populate the
planned independent economic model of INTRABEAM for breast cancer discussed in Independent
economic evaluation.
The methods used to identify studies are described in Chapter 3, Methods, although the selection criteria
were modified slightly. First, as stated in Chapter 3, Inclusion and exclusion criteria, inclusion was not
limited to women with early breast cancer. After considering previous research, such as the TARGIT-A
trial (discussed in Chapter 4, Quantity and quality of research available) and other cost-effectiveness studies
(discussed Systematic review of existing cost-effectiveness evidence), it was anticipated that the following
health states would be of potential relevance for developing an economic model. These health states were
then specified a priori as eligibility criteria for the systematic review of HRQoL:
l disease free after WLE
l WLE+ INTRABEAM
l WLE+WB-EBRT
l WLE+ INTRABEAM+WB-EBRT
l mastectomy and reconstruction
l disease free after local recurrence
l distant recurrence/metastases.
Second, although the initial intention was to include studies that reported either preference-based
measures of health such as European Quality of Life-5 Dimensions (EQ-5D), Short Form questionnaire-6
Dimensions, Health Utilities Index Mark 3, disease-specific measures such as EORTC QLQ-BR23, EORTC
QLQ-C30; or Short Form questionnaire-36 items, this resulted in a large number of HRQoL studies of
potential relevance. Therefore, the selection criteria were narrowed to only those studies that reported
patients’ QoL using the EQ-5D measure. The EQ-5D consists of five dimensions of health: mobility,
self-care, ability to undertake usual activities, pain and discomfort, and anxiety and depression. It is the
preferred measure of HRQoL by NICE, as it permits comparison of cost-effectiveness (e.g. in terms of
QALYs) with other health-care interventions to inform decisions about recommended treatments.
In addition, it has been widely used and validated in many different patient populations.
The eligibility criteria for the systematic review of QoL are summarised below.
l Participants
¢ Women with breast cancer and meeting any of the health states defined above.
l Intervention/comparator
¢ Radiotherapy, endocrine/hormonal therapy, chemotherapy.
l Outcomes
¢ EQ-5D index [EQ-5D visual analogue scale (VAS) was excluded].
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l Design
¢ Primary research studies [mapping studies (which seek to create a mathematical link between two
different QoL instruments) were excluded].
¢ Studies based in the UK, Europe, North America and Australasia.
¢ Studies published as abstracts or conference presentations were included only if sufficient details
were provided to allow an appraisal of the methodology and assessment of the results.
¢ Non-English-language studies were excluded.
A total of 939 potentially relevant studies were identified through the systematic searches, the majority of
which (874 studies) were excluded based on titles and abstracts. Full papers of the remaining 65 studies
were retrieved for further inspection. These studies were first screened to check they met all of the
following five selection criteria:
l breast cancer patients (including metastases)
l primary research
l EQ-5D
l published in the English language
l full paper or abstract with sufficient information available.
Any study that did not meet any of the above five criteria was excluded. If studies met all five criteria,
they were further screened to check:
l if EQ-5D data were reported for any of the seven health states of interest
l if the geographical origin of the participants was the UK, Europe, North America or Australasia.
The geographical locations were limited to these regions owing to similar racial compositions.
Studies were included in this review if they met all of the above criteria.
Nine studies met the inclusion criteria. Some studies were excluded for more than one reason and the
main reasons for exclusion of the remaining 55 studies were: not primary research (n= 3), abstracts with
insufficient details (n= 19), inappropriate participants (n= 9), studies not reporting EQ-5D data (n= 11)
and no utility data on any of the seven health states of interest for the purpose of this review (n= 13).
A summary of the selection process and the reasons for exclusion are presented in Figure 4 and
Appendix 7, respectively.
The characteristics of the nine included studies are presented (Table 18) and discussed according to the
health states outlined earlier. The studies were diverse in terms of their aims, comparisons made, patient
characteristics and locations. Full data extraction of all the included studies is shown in Appendix 8. The
nine studies provided data for five out of the seven health states potentially relevant for the independent
model: disease free after WLE (one study),126 WLE+WB-EBRT (three studies),127–129 disease free after local
recurrence (one study),132 mastectomy and reconstruction (two studies),130,131 and distant recurrence/
metastatic breast cancer (three studies).132,133,134 No EQ-5D data were identified for the health states
WLE+ INTRABEAM or WLE+ INTRABEAM+WB-EBRT. Out of the nine studies, two studies each were
based in the UK,126,128 the USA,127,129 and Sweden,131,132 one study each was based in Canada130 and
Germany,134 and the remaining study was based on a RCT conducted across the UK and USA.133
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References for retrieval
and screening
(n = 65)
Titles and abstracts
inspected
(n = 939)
Total identified from
searching (after
deduplication)
(n = 939)
Excluded
(n = 874)
Excluded
(n = 55)
• Not primary research, n = 3
• Abstract, n = 19
• Inappropriate participants, n = 9
• No EQ-5D index, n = 11
• No utility data on health states, n = 13Studies included
(n = 9)
Full papers screened
(n = 64)
Paper could not be obtained
(n = 1)
FIGURE 4 Flow chart of identification of studies for inclusion in the review of QoL.
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Critical appraisal of the included studies
A summary of the critical appraisal of the included studies is presented in Appendix 9.
The designs of the included studies varied: three were RCTs,126,128,133 two were single-cohort studies,127,129
one was a longitudinal study,130 one was a retrospective descriptive study131 and two were
cross-sectional studies.132,134
All nine included studies defined the study question and explained the treatment strategies. Across
the studies, the study designs as well as the methods of recruiting participants were clearly outlined.
The studies were transparent with regard to the information provided for the methodologies applied.
One study did not include patients aged < 65 years,128 another excluded those aged > 65 years130 and
three studies did not state clearly if any individuals relevant to this review were excluded.129,131,134 One
study131 did not describe participant characteristics. With respect to the sample size, only two studies126,129
provided an appropriate justification for the study sample size. The response rates to EQ-5D were not
reported in two studies128,133,134 thereby raising questions on the validity of the reported results as a lower
response rate could possibly result in biased outcomes. Similarly, loss to follow-up was not reported by
four studies127,129,131,134 and loss to follow-up would also impact on the validity of the results.
The included studies were assessed on the basis of their relevance to the NICE reference case. Of the nine
included studies, only three128,126,132 met all of the criteria (see Appendix 8). Five studies did not meet one
of the criteria, as valuations of HRQoL were not undertaken from the general UK population.127,129,131,133,134
The population characteristics in the remaining study did not match those described in the decision
problem as they included women with a poor prognosis (stage II/III).130
Of the included studies, only one study reported utility value for disease free after WLE.126 This study
was UK based and included patients aged ≥ 18 years. Three studies reported utility values for the
WLE+WB-EBRT health state, of which one was based in the UK128 and two were US based.127,129 Patients
in the study by Freedman et al.127 were > 18 years of age and those in the study by Serra et al.129 ranged
from 28 years to 77 years of age. The UK-based study by Prescott et al.128 excluded women aged
< 65 years and the mean age of the baseline cohort was 72 years. It was observed that the baseline patient
characteristics with respect to age differed across the three studies. Freedman et al.127 included women with
early-stage breast cancer for their analysis, which was similar to the population of interest for the independent
model. In addition, they reported outcomes at a longer follow-up of up to 15 years.
The utility values for the health state of mastectomy and immediate reconstruction were reported by two
studies.130,131 Robertson et al.131 conducted a retrospective study based on Swedish breast cancer patients
who had undergone immediate breast reconstruction with implants. Conner-Spady et al.,130 on the other
hand, conducted a longitudinal study in Canadian women with stage II or III breast cancer and at high risk
of relapse. The study by Robertson et al.131 had advantages over Conner-Spady et al.130 with respect to
larger sample size, recent publication date and longer follow-up period. Furthermore, women aged
> 65 years were not included in the Canadian study.130
Three studies reported utility associated with distant metastases,132,133,134 one of which also reported utility
associated with disease-free status after local recurrence.132 Sample size ranged from 345132 to 497.134 In
two of these studies, the median age of population was reported and was 57 years132 and 59 years;134 no
information related to age was provided in the other study.133 Lidgren et al.132 included women with a
previous diagnosis of breast cancer, while Sherrill et al.133 focused on those with advanced or metastatic
HER-2-positive (HER-2+) breast cancer who had progressive disease. Hildebrandt et al.134 included both
male and female patients affected by breast, cervical, endometrium, ovarian and other gynaecological
cancer, and reported data separately for each disease.
DOI: 10.3310/hta19690 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 69
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Picot et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
47
Results
The utility values for the potentially relevant health states extracted from the nine included studies are
tabulated in Table 19.
Disease free after wide local excision
Turnbull et al.126 reported EQ-5D estimates for women with biopsy-proven primary breast cancer who were
scheduled for WLE. The utility estimate for women randomised to the group undergoing magnetic
resonance imaging (MRI) was 0.86 at baseline, 0.78 at 8 weeks post randomisation, and 0.80 and 0.81 at
6 and 12 months post initial surgery, respectively. Those randomised to receive no MRI scan had similar
utility estimates to those receiving a MRI scan at baseline and 12 months post initial surgery, but slightly
lower values of 0.77 and 0.79 at 8 weeks post randomisation and 6 months post initial
surgery, respectively.
TABLE 19 The EQ-5D values from included studies
Study (country) Health state EQ-5D estimates
Turnbull et al.126 (UK) Disease free after WLE MRI scan No MRI scan
Baseline 0.8567 0.8601
8 weeks post
randomisation
0.7791 0.7728
6 months post
initial surgery
0.8040 0.7935
12 months post
initial surgery
0.8101 0.8112
Freedman et al.127 (USA) WLE+WB-EBRT 0.89 (95% CI: 0.87 to 0.91) at 5 years
0.90 (95% CI: 0.86 to 0.94) at 10 years
0.90 (95% CI: 0.83 to 1.00) at 15 years
Prescott et al.128 (UK) WLE+WB-EBRT
Radiotherapy
No
radiotherapy
Baseline 0.77 0.74
3.5 months 0.78 0.76
9 months 0.76 0.72
15 months 0.74 0.73
Serra et al.129 (USA) WLE+WB-EBRT 0.88 prior to the start of guided imagery therapy,
0.86 at the end of therapy
Conner-Spady et al.130 (Canada) Mastectomy and immediate
reconstruction
Pre induction: 0.78
Day 1 third cycle of FAC chemotherapy: 0.75
3 week post HDC: 0.61
6 months or 8 weeks post HDC: 0.79
12 months: 0.84
18 months: 0.84
24 months: 0.89
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Wide local excision plus whole-breast external beam radiotherapy
Freedman et al.127 reported EQ-5D estimates for women in early-stage breast cancer treated by BCS
and radiotherapy with or without systemic therapy as 0.89, 0.90 and 0.90 at 5 years, 10 years and
15 years, respectively.
Prescott et al.128 included breast cancer patients who had undergone BCS and endocrine therapy to assess
the QoL and cost-effectiveness of omission of post-operative radiotherapy in women with ‘low-risk’ axillary
node-negative breast cancer (T0–2). For the radiotherapy arm, reported EQ-5D estimates varied between
0.77 at baseline and 0.74 at 15 months and utility estimates varied between 0.74 at baseline and 0.73 at
15 months for the no radiotherapy arm. This study did not include patients aged < 65 years.
Serra et al.129 assessed EQ-5D estimates on people undergoing radiotherapy for breast cancer to evaluate
the impact of guided imagery (a stress reduction technique). The utility values prior to the start of
radiotherapy plus guided imagery therapy and at the end of radiation therapy were reported as 0.88 and
0.86, respectively. One of the disadvantages of this study was that it reported very limited details on the
inclusion/exclusion criteria; hence, it was not transparent whether or not any relevant individuals were
excluded from the analysis.
TABLE 19 The EQ-5D values from included studies (continued )
Study (country) Health state EQ-5D estimates
Robertson et al.131 (Sweden) Mastectomy and immediate
reconstruction
0.83
Lidgren et al.132 (Sweden) Disease free after local
recurrence, distant
metastases
Patients in their first year after a primary breast cancer:
0.696 (95% CI 0.634 to 0.747)
Patients in first year after a recurrence: 0.779 (95% CI
0.700 to 0.849)
Patients in their second and following years after
primary breast cancer/recurrence: 0.779 (95% CI 0.745
to 0.811)
Patients with metastatic disease: 0.685 (95% CI 0.620
to 0.735)
Sherrill et al.133
(UK and the USA)
Distant metastases Lapatinib (Tyverb®,
GSK)+ capecitabine
(Xeloda®, Roche) Capecitabine
Toxicity grade
(3/4)
0.60 0.59
TWiST 0.66 0.66
Relapse 0.41 0.44
Hildebrandt et al.134 (Germany) Distant
recurrence/metastases
Breast cancer Median
Overall 0.8870
Primary disease 0.8870
Metastatic disease 0.8870
Recurrent disease 0.8870
Both 0.8870
BAN, British Approved Name; FAC, fluorouracil, Adriamycin (doxorubicin; BAN); GSK, GlaxoSmithKline; HDC, high-dose
chemotherapy; MRI, magnetic resonance imaging; TWiST, time without symptoms of disease progression or toxicity.
DOI: 10.3310/hta19690 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 69
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Picot et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
49
Mastectomy and immediate reconstruction
Conner-Spady et al.130 evaluated EQ-5D estimates in Canadian patients with stage II/III breast cancer who
were at high risk of relapse and were receiving high-dose chemotherapy (HDC) treatment with autologous
blood stem cell transplantation. There was a decrease in HRQoL from pre-induction (0.78) to 3 weeks post
HDC (0.61) and return to baseline levels at 8 weeks post HDC (0.79). The EQ-5D estimate at 2 years was
0.89. In the short term, there was a negative impact on HRQoL by treatment, but this quickly rebounded
and no data were available for the long term. EQ-5D estimates specific to different types of surgery
(modified radical mastectomy, total mastectomy and segmental surgery) were not reported. Patients aged
> 65 years were excluded.
Robertson et al.131 presented an audit of all immediate breast reconstructions (IBRs) during the period
2005–8 performed by breast surgeons and investigated post-operative HRQoL in a Swedish setting. The
EQ-5D estimate was reported as 0.83. The study did not state clearly if any relevant individuals were
excluded; therefore, generalisability of the results is unclear.
Disease free after local recurrence, distant metastases
In a cross-sectional observational study, Lidgren et al.132 estimated HRQoL for different breast cancer
disease states in Swedish women with a previous diagnosis of breast cancer. This study reported EQ-5D
estimates for two health states: disease free after local recurrence and distant metastases. Patients in the
first year after a primary breast cancer had a EQ-5D estimate of 0.696. EQ-5D estimates in the first year
after local recurrence and in the second and following years after both primary breast cancer and local
recurrence were same at 0.779, and patients in metastatic disease had a EQ-5D estimate of 0.685.
Sherrill et al.133 conducted a quality-adjusted time without symptoms of disease or toxicity of treatment
(Q-TWiST) analysis in patients with advanced or metastatic HER-2+ breast cancer who had progressive
disease following prior therapy including an anthracycline, a taxane and trastuzumab (Herceptin®, Roche).
The study compared health states in patients receiving combination therapy of lapatinib (Tyverb®,
GlaxoSmithKline) plus capecitabine (Xeloda®, Roche) and those receiving capecitabine alone. The EQ-5D
estimate associated with the relapse health state was reported as 0.41 for the lapatinib plus capecitabine
arm compared with 0.44 for capecitabine monotherapy arm. However, this trial was stopped early before
attaining the sample size.
In a cross-sectional survey, Hildebrandt et al.134 investigated health utilities as cardinal values of individuals’
preferences for specific health-related outcomes in women treated in Germany in the fields of
gynaecological oncology and mastology to provide local German data. The study found that patients with
breast cancer who had primary disease had the highest estimates of QoL as measured by EQ-5D VAS and
these declined if the disease was already advanced. However, this difference was not evident from the
EQ-5D health index in patients with primary disease, metastatic disease, recurrent breast cancer, or both
recurrence and metastatic disease, which had a consistent median value of 0.8870.
When comparing the EQ-5D estimates across the potentially relevant health states in breast cancer patients
reported in the studies included in this review, it is observed that there are variations in EQ-5D estimates
for similar health states. These differences could be explained by the differences in patient characteristics,
country settings, nature of the intervention(s) and comparators(s) used in the treatment of breast cancer
patients across different countries, and length of follow-up.
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Summary and conclusions of the health-related quality-of-life review
The key findings of this systematic review are summarised below.
l Nine studies met the inclusion criteria of the HRQoL systematic review.
l Two studies were UK based and the remaining studies were based in Europe and North America.
l The included studies were diverse with respect to their aims, population of interest, geographical
locations, interventions, comparators, study designs and methodologies adopted.
l The review identified utilities that could be used to inform the independent cost-effectiveness model
for five out of seven potentially relevant health states: disease free after WLE; WLE+WB-EBRT; disease
free after local recurrence; mastectomy and immediate reconstruction; and distant recurrence.
l The review did not identify any relevant study to populate the utilities for two potentially relevant
health states: WLE+ INTRABEAM or WLE+ INTRABEAM+WB-EBRT.
Review of the evidence submission from Carl Zeiss, UK,
to the National Institute for Health and Care Excellence
A structured data extraction form was used to guide the review of the submission by Carl Zeiss, UK, to
NICE (see Appendix 4). The MS evaluated the cost-effectiveness of INTRABEAM in early breast cancer
patients when compared with radiotherapy, which is usually given in the UK over 3–6 weeks as WB-EBRT.
The total costs, QALYs gained and cost-effectiveness associated with the intervention and comparator
under consideration in the appraisal were reported in the MS. The perspective adopted in the submission
was that of the NHS, capturing direct costs and benefits only. A systematic review of any relevant
cost-effectiveness models was not conducted. Very limited information on the model was presented in the
main submission document and, although further details were contained within the Microsoft Excel
(Microsoft Corporation, Redmond, WA, USA) model, these too were limited.
Modelling approach
A multistate Markov model, developed in Microsoft Excel, was used in the submission. The model used a
cohort of breast cancer patients aged ≥ 55 years who were disease free after WLE. The economic model
was based on the results of the pre-pathology stratum of the TARGIT-A trial65 with 2298 patients. This was
because results were less favourable in post-pathology stratum (see Chapter 4, Assessment of effectiveness)
and the submission recommended that INTRABEAM be used in pre-pathology patients only (MS, pp. 3–4).
It was not reported whether the model was constructed de novo or adapted from another previously
existing model. The model consisted of four health states:
l disease free
l local recurrence treated by mastectomy/lumpectomy
l non-breast cancer death
l breast cancer death.
Patients in the disease-free state could remain in that state or transition to either local recurrence or non-breast
cancer death. Those in the local recurrence state could remain in that state or die from either non-breast cancer
or breast cancer-related deaths. The two death states were the absorbing states. The analysis was conducted
for a time period of 20 years with an annual cycle length.
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Assumptions
The manufacturer’s model made the following assumptions:
l After local recurrence, INTRABEAM patients would undergo salvage lumpectomy.
l After local recurrence, WB-EBRT patients would undergo salvage mastectomy. There is also an
undocumented assumption that all patients undergoing mastectomy have reconstruction, which is
reflected in the high cost of mastectomy.
l The death rate in disease-free patients was equal to that in the general population.
l An average of 23 fractions of WB-EBRT per patient were delivered, based on 15–30 fractions in the
clinical practice.
l All patients were given INTRABEAM concurrent with initial lumpectomy (pre-pathology stratum of
TARGIT-A trial).
A few of the model assumptions are not relevant to UK practice. The model assumed that INTRABEAM
patients would undergo salvage lumpectomy after local recurrence; however, clinical experts advised that
in the UK most patients would undergo mastectomy after local recurrence instead. Furthermore, the
undocumented assumption that all mastectomy patients would undergo reconstruction is not in line with
UK practice, as only around 31% of the patients undergoing mastectomy will have reconstructions, as
shown in the independent model discussed in Methods for economic analysis. In addition, the assumption
of using an average of 23 fractions of WB-EBRT per patient was not appropriate as the current standard
UK practice is 15 fractions.
Critical appraisal of model
The manufacturer’s economic evaluation was appraised for methodological quality and generalisability
to the UK NHS using a checklist adapted from the NICE reference case requirements and the Philips et al.58
checklist (Table 20). The evaluation met half of the requirements for methodological quality and
generalisability, and the remaining criteria were either not met or unclear; therefore, the evaluation did not
fully meet the NICE reference case. A brief description is presented below.
The manufacturer’s evaluation provided a clear statement of the decision problem to be addressed, which
appeared to follow the scope for the appraisal issued by NICE. Although the comparator included
WB-EBRT, which is routinely used within the NHS, its appropriateness is questionable as the number
of WB-EBRT fractions used in the UK practice is 15 compared with 23 fractions used in the model.
Six out of 33 centres in the TARGIT-A trial were based in the UK and centres were allowed to follow local
policy for WB-EBRT delivery. The MS reported 23 fractions as the average of the range between 15 and 30
fractions being used in all the countries in the trial, but it was not clear if this was a weighted average
of fractions used in the trial or a midpoint. The perspective adopted in the model was appropriate and,
although the MS reported that the analysis was UK based, limited details were provided on the baseline
characteristics of the patient population. A Markov modelling methodology was used, which seemed
appropriate given the clinical nature of breast cancer; however, the AG considered that the reported
model was a simplified structure with only four health states and that an additional health state for
progressed disease would have been appropriate. Another limitation was that a lifetime horizon was
not adopted.
Patients entering the model were aged 55 years (on average) and were followed for 20 years. This time
span might not reflect the entire follow-up period of the disease. Patients transitioned through the health
states in annual cycles, which is an appropriate assumption. The model structure was presented
diagrammatically but no justification of the key assumptions and description of the data inputs used was
provided. Measures of clinical effectiveness were obtained from a single study;65 however, no other
relevant trials were identified by the SHTAC’s systematic review. Benefits for the model were measured
in QALYs using standard gamble for measuring utility, although the source study was dated 1997.135
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It was not clear if a systematic review was conducted to identify the study. The model extrapolated
local recurrence and survival data beyond 5 years by tacitly assuming an exponential fit to time to local
recurrence; however, the AG considers that a log-normal distribution would be the best fit based on
comparison with external data (see Data sources). All benefits and costs were discounted at 3.5% as
outlined in NICE guidance. Uncertainty was assessed through PSA and no one-way or scenario analyses
were conducted. Finally, no details around model validation were provided.
Estimation of effectiveness
Data on effectiveness for both the intervention (INTRABEAM) and the comparator (WB-EBRT) were derived
from a single RCT (TARGIT-A) by Vaidya et al.65 and 5-year cumulative risks reported in the source study
were converted to annual probabilities and populated in the model. It was not reported whether or not a
systematic review was conducted to identify the source study; however, no other relevant trials were
identified by the SHTAC’s systematic review (see Chapter 4, Quantity and quality of research available).
No adverse events were included in the analysis, which was considered appropriate by the AG.
Estimation of quality-adjusted life-years
Health-related quality-of-life utility values were assigned to patients in the disease-free state, those
undergoing salvage lumpectomy and those undergoing salvage mastectomy. A utility value of 0.92 was
assigned to patients in the disease-free state, a value of 0.87 to patients undergoing salvage lumpectomy
and a value of 0.82 to those undergoing salvage mastectomy. The MS obtained these values from a
single study by Hayman et al. published in 1997.135 No details were provided of the method of deriving
TABLE 20 Critical appraisal checklist of the manufacturer’s economic evaluation (based on Drummond et al.57 and
Philips et al.58)
Item number Item Carl Zeiss
1 Is there a clear statement of the decision problem? Yes
2 Is the comparator routinely used in UK NHS? ?a
3 Is the patient group in the study similar to those of interest in UK NHS? ?b
4 Is the health care system comparable to that in the UK? Yes
5 Is the setting comparable to the UK? Yes
6 Is the perspective of the model clearly stated? Yes
7 Is the study type appropriate? Yes
8 Is the modelling methodology appropriate? ?
9 Is the model structure described and does it reflect the disease process? Yes
10 Are assumptions about model structure listed and justified? No
11 Are the data inputs for the model described and justified? No
12 Is the effectiveness of the intervention established based on a systematic review? No
13 Are health benefits measured in QALYs gained? Yes
14 Are health benefits measured using a standardised and validated generic instrument? Yes
15 Are the resource costs described and justified? No
16 Have the costs and outcomes been discounted? Yes
17 Has uncertainty been assessed? ?
18 Has the model been validated? No
?, unclear.
a Different number of WB-EBRT fractions used in the model (23 fractions) than standard UK practice (15 fractions).
b Baseline characteristics were not provided.
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these values or the rationale used. The source study135 used a standard gamble approach to estimate utility
values, which were not obtained from the general population. This is a limitation as it was shown in the
systematic review of HRQoL (see Southampton Health Technology Assessments Centre’s systematic review
of health-related quality-of-life studies) that there were several other more recent and relevant HRQoL
studies that used the EQ-5D measure.
Estimation of costs
Treatment unit costs were obtained from the following sources: expert opinion, reference costs 2012–13,136
payments by results tariff 2013–14,137 and the study by Wolowacz et al.138 As with clinical effectiveness
and utilities, the methods of deriving the costs were not adequately described. The costs associated with
travel/parking/accommodation were appropriately not included within the WB-EBRT arm (it was stated that
these expenses might range from £50 to £100 per patient per fraction delivered).
The validity of the costs estimates is questionable. The cost of INTRABEAM per patient was obtained from
expert opinion and although the manufacturer provided the cost compositions of INTRABEAM, it was not
transparent in explaining the assumed cost per patient. In addition, cost of WB-EBRT was obtained from an
inappropriate Healthcare Resource Group (HRG) code, the code used in the model for WB-EBRT was for
‘other radiotherapy treatment’, whereas the AG considers that the HRG code description required for the
purpose of this analysis is ‘deliver a fraction of radiotherapy on a megavoltage machine’, which includes
WB-EBRT delivered by linear accelerator, as per the NICE scope. The AG considers that HRG codes SC22Z
and SC23Z are required for treatment delivery, and SC45Z, SC46Z, SC47Z and SC48Z are required for
WB-EBRT (see Data sources and Table 31). Costs were only varied by ± 10% in PSA. There were also
inconsistencies in the sources used to populate the reported costs; for instance, the costs of treating
post-INTRABEAM local recurrence (salvage lumpectomy) and that of treating post-WB-EBRT local recurrence
(salvage mastectomy) were obtained from payments by results tariff 2013–14, whereas the cost of
WB-EBRT was obtained from the reference costs 2012–13.137 The use of reference costs is preferable and
would be considered standard practice.
Cost-effectiveness results
The base-case results from the submission are shown in Table 21 and indicate that INTRABEAM is
associated with higher QALYs and lower costs. The submission states that the incremental analysis shows
dominance of INTRABEAM over WB-EBRT.
One-way sensitivity analyses and scenario analyses were not conducted. A PSA was undertaken using
Monte Carlo simulation with 1000 iterations. The cost parameters in the model were assigned to
beta-project evaluation and review technique (PERT) distributions and beta distributions were assigned to
utilities. For the cost parameters, the AG considers that gamma distribution would have been a more
standard choice. It is not usual practice to assign beta-PERT distribution; however, it is expected that this
would have little impact. For the PSA, at the £20,000 and £30,000 willingness-to-pay (WTP) thresholds,
INTRABEAM has the highest probability of being cost-effective, at 100% for both thresholds.
TABLE 21 Base-case results for the Carl Zeiss submission
Intervention Mean QALYs Mean cost (£) ICER vs. WB-EBRT (cost/QALY)
INTRABEAM 13.230 14,461 Dominates
WB-EBRT 13.223 20,926
Incremental 0.012 –6465
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Critique of the manufacturer’s submission
l The MS provides very limited information on model structure, baseline characteristics of the patient
population and setting.
l Limited information is provided with respect to input parameters such as costs and utilities. The MS is
not transparent in providing the methodology adopted to inform the input parameters.
l The method to derive costs of INTRABEAM is not clear.
l No rationale is provided for using the specific distributions assigned to the parameters.
l The method of extrapolation of local recurrence and survival data is not justified.
l The number of fractions for the WB-EBRT arm used in the model (23 fractions) is higher than UK
practice; this will lead to an overestimation of WB-EBRT costs.
l The manufacturer’s model assesses health benefit in terms of QALYs, which is a valid measure of
health in the UK NHS setting. The source study135 used standard gamble from a 1997 publication to
estimate utilities. No details were provided as to whether or not a systematic search was conducted to
identify utilities for the model.
l Model validation was not conducted; hence, the generalisability of model results remains questionable.
l Probabilistic sensitivity analysis was conducted for only 1000 simulations and no one-way or scenario
analyses were conducted. Limited sensitivity analyses conducted around the base-case model results
raise questions on the robustness of the model predictions.
l In summary, results of the MS model should be viewed with caution owing to the methodological and
reporting limitations outlined above.
Independent economic evaluation
Overview
We developed a new model to estimate the costs, benefits and cost-effectiveness of the INTRABEAM
Photon Radiotherapy System compared with WB-EBRT for early operable breast cancer.
The effects of the intervention on the clinical course of the disease are obtained from the TARGIT-A trial
included in the systematic review of clinical effectiveness (see Chapter 4). The patient population included
in the economic model reflects the patient population in the pre-pathology stratum of this trial. This is
because the TARGIT-A study recommends INTRABEAM concurrent with lumpectomy as an alternative
to post-operative WB-EBRT65 but does not recommend the use of post-operative INTRABEAM as an
alternative to WB-EBRT (as non-inferiority was not established in this stratum). Furthermore, use of the
pre-pathology stratum provides consistency with the manufacturer’s economic model, which is also based
on the results of the pre-pathology stratum.
The analysis takes the perspective of the NHS and PSS in the UK. The model adopts a lifetime (40-year)
horizon to estimate costs and benefits from each treatment. Future costs and benefits are discounted at
3.5% per annum as recommended by the UK Treasury.139 The outcome of the economic evaluation is
reported as the cost saved per QALY lost.
Methods for economic analysis
The model uses transition probabilities obtained from the clinical literature to simulate the progression
of early operable breast cancer in a cohort of patients and to estimate the cost-effectiveness of the
radiotherapy treatments under consideration. The model was constructed using the TreeAge Pro 2014
software (TreeAge Software, Inc., Williamstown, MA, USA). The model structure was informed by a review
of other published models of early breast cancer106,109,120,140–142 and the evidence available to inform disease
progression, which is drawn from the only existing RCT, the TARGIT-A trial65 (see Chapter 4).
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The model structure follows the disease pathway for early-stage breast cancer. It is slightly modified from
an economic model structure used in a previous HTA report to NICE140 in order to reflect the clinical
evidence available. The structure is also similar to the model structure adopted by Alvarado et al.106 in their
cost-effectiveness analysis of IORT. The SHTAC’s model uses six distinct health states: recurrence free, local
recurrence, disease free after local recurrence, any other recurrence, death from breast cancer, and death
from other causes (Figure 5). The local recurrence, disease free after local recurrence and any other
recurrence health states were chosen pragmatically in order to match the definitions and data supplied by
the TARGIT-A trial publication.65
Local recurrence is defined in the TARGIT-A trial as recurrence in the conserved breast while any other
recurrence incorporates regional recurrence (axilla plus supraclavicular), contralateral breast recurrence and
distant recurrence.65 The AG notes that regional recurrence, contralateral recurrence and distant recurrence
have very different prognoses and costs but they are not modelled separately as no data were available to
inform possible transitions to or from these health states.
Non-death health states are associated with a HRQoL utility and a cost estimate.
All patients start the model in the recurrence-free state and may then either stay in the recurrence-free
state, have a local recurrence and move to the local recurrence state, have another type of recurrence and
move to the any other recurrence state, or die from non-breast cancer causes. From the local recurrence
state, a patient may move to the disease free after local recurrence state, suffer any other recurrence or die
from other causes. A patient in the disease free after local recurrence state may remain either in this state,
suffer any other recurrence or die from other causes. From the any other recurrence state, it is possible to
die from breast cancer, die from other causes or stay in the state. The local recurrence state is temporary
and it is only possible to remain here for one cycle.
Recurrence free
Local recurrence
Disease free after
local recurrence
Any other
recurrence
Death from breast
cancer
Death from other
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FIGURE 5 Influence diagram for the SHTAC’s breast cancer cost-effectiveness model.
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Model cycle length is 1 year and a lifetime horizon of 40 years was adopted in the base case, which is
sufficiently long to capture all clinically and economically important events. A half-cycle correction
was applied.
The baseline disease progression parameters used in the model were obtained from the TARGIT-A trial
(see Chapter 4).65 These inform the annual probabilities of local recurrence, any other recurrence while
recurrence free, and death from breast cancer. Data from de Bock et al.143 were used to inform the
probability of any other recurrence given local recurrence at the suggestion of the advisory group. Data
from the Office for National Statistics (ONS) were used to inform the probability of all-cause mortality by
age.144 Parametric curves were fitted to Kaplan–Meier data in order to provide the probabilities of local
recurrence in both treatment arms.
The costs included in the model are those for initial radiation treatment and repeat lumpectomy and
mastectomy and reconstruction, with or without radiation treatment, at local recurrence. Full details of
the costs used in the model are given in Data sources.
The model includes the following assumptions:
l All patients enter the model in the recurrence-free state after initial BCS and radiation therapy.
l It is not possible to die from breast cancer while in the local recurrence state or the disease free after
local recurrence state. It is only possible to die from breast cancer while in the any other
recurrence state.
l Only one local recurrence is allowed; repeat local recurrence is not modelled.
l Death rates for non-breast cancer causes are based on mortality statistics for England and are applied
across all health states.
l The survival of patients with recurrence of any sort is assumed to be independent of the time
of recurrence.
A further simplification is that, owing to data limitations, the costs of post-progression therapies are not
included in the base case.
In each cycle, the total costs and QALYs are calculated by multiplying the individual costs and HRQoL of
each model state by the proportion of the model cohort in that state, for each of the radiotherapy types.
The total discounted lifetime costs and QALYs are calculated by aggregating the costs and QALYs for all
cycles. The ICER is calculated as:
ICER=
Cost of therapy B−cost of therapy A
QALYs of therapy B−QALYs of therapy A
, (1)
where convention therapy A is the current standard of care and therapy B is a new therapy. The associated
incremental net monetary benefit (NMB) of a specific treatment compared with a comparator may be
calculated as:
incremental NMB= incremental QALYsWTP− incremental costs, (2)
when the incremental QALYs and incremental costs are simply the denominator and numerator,
respectively, of equation (1) and WTP is the maximum amount a decision-maker is prepared to pay per
QALY gained.57 As long as the incremental NMB is more than zero, then a treatment is cost-effective and
larger NMBs represent greater cost-effectiveness than smaller NMBs.
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Model validation
The model was validated by checking the model structure, calculations and data inputs for correctness.
The structure was reviewed by clinical experts to establish that it was appropriate for the disease and its
treatment. Internal consistency was examined by varying input values and verification that any change
to the input values produced changes in the model outputs of the expected direction and magnitude.
A second modeller reproduced the model in Microsoft Excel and checked that the outputs were the same
as the TreeAge Pro implementation. To establish its external consistency, the model results were compared
with published outcomes of survival in early breast cancer.
Evaluation of uncertainty
The evaluation of the cost-effectiveness of radiotherapy treatment options for early operable breast cancer
is based on uncertain information that includes uncertainty about the clinical effects of treatment, HRQoL
while in the various health states, and resource use. Such uncertainty is examined using deterministic and
probabilistic sensitivity analyses.
One-way deterministic sensitivity analyses were conducted to test the robustness of the cost-effectiveness
results to variations in parameter input values when altered one at a time (see Results of independent
economic analysis).
Joint variation and potential correlation in multiple parameters was addressed using PSA (see Results of
independent economic analysis). In the PSA, probability distributions were assigned to the parameter point
estimates used in the base-case analysis. The model was then run for 10,000 iterations with parameter
values sampled at random from these distributions. The uncertainty surrounding the cost-effectiveness
of the treatments is represented on a cost-effectiveness acceptability curve (CEAC), which plots the
probability that an intervention will be cost-effective at a particular WTP threshold.
Scenario analysis was used to investigate the effect of uncertainty in model assumptions and structure.
Data sources
Recurrence-free state: probability of local recurrence
The baseline risk of local recurrence in the economic model is taken from the pre-pathology subgroup of
the TARGIT-A trial.65 The TARGIT-A trial was the only trial included in the review of clinical effectiveness
(see Chapter 4) and as such is the main source of evidence of the clinical efficacy of INTRABEAM.
Local recurrence probabilities in the pre-pathology substratum for INTRABEAM and WB-EBRT were
extracted from a Kaplan–Meier plot in the trial publication65 using the digitising software PlotDigitizer
(© 2000–14 Joseph A Huwaldt) and the method of survival curve reconstruction described in
Guyot et al.145 Parametric survival models were then fitted to the observed data using Stata software
version 11.0 (StataCorp LP, College Station, TX, USA) in order to extrapolate local recurrence beyond the
5 years reported.65 In line with the recommendation of Latimer146 all of the ‘standard’ parametric models
were considered (exponential, Weibull, Gompertz, log-logistic, log-normal).
Akaike information criterion (AIC) values obtained for each distribution are given in Table 22, which shows
that the log-normal, log-logistic and Weibull distributions provide the best fit to the data based on this
criterion. The Gompertz and exponential distributions fit the data less well. The log-normal and Weibull fits
are compared graphically with the 5 years of trial data in Figure 6. The log-logistic fit is similar to the
log-normal and is not considered further. Figure 6 demonstrates that the log-normal and Weibull fits are
similar over this time period. Figure 7 shows the behaviour of the log-normal and Weibull fits over the
model time horizon of 40 years and it can be seen that local recurrences continue to occur throughout the
time horizon with both models, but that the proportion with local recurrence after 40 years is much higher
under the Weibull model than under the log-normal model. Previous economic evaluations to NICE have
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TABLE 22 Values of AIC obtained for parametric survival models fitted to reconstructed local recurrence data from
TARGIT-A triala,65
Model AIC
Log-normal 213.0
Log-logistic 214.2
Weibull 214.2
Gompertz 217.6
Exponential 219.2
a Lower values of AIC indicate a better fit to the data.
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FIGURE 6 Kaplan–Meier plot of local recurrence in the pre-pathology subgroup of the TARGIT-A trial65 compared
with fitted log-normal and Weibull local recurrence curves.
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assumed that patients who have experienced an episode of early-stage breast cancer but are in remission
after 15 years will have the same risk of progression as the general population.140 However, clinical advice
to the AG is that the risk of local recurrence continues throughout life and is relatively linear over time.
Data on local recurrence at 9 years from the ELIOT trial,147 and the study of Kreike et al.,148 which follows
up BCS+ radiotherapy patients for 15 years, also suggest that risk of local recurrence does not decrease
over time.
The model adopts the log-normal curve in the base case. Not only is this a better fit by the AIC criterion,
but the rate of local recurrence does not increase as steeply over time as in Weibull model (see Figure 7;
see also Figure 6 for more detail of the first 5 years). This behaviour means that median survival is longer
under this model and, thus, it provides a better fit to other published data on survival after breast cancer
(see Model validation). Coefficients of the fitted log-normal regression model are given in Table 23.
Recurrence-free and local recurrence states: probability of any
other recurrence
The baseline risk of any other recurrence while in the recurrence-free state is taken from the pre-pathology
subgroup of the TARGIT-A trial.65 The 5-year probability of any other recurrence in the WB-EBRT
pre-pathology subgroup is given in the trial publication as 4.7%. The corresponding 5-year probability for
INTRABEAM is 4.8%.65 These probabilities are converted to 1-year probabilities for use in the economic
model to inform the transition from the recurrence free health state to the any other recurrence health
state (Table 23).
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FIGURE 7 Kaplan–Meier plot of local recurrence in the pre-pathology subgroup of the TARGIT-A trial65 compared
with fitted log-normal and Weibull local recurrence curves over 40 year time horizon.
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The probability of any other recurrence is higher for those who have already experienced a local recurrence
than for those who have not, but these more detailed data are not available from the TARGIT-A trial and
would not be robust owing to the low numbers in TARGIT-A with local recurrence.65 A previous HTA
submission to NICE140 uses the study of Kamby and Sengelov149 to inform a model transition from
locoregional relapse to metastatic disease. In this study, the proportion with distant disease was 72% at
10 years after locoregional relapse, giving a 1-year probability of distant disease of 0.1195 (see Table 23).
In an analysis of 3601 women enrolled in randomised trials and treated for early-stage breast cancer, de
Bock et al.143 report that, of 310 women who experience locoregional recurrence, 129 experienced distant
metastases after locoregional recurrence, at a median follow-up of 10.2 years. This broadly equates to a
1-year probability of distant disease given local recurrence of 0.0514. This probability is based on a much
bigger sample and is more recent than the study of Kamby and Sengelov.149 Consequently, the probability
of 0.0514 derived from de Bock et al.143 data is adopted for use in the economic model to inform the
transitions from the local recurrence and disease free after local recurrence health states to the any other
recurrence health state (see Table 23).
Probability of breast cancer death
In common with other economic models of early breast cancer, the SHTAC’s model assumes that all breast
cancer deaths occur from the ‘any other recurrence’ state, which includes metastatic cancer.120,140,142
Thus, in the model a breast cancer death is conditional on having had any other recurrence beforehand
(see Figure 5). The TARGIT-A trial ascribed a death to breast cancer if breast cancer was present at the
time of death.65 Consequently, it is possible that a small proportion of the breast cancer deaths observed
in the TARGIT-A trial occurred while a patient was experiencing local recurrence, before repeat surgery.
However, given the small numbers of likely deaths from the local recurrence state, which patients only
pass through for one model cycle, this is felt to be an acceptable modelling simplification.
TABLE 23 Summary of baseline disease progression parameters
Variable Values
Transition probability
per one year model
cycle Source
Log-normal model of time to local recurrence
WB-EBRT
Constant= 4.97,
sigma= 0.436
Varies through time Model fitted to KM data
in Vaidya 201465
β-coefficient for INTRABEAM in log-normal
model of time to local recurrence
–0.256 NA Model fitted to KM data
in Vaidya 201465
Probability of any other recurrence WB-EBRT
while recurrence free
0.047 (5 years) 0.0096 Vaidya 201465
Probability of any other recurrence
INTRABEAM while recurrence free
0.048 (5 years) 0.0098 Vaidya 201465
Probability of any other recurrence given
local recurrence
0.416 (10.2 years) 0.0514 de Bock et al.144
Probability of breast cancer death WB-EBRT 0.027 (5 years) 0.0055 Vaidya 201465
Probability of breast cancer
death INTRABEAM
0.033 (5 years) 0.0067 Vaidya 201465
Probability of breast cancer death given other
recurrence WB-EBRT
– 0.5698 Calculation
Probability of breast cancer death given other
recurrence INTRABEAM
– 0.6832 Calculation
Probability of non-breast cancer death Age dependent Varies through time ONS mortality tables145
NA, not applicable; KM, Kaplan–Meier.
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The model requires the probability that a patient in the ‘any other recurrence’ state dies from breast cancer
in a given cycle. The TARGIT-A trial publication reports both the probability of death from breast cancer
and the probability of any other recurrence, by treatment arm.65 Thus, with the model assumption that all
breast cancer deaths occur after ‘any other recurrence’, the 5-year probability of death from breast cancer,
given any other recurrence, can be calculated. For the WB-EBRT pre-pathology subgroup, this probability is
approximately given by 0.0055/0.0096 (= 0.5698, with no input data rounding), while for the INTRABEAM
pre-pathology subgroup the corresponding probability is approximately 0.0067/0.0098 (= 0.6832,
with no input data rounding) (see Table 23). Assuming that time to death after any other recurrence is
exponentially distributed, these probabilities correspond to a mean survival after any other recurrence of
around 21 months for WB-EBRT and 17.5 months for INTRABEAM.
Probability of non-breast cancer death
The general underlying risk of mortality was modelled using a cohort life table generated from the
2010–12 female interim life tables for England.144 The age-related mortality for each year in the model was
determined from these data using the demographic characteristics of breast cancer patients in England.
Specifically, in the base case, patients enter the model at an age of 62 years. This is the median age at
which breast cancer is diagnosed in females in England.150
In the model base case, the same probabilities of non-breast cancer death by age are used for both
treatment arms; however, the TARGIT-A trial publication notes a statistically significant difference in
non-breast cancer deaths between treatment arms, with fewer deaths in the INTRABEAM arm.65 These
data are based on a small number of events (12 non-breast cancer deaths on the INTRABEAM arm and
27 on the WB-EBRT arm). The TARGIT-A trial publication shows that the higher number of deaths on the
WB-EBRT arm is due to cardiovascular causes and other cancers and states that it is improbable that there
was a substantial imbalance in baseline comorbidities between the two randomised groups.65 The AG
notes, however, that patients on the WB-EBRT arm were slightly older at baseline.64 A mean age is not
supplied but the AG calculates a mean age of 62.5 years for the WB-EBRT arm and of 62 years for the
INTRABEAM arm, for all patients. (Ages at baseline for the pre-pathology stratum alone are not supplied.)
The AG has also compared the annual probabilities of death on the WB-EBRT arm with annual all-cause
mortality probabilities obtained from ONS data144 and found that they are similar. Therefore, the AG does
not consider that there is an excess of deaths on the WB-EBRT arm, but rather a shortfall of deaths on the
INTRABEAM arm, which is likely to have arisen owing to chance and/or the slightly younger mean age of
patients in this arm of the trial.
Therefore, the model does not adopt trial-observed non-breast cancer mortality data for use in the base
case, but they are examined in scenario analysis reported in Results of independent economic analysis.
Health-related quality of life
The systematic review of HRQoL identified nine studies that met the inclusion criteria (see Table 18).
Six of the included studies provide EQ-5D values for the ‘recurrence-free’ state in the economic model
(see Table 19).126–128,132,134 Two of these studies are US based,127,129 one is Swedish,132 one is German134
and two are UK based.126,128 Breast cancer treatment in other countries can differ from the UK and so a
UK-based study is preferable. However, one of the UK-based studies128 has a mean participant age of
approximately 72 years. This is 10 years older than the population under consideration here. Consequently,
the other UK study, the COMICE (comparative effectiveness of MRI in breast cancer) trial of Turnbull et al.,126
was selected as it provides EQ-5D values for younger patients after WLE.126 The COMICE trial was a
reasonably large RCT (1623 participants in two arms) of women with biopsy-proven primary breast cancer
scheduled for WLE and reports EQ-5D values at four time points. Participants had a mean age at
randomisation of 57 years. The time points of ‘8 weeks post randomisation’ and ‘12 months post initial
surgery’ were chosen from the no intervention arm of the trial for use in the recurrence-free state in the
model. These reflect utility in the first year after WLE and utility thereafter (Table 24).
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The Swedish study by Lidgren et al.132 identified in the systematic review of QoL provides EQ-5D estimates
for four states of breast cancer and uses the UK EQ-5D index tariff (see Table 19). A total of 52% of
participants in this study were aged 50–64 years and 22% were aged ≥ 65 years and, as such, it conforms
reasonably well to the population age in the SHTAC’s model. The study indicates that utilities in the first
year after local recurrence and in the second and following years, after both primary breast cancer and
local recurrence, are the same.132 Accordingly, the SHTAC’s model uses the same utility value from the
COMICE trial of 0.8112 for these three health states, as shown in Table 24.
The similarity of EQ-5D values across breast cancer health states is also reflected in the recent study in the
German population by Hildebrandt et al.134 which found the same median EQ-5D scores for primary disease,
metastatic disease and recurrent disease (see Table 19). A previous HTA report to NICE uses utilities valued
by either patients or clinical experts using time trade-off (TTO).140 This set of utilities is examined in scenario
analysis described in Results of independent economic analysis. It is not adopted in the base case as the
utilities were not valued by the general population and were not obtained via the EQ-5D.
It is assumed that utility while in the ‘any other recurrence’ health state is equivalent to utility for
metastatic disease. The Lidgren et al.132 study gives a utility of 0.685 for metastatic disease (see Table 19).132
This was adopted in the economic model as no utility for metastatic disease is given in the COMICE trial
publication.126 A utility for metastatic disease is given in Sherrill et al.,133 but this is based on an international
multicentre study of relatively young participants (median in pooled population approximately 52 years)151
and, therefore, does not appear to be as relevant to the model; however, the EQ-5D value of 0.66 is similar
to the value of 0.685 given in Lidgren et al.132 for this state (see Table 24). Alternative values are examined in
scenario analysis (see Results of independent economic analysis).
The systematic review of QoL identified two studies that give EQ-5D values for mastectomy and immediate
reconstruction.130,131 Conner-Spady et al.130 do not report the EQ-5D for mastectomy patients specifically.
Robertson et al.131 report a EQ-5D value of 0.83 for mastectomy and reconstruction at a median of 4 years’
follow-up, but an immediate post-operative value is not reported. The value of 0.83 is higher than the
utility given in the COMICE trial at the 12-month time point after WLE.126 This may reflect the lower mean
age of 50 years131 but, on the basis of this study, mastectomy and reconstruction does not appear to be
associated with disutility compared with WLE utility observed in the COMICE trial. Consequently, a
mastectomy disutility is not included in the base case, but is examined in scenario analysis described in
section Results of independent economic analysis.
In common with the manufacturer’s economic model and the IORT economic evaluation of Alvarado
et al.,106 the SHTAC’s model does not reflect any utility benefit associated with initial INTRABEAM
treatment. Given that the duration of WB-EBRT in England is 3 weeks, any utility benefit associated with
TABLE 24 European Quality of Life-5 Dimensions utility values by model health state
Model health state EQ-5D (SE) Source
Recurrence free in first year 0.7728 (0.0079) Turnbull et al.,126 no MRI arm at the 8-week post
randomisation time point
Recurrence free after first year 0.8112 (0.0072) Turnbull et al.,126 no MRI arm at the 12 months post initial
surgery time point
Local recurrence 0.8112 (0.0072) Turnbull et al.,126 no MRI arm at the 12 months post initial
surgery time point
Disease free after local recurrence 0.8112 (0.0072) Turnbull et al.,126 no MRI arm at the 12 months post initial
surgery time point
Any other recurrence 0.685 (0.0293) Lidgren et al.132
SE, standard error.
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the one-off INTRABEAM delivery is likely to be very small when considered within the annual model cycle
length. Any impact of treatment on HRQoL is assumed to occur because of its effect on disease
progression and this is already accounted for in the model.
A summary of the health state utility values used in the economic model base case is given in Table 24.
Resource use and costs
This section considers the resource use and costs associated with the clinical pathway of the
modelled population.
The proportion of INTRABEAM patients who also receive WB-EBRT is taken from the TARGIT-A trial,
in which 15.2% of INTRABEAM patients also received WB-EBRT (Table 25).65 The model assumes that
15 WB-EBRT deliveries are required to complete a course of treatment, as recommended in NICE Clinical
Guideline 80.11 Alternatives to this value are examined in deterministic sensitivity analysis (DSA) described
in Results of independent economic analysis.
In contrast to the manufacturer’s model, in which it is assumed that all INTRABEAM patients will undergo
repeat lumpectomy in the event of local recurrence, the SHTAC’s model assumes that only a minority of
INTRABEAM patients will undergo repeat lumpectomy on local recurrence. Clinical advice to the AG is that
the most common and evidence-based approach in the UK is to offer mastectomy for local recurrence and
that approximately 70–80% of patients opt for this. The SHTAC’s model assumes 80% in the base case
(see Table 25). All WB-EBRT patients are assumed to undergo mastectomy for local recurrence based on
clinical opinion from the advisory group and evidence-based clinical practice.
Clinical advice to the AG also indicates that well under 50% of patients who undergo mastectomy will
opt for reconstruction. This is borne out by figures obtained from the National Mastectomy and Breast
Reconstruction Audit,152 which shows that only around 31% of those undergoing mastectomy choose to
have a reconstruction (see Table 25).
The working lifetime of an INTRABEAM device is assumed to be 10 years in the base case (Table 26). This
value is informed by the manufacturer and radiotherapy expert opinion; an alternative value of 5 years is
examined in DSA described in Results of independent economic analysis.
TABLE 25 Model parameter values for clinical pathway
Parameter Units Value Source
Proportion of INTRABEAM patients who also
receive WB-EBRT
Proportion 0.152 Vaidya 201465
Number of WB-EBRT deliveries required to
complete a course of treatment
Deliveries 15 NICE Clinical Guideline 8011
Proportion of INTRABEAM patients having
mastectomy at local recurrence
Proportion 0.8 Clinical advice
Proportion of mastectomy patients who
have reconstruction
Proportion 0.31 National Mastectomy and Breast
Reconstruction Audit 2011152
TABLE 26 INTRABEAM device lifetime and resource-use assumptions in model base case
Parameter Units Value Source
Lifetime of INTRABEAM device Years 10 Carl Zeiss, UK
Proportion of INTRABEAM patients requiring radiation shield Proportion 1 AG assumption
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Use of INTRABEAM requires appropriate shielding from radiation. The manufacturer observes that radiation
protection shields are not required in all hospitals in England (J Richardson, NICE, 2014, personal
communication); however, the proportion of hospitals that would not need shields is unclear. The SHTAC’s
model base case therefore assumes that radiation shields are required in all cases (see Table 26) and
examines alternative values for this proportion in DSA.
The INTRABEAM device requires additional staff time both in support of the device and during its use.
Staff time is costed in the SHTAC’s economic model using the NHS staff pay bands of surgical consultant
and Agenda for Change bands 8b, 7 and 5. Hourly costs for each of these pay bands are taken from the
Personal Social Services Research Unit (PSSRU)’s Unit Costs of Health and Social Care 2013153 and are given
in Table 27.
The staff time required in support of INTRABEAM at each pay band is detailed in Table 28 by activity.
Radiotherapy and clinical expert opinion was used to identify these activities and estimate the staff time
required at each band. Two experts were consulted and the cost of each activity shown in Table 28 is
derived using the unit costs given in Table 27. It is assumed that operating procedure development and
initial INTRABEAM training are one-off costs which are incurred only once within the lifetime of each
device, that is, every 10 years in the base case. Technical commissioning and radiation protection refresher
training costs are assumed to be required on an annual basis. Expert advice to the AG is that technical
commissioning is required annually after annual maintenance by the manufacturer. All other costs are
incurred on a per treatment basis (see Table 28). Variation in these costs is considered in DSA described in
Results of independent economic analysis.
The costs of consumables required for INTRABEAM use, and the number of uses that each consumable
supports, are given in Table 29. Other costs used in the model are shown in Table 30. These include the
capital cost of each INTRABEAM device and its associated annual maintenance cost, provided by Carl Zeiss,
UK. Based on a capital cost of £435,000, a device lifetime of 10 years and a discount rate of 3.5% the
equivalent annual cost of INTRABEAM is £53,025 (see Table 30).
The INTRABEAM device use requires extra time in the operating theatre for both treatment planning and
delivery. The cost of 1 hour in theatre at Southampton General Hospital is £569.00 (see Table 30). This
cost includes nurse cost but does not include any medical staff or anaesthetist cost. Additional staff time in
the operating theatre for INTRABEAM device use is costed separately and given in Table 28.
TABLE 27 Staff unit costs per hour assumed by economic model
Staff band Unit cost per hour (£) Source
Surgical consultant 100.00 PSSRU’s Unit Costs of Health and Social Care 2013 (see table 15.6)153
AfC band 8b 73.00 Mean annual basic pay from PSSRU’s Unit Costs of Health and
Social Care 2013 (see table 17.3); overheads added as per other
staff unit cost derivations in PSSRU 2013153
AfC band 7 50.00 PSSRU’s Unit Costs of Health and Social Care 2013 (see table 14.1)153
AfC band 5 34.00 PSSRU’s Unit Costs of Health and Social Care 2013 (see table 14.3)153
AfC, Agenda for Change.
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TABLE 28 Additional staff resources required for use of INTRABEAM assumed by economic model
Frequency
of cost Activity
Number
of staff Staff band Time required Cost (£) Source
One off INTRABEAM operating
procedure development
1 7 2 daysa 757.00 Expert opinion
One off Initial INTRABEAM
training
4 7 2 daysa 5227.00 Expert opinion of
time/assumption for
number of staff
and band
2 8b
Annual Technical commissioning 2 7 3 daysa 2271.00 Expert opinion
Annual Technical commissioning
sign off
1 8b 0.5 daysa 275.00 Expert opinion
Annual Refresher training on
radiation protection
4 7 1 hour 920.00 Expert opinion of
time/assumption for
number of staff
and band
2 8b
5 5
4 Surgical
consultantb
Per treatment Pre-treatment QC check 1 7 30 minutes 25.00 Expert opinion
Per treatment Planning INTRABEAM
dose in operating theatre
2 Surgical
consultantb
6 minutes 25.00 Expert opinion/
TARGIT-A trial
1 7
Per treatment Delivering INTRABEAM
dose in operating theatre
1 Surgical
consultantb
33 minutes 83.00 Expert opinion/
TARGIT-A trial
1 7
Per treatment Additional time required
by medical physicist in
support of INTRABEAM
use
1 7 1.5 hours 76.00 Expert opinion
QC, quality control.
a Working day is 7.5 hours.
b Includes anaesthetist.
TABLE 29 Cost of consumables required for use of INTRABEAM
Description Cost per unit (£)
Number of
treatments Cost per treatment (£) Source
Spherical applicator 3170.00 100 31.70 Carl Zeiss,
UK
Radiation protection shields pack of 10 1041.00 5 208.20
Sterile plastic drapes pack of five 96.00 5 19.20
TABLE 30 Other costs used in model
Description Cost (£) Source
INTRABEAM device capital cost 435,000.00 Carl Zeiss, UK
Annual maintenance INTRABEAM device 35,000.00
INTRABEAM device equivalent annual cost
of capital and initial costs
53,025.00 Calculation from capital cost and one-off costs (see Table 28)
using device lifetime of 10 years and discount rate of 3.5%
Cost of 1 hour in operating theatrea 569.00 University Hospitals Southampton Finance Department
January 2014
a Includes nurse cost but does not include any medical staff or anaesthetist cost.
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Costs for mastectomy with and without reconstruction, WLE, and planning and delivery of WB-EBRT were
obtained as weighted averages from NHS Reference Costs 2012 to 2013136 and are given in Table 31 with
HRG codes.
Only serious adverse events of common terminology criteria grades 3 and 4 which occur in > 5% of
patients in any treatment arm are included in the economic model as these are considered to be those that
incur additional NHS costs. Moreover, adverse events are included only if the adverse event incidence
differs significantly between treatment arms, in line with the modelling guidelines of Philips et al.58 The
review of clinical effectiveness indicates that, although there are two statistically significant differences in
adverse event incidence between treatment arms (see Table 12), these occur in < 3% of patients.
Therefore, no costs for adverse events associated with INTRABEAM and WB-EBRT are included in the
economic model. This is consistent with the manufacturer’s model and the model of Alvarado et al.106
In order to avoid potentially confounding assumptions, the costs of post-progression therapies are not
included in the model base case. These costs are also not included in the manufacturer’s model (which has
no health state for any other recurrence) but are included in the IORT model of Alvarado et al.106 The AG
notes that, in order to accurately capture the costs of the ‘any other recurrence’ health state, it would be
necessary to know the proportions in this state with regional recurrence, contralateral breast recurrence
and distant recurrence as these types of recurrence are associated with very different costs. However, these
proportions are not given in the trial publication for the pre-pathology stratum.65 The advisory group notes
that INTRABEAM is associated with higher mortality from breast cancer than WB-EBRT and that this may
be because the proportions with each type of ‘any other recurrence’ differed between the treatment arms.
Without information on the proportions with each type of recurrence the AG does not consider that
it is appropriate to include post-progression costs in the base case. A scenario that does include
post-progression costs is given in Results of independent economic analysis.
TABLE 31 Weighted average unit costs of medical procedures assumed by economic model
HRG codes Description
Weighted
average
unit cost (£)
Weighted
average
lower
quartile (£)
Weighted
average
upper
quartile (£) Source
JA27Z, JA28Z Mastectomy with
reconstruction
7822.00 6169.00 9241.00 NHS Reference Costs
2012 to 2013136
JA24D, JA24E, JA24F WLE 1542.00 1185.00 1804.00 NHS Reference Costs
2012 to 2013136
JA20D, JA20E, JA20F Mastectomy 2510.00 2041.00 2850.00 NHS Reference Costs
2012 to 2013136
SC22Z, SC23Z Deliver a fraction of
radiotherapy on a
megavoltage machine
118.44 101.53 138.82 NHS Reference Costs
2012 to 2013136
SC45Z, SC46Z,
SC47Z, SC48Z
Preparation for
simple radiotherapy
323.65 198.08 413.75 NHS Reference Costs
2012 to 2013136
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Demand for the INTRABEAM device
In the base case, the SHTAC’s model assumes that the INTRABEAM device is deployed in a large district
hospital with a catchment population of 1,000,000. With approximately 41,523 incident breast cancer
cases in England in 20111 and an English population in 2011 of approximately 53.1 million (Table 32), the
expected number of breast cancer cases per year in a hospital catchment of this size is 782. Opinion
obtained from two clinical expert members of the advisory group differed as to the proportion of these
incident cases which might be suitable for treatment with INTRABEAM. One expert estimated 10–20% of
cases, while a second expert suggested up to 50%. A study by Leonardi et al.155 retrospectively applies the
American Society for Radiation Oncology consensus statement guidelines for the application of APBI156 to
participants in an intraoperative radiotherapy trial and finds that 16% of the patients would have been
considered suitable using these guidelines. This figure corresponds with the lower estimate provided by the
clinical experts and is adopted for use in the economic model base case. The alternative estimate of 50% is
examined in DSA described in Results of independent economic analysis.
With a hospital catchment of 1,000,000 and 16% of incident cases of breast cancer suitable for
INTRABEAM, 126 INTRABEAM procedures might be carried out per year. This is shown in Table 33.
Table 33 also shows how variations to the base-case assumptions of hospital catchment size and
INTRABEAM device lifetime affect the cost per INTRABEAM procedure. With a device lifetime of 10 years
and a hospital catchment population of one million, the cost per INTRABEAM procedure is £1882. At 100
procedures per year, as assumed in the manufacturer’s economic model, the cost per procedure is £2069
(see Table 33). This is similar to the cost used in the manufacturer’s economic model of £2165
per procedure.
With a 5-year equipment lifetime, the cost per INTRABEAM procedure rises to £2236 with base-case
assumptions (see Table 33). A 5-year device lifetime is examined in DSA described in Results of
independent economic analysis.
TABLE 33 Cost of INTRABEAM use per patient by population served and assumed device lifetime (from SHTAC’s
economic model)
Population served by one device
Calculated number of INTRABEAM
procedures per year
Calculated cost of INTRABEAM
procedure by lifetime of device (£)
10-year lifetime 5-year lifetime
795,000 100 2069 2514
1,000,000 126 1882 2236
5,000,000 631 1302 1373
TABLE 32 Base-case assumptions for INTRABEAM device demand
Parameter Units Value Source
Population served by one INTRABEAM device People 1,000,000 Advisory group assumption
Incident breast cancer cases in England 2011 People 41,523 ONS1
Population of England 2011 People 53,107,200 ONS154
Proportion of incident breast cancer cases which
are early breast cancer and suitable
for INTRABEAM
Proportion 0.16 Expert opinion from one or more
members of the advisory group and
Leonardi et al.155
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Model validation
The overall survival predictions from the model base case are compared with the trial-observed
Kaplan–Meier data for the pre-pathology subgroup in Figure 8. The model overall survival predictions in
Figure 8 were obtained using TARGIT-A trial data to model non-breast cancer death for the first five model
cycles and provide a good fit to the observed data. Data from the TARGIT-A trial show that overall survival
in the INTRABEAM treatment arm is somewhat better than overall survival in the WB-EBRT arm at 5 years,
and this is reflected in the model predictions (see Figure 8). The model thus appears to be performing
satisfactorily in this respect.
The model base case does not use trial-observed data for non-breast cancer death, for reasons given in
Data sources. Figure 9 gives the model predictions for overall survival in each of the treatment arms in the
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FIGURE 8 Kaplan–Meier plot of overall survival in the pre-pathology subgroup of the TARGIT-A trial65 compared
with overall survival predicted by the SHTAC’s economic model using TARGIT-A trial data to model non-breast
cancer death for first five cycles.
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FIGURE 9 Kaplan–Meier plot of overall survival in the pre-pathology subgroup of the TARGIT-A trial65 compared
with overall survival predicted by the SHTAC’s economic model using ONS mortality data to model non-breast
cancer death in all cycles.
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pre-pathology subgroup when only ONS mortality data are used to model non-breast cancer death. Figure 9
shows that, when using these data, predicted overall survival in the INTRABEAM treatment arm is worse than
observed in the trial, although the overall survival prediction for the WB-EBRT arm is still a good fit. This is to
be expected because ONS age-specific all-cause mortality rates are higher than the non-breast cancer mortality
rates seen on the INTRABEAM arm in the TARGIT-A trial. The model predictions change in reflection of these
differences (compare Figure 8 with Figure 9) and so, again, the model appears to be working satisfactorily.
It may be seen from Figures 8 and 9 that median overall survival predicted by the model base case for early
operable breast cancer patients is approximately 21.5 years and that overall survival is approximately 56%
at 20 years. Relative survival at 20 years is 82% and at 25 years is 77%. Relative survival compares the
survival of people with the cancer to that of people without cancer in order to help correct for deaths from
things other than breast cancer. Exact comparison with other data sources is difficult; however, the SEER
(Surveillance, Epidemiology, and End Results) database of the US National Cancer Institute has 20-year
relative survival of 64.7% in breast cancer patients aged ≥ 50 years diagnosed between 1985 and 1989.157
Figures from Cancer Research UK for England and Wales indicate that relative survival from breast cancer
at 20 years is 64.5%.158 Thus, the relative survival of 82% at 20 years given by the model is somewhat
higher than these estimates, but this is to be expected as treatment has improved in the 25 or so years
since the patients on whom these estimates are based were diagnosed.
Relative survival compares the survival of people with the cancer to that of people without cancer in order
to help correct for deaths from things other than breast cancer. Thus, it is reasonable that the overall
survival of 56% in the model is lower than these published estimates of relative survival because it does
reflect deaths from other causes.
Results of independent economic analysis
This section reports the cost-effectiveness of INTRABEAM compared with WB-EBRT in a cohort of early
operable breast cancer patients. Base-case discounted cost-effectiveness summary results are given in
Table 34 and are broken down by health state in Table 35. Results with no discounting of costs and
outcomes are given in Table 36. INTRABEAM is less expensive but also less effective than WB-EBRT as it
has lower total costs but also fewer total QALYs. Therefore, the ICERs given in Tables 34 and 36 represent
the money saved per QALY lost that is associated with replacing WB-EBRT by INTRABEAM.
In situations in which a new intervention (INTRABEAM) is both less costly and less effective than the
current standard of care (WB-EBRT), the ICER for INTRABEAM to replace WB-EBRT must lie above the usual
NICE cost-effectiveness thresholds of £20,000 and £30,000 per QALY if INTRABEAM is to be considered a
cost-effective alternative to WB-EBRT. However, the ICER value of £1596 saved per QALY lost, shown in
Table 34, indicates that WB-EBRT is the cost-effective treatment option within the WTP threshold of
£20,000 per QALY. Over the 40-year time horizon of the model, it is associated with more QALYs at
broadly similar overall cost. WB-EBRT is also cost-effective in the undiscounted analysis in which
incremental QALYs are nearly twice those seen in the discounted results and the ICER (£ saved/QALY lost)
is smaller (see Table 36).
TABLE 34 Base-case discounted cost-effectiveness results
Intervention Total costs (£) Total LYG Total QALYs
Incremental
cost (£)
Incremental
QALYs
ICER (£ saved/
QALY lost)
WB-EBRT 2368.00 20.72 11.329 – – –
INTRABEAM 2227.00 20.51 11.241 –140.00 –0.088 1596a
LYG, life-years gained.
a INTRABEAM is both cheaper and less clinically effective than WB-EBRT; therefore, the ICER represents the £ saved per
QALY lost associated with replacing WB-EBRT with INTRABEAM.
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Sensitivity analysis
Deterministic and probabilistic sensitivity analyses were conducted in order to investigate the effect of
uncertainty in model parameter values on the cost-effectiveness results. DSA was used to highlight the
most influential parameters while the effect of uncertainty and interaction in multiple parameters was
examined using PSA. Scenario analysis was used to investigate the effect of uncertainty in model
assumptions and structure.
Each parameter was assumed to follow a probability distribution and these are given, with the distribution
parameters, in Table 37. For beta distributions, the distribution parameters were fitted using either the
method of moments or information on the sample size and number of events when available. Distribution
parameters were fitted to the gamma distributions using the method of moments. In cases for which a
standard error (SE) or standard deviation (SD) was not supplied in the source literature, the SE was
calculated using an arbitrary ± 20% from the base-case value. Correlation between the parameters of the
log-normal distribution used to inform time to local recurrence was incorporated by sampling from a
multivariate normal distribution with covariance matrix as specified in Table 37.
TABLE 35 Base-case discounted total costs and QALYs by health state
Health state
WB-EBRT INTRABEAM
Total costs (£) Total QALYs Total costs (£) Total QALYs
Recurrence free 2100 10.760 1882 10.551
Local recurrence 268 0.052 345 0.069
Disease free after local recurrence 0 0.348 0 0.469
Any other recurrence 0 0.169 0 0.152
Dead background mortality 0 0 0 0
Dead breast cancer 0 0 0 0
Total 2368 11.329 2227 11.241
TABLE 36 Base-case undiscounted cost-effectiveness results
Intervention Total costs (£) Total LYG Total QALYs
Incremental
cost (£)
Incremental
QALYs
ICER (£ saved/
QALY lost)
WB-EBRT 2522 20.72 16.743 – – –
INTRABEAM 2346 20.51 16.576 –177 –0.167 1062a
LYG, life-years gained.
a INTRABEAM is both cheaper and less effective than WB-EBRT; therefore, the ICER represents the £ saved per QALY lost
associated with replacing WB-EBRT with INTRABEAM.
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TABLE 37 Parameters, distributions and associated upper and lower values used in probabilistic and DSA
Parameter Distribution
Distribution
parameters
Mean/base
case
2.5th
percentile
for mean
97.5th
percentile
for mean
Costs
INTRABEAM commissioninga Gamma α= 96.04; β= 26.51 £2546 £2062 £3080
One WB-EBRT delivery Gamma α= 18.36; β= 6.45 £118 £71 £178
WB-EBRT planning Gamma α= 4.10; β= 78.97 £324 £90 £704
INTRABEAM setup costsa Gamma α= 96.04; β= 62.31 £5984 £4847 £7239
Mastectomy and reconstruction Gamma α= 99.63; β= 78.51 £7822 £6362 £9431
Mastectomy Gamma α= 147.71; β= 16.99 £2510 £2122 £2931
One hour in operating theatrea Gamma α= 96.04; β= 5.92 £569 £461 £688
Pre-treatment QC INTRABEAMa Gamma α= 96.04; β= 0.26 £25 £20 £31
Staff time per hour in theatre
during INTRABEAM deliverya
Gamma α= 96.04; β= 1.57 £150 £122 £182
Staff time per hour in theatre
during INTRABEAM planninga
Gamma α= 96.04; β= 2.61 £250 £203 £303
Annual staff training in
radiation protectiona
Gamma α= 96.04; β= 9.58 £920 £745 £1113
Staff time in support of
INTRABEAM deliverya
Gamma α= 96.04; β= 0.79 £76 £61 £92
Repeat lumpectomy Gamma α= 95.55; β= 16.13 £1542 £1248 £1866
Survival curve parameters
Time to local recurrence Multivariate normalb
β(treatment arm) Covariance matrix
0.081
–0.077 0.531
–0.008 0.131 0.035
–0.256 –0.815 0.307
Constant 4.97 3.553 6.383
Sigma 0.436 0.072 0.797
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TABLE 37 Parameters, distributions and associated upper and lower values used in probabilistic
and DSA (continued )
Parameter Distribution
Distribution
parameters
Mean/base
case
2.5th
percentile
for mean
97.5th
percentile
for mean
Probabilities
Other recurrence INTRABEAM
from recurrence free (5 years)
Beta α= 19.1; β= 378 0.048 0.029 0.071
Other recurrence WB-EBRT from
recurrence free (5 years)
Beta α= 16.7; β= 337.9 0.047 0.028 0.071
Other recurrence after local
recurrence (10.2 years)
Beta α= 129; β= 181 0.416 0.362 0.471
INTRABEAM patient receives
WB-EBRT
Beta α= 239; β= 1332 0.152 0.135 0.170
Mastectomy patient has
reconstruction
Beta α= 5120; β= 11365 0.311 0.304 0.318
INTRABEAM patient has
mastectomy at local recurrencea
Beta α= 18.4; β= 4.6 0.800 0.618 0.933
INTRABEAM patient dies from
breast cancer (5 years)
Beta α= 10.6; β= 310.8 0.033 0.016 0.055
WB-EBRT patient dies from
breast cancer (5 years)
Beta α= 11.3; β= 407.8 0.027 0.014 0.045
Incident breast cancer patients
suitable for INTRABEAMa
Beta α= 294; β= 1528 0.161 0.145 0.179
Resource use
INTRABEAM delivery timea Normal Mean= 33; SE= 3.37 33 26.40 39.60
INTRABEAM planning timea Normal Mean= 6; SE= 0.61 6 4.80 7.20
Utilities
Recurrence free after the
first year
Beta α= 2400; β= 558.5 0.811 0.8 0.83
Recurrence free in the first year Beta α= 2161; β= 635.3 0.773 0.76 0.79
Other recurrence Beta α= 171; β= 78.7 0.685 0.63 0.74
Other
Catchment population served by
one INTRABEAM devicea
Normal Mean= 1,000,000;
SE= 102,041
1,000,000 800,004 1,199,996
QC, quality control.
a Distribution calculated after arbitrary ± 20% variation applied to mean to obtain SE.
b On log scale.
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The model parameters were varied in DSA between the 2.5th and 97.5th percentiles of the assumed
parameter distribution of the mean value and these are given in Table 37. Table 38 gives upper and lower
bounds for parameters examined in DSA when these are different from the upper and lower bounds
examined in PSA.
Deterministic sensitivity analysis
Table 39 shows the results of the deterministic sensitivity analyses for INTRABEAM compared with
WB-EBRT for the most influential parameters. A tornado diagram depicting the range in incremental NMB
given in this table is given in Figure 10. A complete set of DSA results is given in Appendix 10.
TABLE 38 Lower and upper parameter values examined in DSA (when different from 2.5th and 97.5th percentiles
given in Table 37)
Parameter Base case Lower value Upper value
Proportion of incident breast cancer patients suitable for INTRABEAM 0.16 0.1 0.5
Fractions of WB-EBRT required to complete a course of treatment 15 5 23
Lifetime of INTRABEAM device (years) 10 5 10
Proportion of INTRABEAM patients requiring radiation shield 1 0.25 1
Age of cohort entering model (years) 62 55 72
Discount rate for costs (%) 3.5 0.0 6.0
Discount rate for health (%) 3.5 0.0 6.0
TABLE 39 Key DSA results for INTRABEAM compared with WB-EBRT. WTP set to £20,000 per QALY
Variable description
Low
value
High
value
Low value
incremental
NMB (£)
High value
incremental
NMB (£)
Range
(£)
5-year probability of any other
recurrence INTRABEAM
0.029 0.071 5781 –9171 14,952
5-year probability of any other
recurrence WB-EBRT
0.028 0.071 –8760 5977 14,737
Beta coefficient for INTRABEAM arm
time to local recurrence
–0.815 0.307 –4512 118 4630
5-year probability of death from
breast cancer WB-EBRT
0.014 0.045 –4150 –346 3804
5-year probability of death from
breast cancer INTRABEAM
0.016 0.055 1051 –2518 3569
Constant (time to local recurrence) 3.553 6.383 –3367 –836 2531
Discount rate for utilities (%) 0 6 –3192 –1042 2150
Number of WB-EBRT deliveries
required in course of treatment
5 23 –2604 –832 1772
Starting age of model cohort (years) 55 72 –2273 –757 1516
Cost of delivering one fraction
WB-EBRT (£)
71 178 –2211 –877 1334
Proportion of incident cases which are
suitable for INTRABEAM
0.1 0.5 –2064 –1128 936
Sigma (time to local recurrence) 0.072 0.797 –1110 –2018 908
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The incremental NMB rather than the ICER is used in Table 39 and Figure 10 as the ICER for INTRABEAM
compared with WB-EBRT is sometimes negative (Figure 11) and incremental NMB has a more
straightforward interpretation. A WTP of £20,000 and equation (2) (see Methods for economic analysis)
were used to calculate the incremental NMB.
Table 39 and Figure 10 compare INTRABEAM incrementally with WB-EBRT in order to be consistent with the
base case (see Table 34). Thus, a negative incremental NMB indicates that INTRABEAM is not cost-effective
compared with WB-EBRT (or, conversely, that WB-EBRT is cost-effective compared with INTRABEAM).
A positive incremental NMB indicates that INTRABEAM is cost-effective compared with WB-EBRT (or,
conversely, that WB-EBRT is not cost-effective compared with INTRABEAM).
The results show that the incremental NMB is, above all, very sensitive to the probability of any other
recurrence, which is assumed for both WB-EBRT and INTRABEAM as there is a very wide difference in the
incremental NMB between the low and high values of these parameters. The differences lead to a switch
in which treatment is considered cost-effective at a WTP threshold of £20,000 per QALY. At a low
probability of any other recurrence on the INTRABEAM arm, INTRABEAM is cost-effective compared with
WB-EBRT at a WTP of £20,000 (shown by positive incremental NMB in Table 39). At high probability of
any other recurrence on the INTRABEAM arm, WB-EBRT is a cost-effective treatment option at the £20,000
per QALY WTP threshold (shown by negative incremental NMB in Table 39). With low probability of any
other recurrence on the WB-EBRT arm, WB-EBRT is a cost-effective treatment option compared with
INTRABEAM at the £20,000 per QALY WTP threshold, but this is reversed with high probability of any
5-year probability of other
recurrence INTRABEAM
5-year probability of other
recurrence WB-EBRT
5-year probability of death
from breast cancer WB-EBRT
5-year probability of death
from breast cancer INTRABEAM
Constant (time to local 
recurrence) to local recurrence
Beta coefficient for INTRABEAM 
arm time to local recurrence
Discount rate for utilities
Starting age of model cohort
Number of WB-EBRT deliveries
required in course of treatment
Cost of delivering one fraction
WB-EBRT
Proportion of incident cases
which are suitable for 
INTRABEAM
Sigma (time to local 
recurrence) to local recurrence
–10 –5
Incremental NMB between
upper and lower parameter bounds (£000)
0 5 10
FIGURE 10 Tornado diagram showing key results of DSA for INTRABEAM vs. WB-EBRT. Bars indicate spread in
incremental NMB between upper and lower parameter bounds (£). WTP set to £20,000 per QALY.
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other recurrence on the WB-EBRT arm, that is, INTRABEAM becomes cost-effective at the £20,000 per
QALY WTP threshold (see Table 39).
The model is also somewhat sensitive to the probability of death from breast cancer on the INTRABEAM
arm and, again, this difference leads to a switch in which treatment is considered cost-effective at a WTP
threshold of £20,000 per QALY. At low values for probability of death from breast cancer on the
INTRABEAM arm, INTRABEAM is cost-effective at a WTP of £20,000 per QALY, but it is not cost-effective
compared with WB-EBRT at high values for probability of death from breast cancer on the INTRABEAM
arm (see Table 39).
Change in which treatment is considered cost-effective at a WTP threshold of £20,000 per QALY also
occurs between the low and high parameter values considered for the beta coefficient for the INTRABEAM
arm in the log-normal model of time to local recurrence (see Table 39). At low values of this coefficient,
WB-EBRT is cost-effective compared with INTRABEAM but at the highest values considered, INTRABEAM
becomes slightly more cost-effective than WB-EBRT.
In summary, the results of the DSA indicate that there is a degree of uncertainty surrounding the base-case
results. In the case of four parameters, the difference between upper and lower values results in a switch
in the treatment option, which is considered cost-effective at a WTP of £20,000 per QALY.
Probabilistic sensitivity analysis
A total of 10,000 PSA simulations were run, and the mean results for these simulations are presented in
Table 40 and are similar to results for the base case given in Table 34. The scatterplot for cost and health
outcomes is shown in Figure 11 and, similar to the DSA findings, indicates considerable uncertainty in the
results. There are many points in the north-west quadrant of Figure 11, which demonstrates that in a large
number of the PSA simulations INTRABEAM is less effective than WB-EBRT, as well as being more costly.
Conversely, in many of the PSA simulations WB-EBRT is more effective and cheaper than INTRABEAM,
shown by the large number of points in the south-east quadrant of Figure 11.
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FIGURE 11 Scatterplot of the costs and health benefits from PSA: INTRABEAM compared with WB-EBRT.
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The CEAC calculated from the PSA simulations is given in Figure 12 and indicates that at the £20,000 WTP
threshold WB-EBRT has the highest probability (61.3%) of being cost-effective. WB-EBRT also has the
highest probability of being cost-effective (61.4%) at a WTP of £30,000 per QALY. INTRABEAM has a
higher probability of being cost-effective than WB-EBRT at WTP thresholds of around £5000 per QALY or
less (see Figure 12).
Scenario analysis
In addition to the sensitivity analyses, five scenarios were examined to investigate the uncertainty
surrounding the structural assumptions made by the model.
Trial-observed non-breast cancer mortality data The model base case uses ONS all-cause mortality
tables to give the probability of non-breast cancer death. As an alternative to using ONS data in all model
cycles, the use of non-breast cancer mortality data from the TARGIT-A trial was examined. A Weibull fit to
TARGIT-A Kaplan–Meier data65 was used to obtain trial-observed non-breast cancer mortality probabilities
for the first five model cycles. ONS mortality data were used thereafter. INTRABEAM dominates WB-EBRT
in this scenario, as it is associated with lower total costs and greater total QALYs (Table 41).
TABLE 40 Baseline PSA cost-effectiveness results
Intervention Total costs (£) Total LYG Total QALYs
Incremental
cost (£)
Incremental
QALYs
ICER (£ saved/
QALY lost)
WB-EBRT 2398 20.73 11.327 – – –
INTRABEAM 2272 20.52 11.240 –126 –0.087 1447a
LYG, life-years gained.
a INTRABEAM is both cheaper and less effective than WB-EBRT; therefore, the ICER represents the £ saved per QALY lost
associated with replacing WB-EBRT with INTRABEAM.
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FIGURE 12 Cost-effectiveness acceptability curve from the PSA.
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Population served by one device The manufacturer’s model assumes that 100 patients are treated
with INTRABEAM each year in a district general hospital (P Pinilla-Dominguez, NICE, 2014, personal
communication). To replicate this assumption in the SHTAC’s model requires a corresponding assumption
about the typical catchment population of a hospital offering INTRABEAM. In the base case, the SHTAC’s
model assumes that the catchment population is one million, which implies 126 INTRABEAM procedures a
year (see Table 33). A catchment population of 795,000 is required to give 100 INTRABEAM procedures
a year. Results using this catchment population are given in Table 42. The table shows that INTRABEAM is
now dominated by WB-EBRT as it is associated with slightly higher total cost, but fewer QALYs.
Mastectomy disutility The manufacturer’s model uses a utility of 0.87 for lumpectomy at local recurrence
and a utility of 0.82 for mastectomy. These figures imply a disutility for mastectomy of 0.05. The AG
considers that it is unclear from the literature if mastectomy is associated with significant disutility to
HRQoL as measured with EQ-5D.160,161 A scenario analysis was conducted to examine the effect of a
mastectomy disutility of 0.05 on model outcomes. In the SHTAC’s model it is assumed that this disutility is
a weighted average of the disutilities associated with mastectomy and mastectomy and reconstruction.
The results are given in Tables 43 and 44. Table 43 shows results obtained when it is assumed that the
mastectomy utility decrement applies to both the local recurrence and disease free after local recurrence
health states; Table 44 shows the results obtained when it is assumed that the mastectomy utility
TABLE 41 Cost-effectiveness results using trial-observed non-breast cancer mortality data for first five model cycles
Intervention Total costs (£) Total LYG Total QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£/QALY)
WB-EBRT 2366 20.58 11.259 – – –
INTRABEAM 2234 20.83 11.425 –132 0.166 Dominating
LYG, life-years gained.
TABLE 43 Cost-effectiveness results using a utility decrement of 0.05 for mastectomy (applied to local recurrence
and disease free after local recurrence health states)
Intervention Total costs (£) Total LYG Total QALYs
Incremental
cost (£)
Incremental
QALYs
ICER (£ saved/
QALY lost)
WB-EBRT 2368 20.72 11.304 – – –
INTRABEAM 2227 20.51 11.214 –140 –0.090 1563a
LYG, life-years gained.
a INTRABEAM is both cheaper and less effective than WB-EBRT; therefore, the ICER represents the £saved per QALY lost
associated with replacing WB-EBRT with INTRABEAM.
TABLE 42 Cost-effectiveness results using a population served by one INTRABEAM device of 795,000
Intervention Total costs (£) Total LYG Total QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£/QALY)
WB-EBRT 2368 20.72 11.329 – – –
INTRABEAM 2414 20.51 11.241 47 –0.088 Dominated
LYG, life-years gained.
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decrement applies to the local recurrence health state only. Applying the utility decrement to both the
local recurrence and disease free after local recurrence health states has more impact on final ICER than
applying the decrement to the local recurrence state alone, but in neither case does the utility decrement
make an appreciable difference to model outcome. The ICER decreases by less than £50 per QALY
compared with the base case (see Table 34).
The decrease in ICER compared with the base case indicates that WB-EBRT becomes more cost-effective
than INTRABEAM in this scenario. Although in the base case a smaller proportion of INTRABEAM patients
undergo mastectomy for local recurrence (80% compared with 100% for WB-EBRT), more INTRABEAM
patients experience a local recurrence. The net effect is that the total mastectomy utility decrement is
greater on the INTRABEAM arm and, consequently, the incremental QALYs associated with WB-EBRT are
slightly higher than in the base case.
Alternative set of health state utilities The health state utilities used in the model base case are
the same in the local recurrence health state and the recurrence-free health state after the first year
(see Table 24). Although these utilities are based on the studies of Lidgren et al.132 and Turnbull et al.,126
it is arguably not appropriate that these two health states should have the same utility. Their identical
values may arise because EQ-5D is not a particularly sensitive instrument to use when examining QoL in
early breast cancer patients as found, for example, by Hildebrandt et al.134 An alternative set of health state
utility values used in a previous HTA report to NICE was examined.140 These were valued by either patients
or clinical experts using the TTO and are given in Table 45.
The results for the scenario are given in Table 46. These show that, although total QALYs decline in both
treatment arms with use of the alternative utility set, the incremental QALYs do not change appreciably
from the base case. Thus, the overall ICER is very similar to the base case: £1517 saved per QALY lost,
compared with £1596 in the base case (see Table 34).
TABLE 44 Cost-effectiveness results using a utility decrement of 0.05 for mastectomy (applied to local recurrence
health state only)
Intervention Total costs (£) Total LYG Total QALYs
Incremental
cost (£)
Incremental
QALYs
ICER (£ saved/
QALY lost)
WB-EBRT 2368 20.72 11.326 – – –
INTRABEAM 2227 20.51 11.238 –47 –0.088 1592a
LYG, life-year gained.
a INTRABEAM is both cheaper and less effective than WB-EBRT; therefore, the ICER represents the £ saved per QALY lost
associated with replacing WB-EBRT with INTRABEAM.
TABLE 45 Alternative health state utility values examined in scenario analysis
Health state Utility value Source
Recurrence free 0.78 Hind et al.140
Local recurrence 0.61
Disease free after local recurrence 0.71
Any other recurrence 0.42
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Costs post progression The base case does not include costs of treatment after any other recurrence
because of lack of information on the types of recurrence within this category. The trial publication reports
the proportions with regional recurrence (1.1% INTRABEAM compared with 0.9% WB-EBRT) and distant
recurrence (3.9% INTRABEAM compared with 3.2% WB-EBRT) for all patients, but does not give these
data for the pre-pathology stratum.65 However, the costs of treating these types of recurrence are quite
different.140 Using costs given in the HTA report of Hind et al.,140 inflated to 2013 using the Hospital and
Community Health Services prices index,153 the AG calculated the annual cost of metastatic disease (active
treatment and supportive care) as £12,122 and the cost of end-of-life care for a breast cancer patient as
£3669. In contrast, the costs of contralateral disease are more similar to those incurred at local recurrence.140
For illustrative purposes, the AG has considered a scenario in which 60% of recurrences in the ‘any other
recurrence’ health state are assumed to be distant recurrences and where mortality following any other
recurrence is the same in both treatment arms (using the probability for WB-EBRT in the base case; see
Table 23). This assumption is necessary because trial data show that mortality following any other recurrence
is higher for INTRABEAM and, consequently, including costs for this state without such adjustment would
simply result in additional incremental cost for WB-EBRT (as WB-EBRT patients live longer in this state). A
figure of 60% with distant recurrence was estimated based on data given in the TARGIT-A publication for all
patients and data in the literature.140 The costs of distant recurrence are the major costs in the any other
recurrence health state and as a simplification costs for the types of recurrence in this category were not
considered. Using the costs given above for distant recurrence and end-of-life care, the results shown in
Table 47 were obtained. Health state costs for this scenario are given in Table 48.
TABLE 46 Cost-effectiveness results using alternative set of health state utilities from Hind et al.140
Intervention Total costs (£) Total LYG Total QALYs
Incremental
cost (£)
Incremental
QALYs
ICER (£ saved/
QALY lost)
WB-EBRT 2368 20.72 10.812 – – –
INTRABEAM 2227 20.51 10.719 –140 –0.093 1517a
LYG, life-years gained.
a INTRABEAM is both cheaper and less effective than WB-EBRT; therefore, the ICER represents the £ saved per QALY lost
associated with replacing WB-EBRT with INTRABEAM.
TABLE 47 Illustrative cost-effectiveness results using post-progression costs
Intervention Total costs (£) Total LYG Total QALYs
Incremental
cost (£)
Incremental
QALYs
ICER (£ saved/
QALY lost)
WB-EBRT 4652 20.72 11.329 – – –
INTRABEAM 4662 20.51 11.268 –10 –0.061 157a
LYG, life-years gained.
a INTRABEAM is both cheaper and less effective than WB-EBRT; therefore, the ICER represents the £ saved per QALY lost
associated with replacing WB-EBRT with INTRABEAM.
TABLE 48 Costs by health state including post-progression costs
Health state WB-EBRT total costs (£) INTRABEAM total costs (£)
Recurrence free 2100 1882
Local recurrence 268 345
Disease free after local recurrence 0 0
Any other recurrence 1795 1897
Dead background mortality 0 0
Dead breast cancer 499 527
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Table 47 shows that the base-case conclusion does not change when post-progression costs for distant
disease and end-of-life care are considered, that is, INTRABEAM is not cost-effective compared with WB-EBRT
at a WTP threshold of £20,000 per QALY. However, the cost saving associated with replacing WB-EBRT with
INTRABEAM is much smaller as the ICER is reduced from £1596 saved per QALY lost in the base case to £157
saved per QALY lost in the scenario. INTRABEAM is only £10 less expensive than WB-EBRT per patient over
the 40-year time horizon considered in the model.
Discussion
INTRABEAM is less expensive but also less effective than WB-EBRT as it is associated with lower total costs
but fewer total QALYs. The base case ICER for replacing WB-EBRT with INTRABEAM is £1596 saved per
QALY lost (this represents the money saved per QALY lost that is associated with replacing WB-EBRT by
INTRABEAM). INTRABEAM is therefore not cost-effective compared with WB-EBRT at the WTP threshold of
£20,000 per QALY as the cost saved per QALY lost is less than £20,000.
The CEAC calculated from PSA indicates that at the £20,000 WTP threshold WB-EBRT has a greater
probability than INTRABEAM of being cost-effective, at 61.3%. WB-EBRT also has the highest probability
of being cost-effective (61.4%) at a WTP of £30,000 per QALY.
The base-case result is subject to a degree of uncertainty as the disease progression parameters included in the
model are largely drawn from the TARGIT-A trial.65 As discussed in Chapter 4, Assessment of effectiveness, and
Chapter 7, Statement of principal findings and Strengths and limitations of the assessment, this trial has
relatively short follow-up. The numbers experiencing local recurrence in the pre-pathology stratum, which is
used to inform the economic model, are also quite small. Results of DSA show that the base-case finding that
INTRABEAM is not cost-effective at a WTP of £20,000 per QALY compared with WB-EBRT would be reversed if
the probability of experiencing any other recurrence on the INTRABEAM arm was at the low end of its likely
range, or if the probability of death from breast cancer on the INTRABEAM arm was at the low end of its
likely range.
A strength of the economic model is that it is based on data identified from systematic searches for clinical
effectiveness, cost-effectiveness and QoL evidence. Other strengths are that QoL/health state utility weights
are taken from studies using the EQ-5D and valued using the UK general population tariff, and that a
transparent approach was taken to costing the use of INTRABEAM per procedure by considering all
elements of the cost base.
Possible weaknesses of the model are that the systematic review of QoL did not find EQ-5D values to
populate all of the model health states and that the clinical effectiveness data used to inform disease
progression in the model are drawn largely from one study which has a relatively short follow-up time.64,65
This study also has a small number of events for the primary outcome in the pre-pathology stratum and
the base-case results are therefore subject to some uncertainty. Owing to data limitations, the model does
not include costs for the any other recurrence health state in the base case.
Comparison of the economic models
A key structural difference between the Carl Zeiss economic model and the SHTAC’s model is that the
Zeiss model has four health states while the SHTAC’s model has six. The SHTAC’s model includes an
additional (temporary) health state at local recurrence and also an ‘any other recurrence’ health state
which includes metastatic disease. A further structural difference is that the Zeiss model uses an
exponential assumption to extrapolate trial local recurrence data over the time horizon of the model, while
the SHTAC’s model assumes a log-normal fit to these data. The Zeiss model is run over a 10-year time
horizon rather than the 40-year horizon used in the SHTAC’s model.
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Different cost and utility data were also used. The Zeiss model uses expert opinion to inform the cost of
each INTRABEAM procedure while the SHTAC’s model uses a microcosting approach. The Zeiss model
assumes that at local recurrence all INTRABEAM patients have salvage lumpectomy and that all WB-EBRT
patients have salvage mastectomy. The cost of salvage mastectomy in the Zeiss model appears to include
the cost of breast reconstruction for all patients. In contrast, the SHTAC’s model considers that most
INTRABEAM patients will have mastectomy at local recurrence and that of patients having mastectomy,
not all of them will have reconstruction.
Utilities used in the Zeiss model were obtained via standard gamble and were not obtained from the
general population. Utilities used in the SHTAC’s model were obtained using the EQ-5D and valued with
the UK tariff.
ECONOMIC ANALYSIS
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Chapter 6 Assessment of factors relevant to the
NHS and other parties
The report ‘Radiotherapy Services in England 2012’161 states that there are currently 265 linear acceleratorsoperating in the UK/England across 58 sites, with new sites planned. Breast cancer accounted for 28% of
radiotherapy services activity for the year 2011/2012. To meet projected increases in the need for radiotherapy
(owing to cancers in an ageing population) it has been estimated that 412 linear accelerators will be
required by 2016. In contrast, as noted in Chapter 1, Description of technology under assessment, just eight
INTRABEAM devices are known to have been purchased (four in London and one each in Winchester, Dundee,
Liverpool and Harlow) for use in the NHS, with a further 10 NHS trusts expressing an interest in purchasing
the device. Therefore, there would be a need for significant investment in INTRABEAM equipment if this
technology were to be available across the NHS. Furthermore, in addition to the investment in equipment there
would also need to be investment in staff training both for surgeons, physicists, oncologists and radiographers.
Advice from the advisory group for this assessment indicated that theatre capacity is also a consideration.
The additional time needed in theatre to administer INTRABEAM therapy could add to pressure on breast
clinics, especially if they already find it difficult to meet waiting time targets. However, in centres where
lymph node analysis is already undertaken intraoperatively using the RD-100i OSNA system (Sysmex Europe
GmbH, Norderstedt, Germany) (currently 22 in use in the UK; see Chapter 1, Current service provision),
INTRABEAM therapy could be delivered and completed within this time and, therefore, would have less
impact on theatre time.
As noted above, breast cancer currently accounts for about 28% of activity across radiotherapy centres. How
much radiotherapy resource could be freed up by increased use of INTRABEAM therapy depends in part on the
proportion of patients who would be eligible for INTRABEAM treatment. In the AG’s independent economic
model (see Chapter 5, Data sources, Demand for INTRABEAM), the proportion of incident cases of early breast
cancer suitable for INTRABEAM therapy is estimated at 16%. If this were the case, breast cancer would then
account for about 24% of radiotherapy centre activity, a drop of 4%. However, it should be remembered that
the actual drop would be likely to be lower than this for two reasons. First, after INTRABEAM treatment some
patients may be found to have tumours with unfavourable features that put them at high risk of recurrence, in
which case they would receive WB-EBRT in addition. Second, some patients will experience recurrence and,
depending on their preference and extent of disease at recurrence, may opt for local excision and WB-EBRT.
In the future, radiotherapy resources may also be freed up if the current 3-week WB-EBRT treatment schedule
can be shortened. For example, a clinical trial, the FAST-Forward non-inferiority RCT162 is currently testing a
1-week (5-fraction) course of WB-EBRT to see if it is as effective and as safe as the current UK 15-fraction
standard. The estimated publication date for this HTA-funded trial is 2021. If this trial demonstrates that a
1-week course of WB-EBRT is as effective and safe in this patient group, then adoption of this shortened
radiotherapy regimen would have a larger impact on radiotherapy resources than the introduction of
INTRABEAM. The ability to identify a subset of women who could safely be treated without receiving WB-EBRT
might also free up radiotherapy resources in the future.
From the patient perspective, INTRABEAM therapy may be viewed as an attractive option because the
standard 15 fraction course of WB-EBRT would be avoided for the majority of those eligible for
INTRABEAM treatment. The benefits of this include a reduction in the disruption to work and family life
both in terms of time (for travel as well as for treatment) and costs (e.g. travel, parking, loss of earnings)
which may be significant particularly for those who live farthest from a radiotherapy centre and for those
at the lower end of the income spectrum.
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Chapter 7 Discussion
Statement of principal findings
l One international, multicentre, non-inferiority RCT64,65 was included in the systematic review of clinical
effectiveness. It examined IORT using the INTRABEAM device compared with conventional WB-EBRT
and was judged to be at a low risk of bias.
l Participants could be randomised to INTRABEAM or WB-EBRT prior to surgery to remove the tumour
(pre-pathology stratum) or could receive surgery to remove the tumour and be randomised into the
trial after surgery providing initial histopathology showed no adverse criteria (post-pathology stratum).
Participants in either stratum who were randomised to INTRABEAM and subsequently found to have
unfavourable pathological features also received WB-EBRT (i.e. INTRABEAM+WB-EBRT).
l The primary outcome of the RCT was local recurrence in the conserved breast. The pre-stated
non-inferiority margin was an absolute difference of 2.5% between groups. Non-inferiority of
INTRABEAM compared with WB-EBRT was demonstrated for the whole trial population and for the
pre-pathology stratum. However, non-inferiority was not established for the post-pathology stratum for
which the absolute difference in the 5-year local recurrence exceeded the pre-defined non-inferiority
margin of 2.5%. In considering these results it should be remembered that the median follow-up of
the total trial population was 2 years 5 months and 1222 (35%) had reached a median follow-up
of 5 years.
l Overall survival was a secondary outcome of the RCT. Differences between the groups in overall
mortality and for breast cancer mortality were not statistically significant for the whole trial population,
the pre-pathology stratum or the post-pathology stratum. In contrast, the analysis of non-breast cancer
deaths showed that there were significantly fewer non-breast cancer deaths in the INTRABEAM group
compared with the WB-EBRT group in the whole trial population and when the pre-pathology stratum
was analysed separately. In the post-pathology stratum, there was no statistically significant difference
in non-breast cancer mortality between the groups.
l For participants in the pre-pathology stratum, treatment with INTRABEAM resulted in a 1% increase in
local recurrence but this was counterbalanced with a potential 2.3% decrease in overall mortality.
l Clinically significant complications reported to differ statistically significantly between the groups were
wound seroma requiring more than three aspirations, which occurred more frequently in the INTRABEAM
group, and RTOG toxicity score of grade 3 or 4, which was less frequent in the INTRABEAM group. Early
complications and complications arising 6 months after randomisation appeared similar between
the groups.
l Limited information was available from one substudy undertaken by one trial centre on QoL.63
Approximately 2.5% of the total trial population were involved in this study, which did not identify any
statistically significant differences in QoL measures [EORTC QLQ-C30 (version 3) and the QLQ-BR23]
between the study arms.
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Cost-effectiveness
l The systematic review identified two relevant economic evaluations,106,108 both of which were based on
the TARGIT-A trial. Both studies were associated with a number of limitations.
l Alvarado et al.106 developed a Markov decision-analytic model with six health states. Costs and benefits
were discounted at 3%, costs were expressed in US$ and the price year was 2011. INTRABEAM was
found to be associated with less cost and greater QALYs than WB-EBRT.
l Shah et al.108 analysed cost-effectiveness through reimbursement models and conducted a
cost-minimisation analysis. Methods and assumptions were based on previously published articles. The
authors concluded that although INTRABEAM represented a potential cost-saving alternative, WB-EBRT
represented a cost-effective modality compared with INTRABEAM based on cost per QALY analyses
when additional medical costs and non-medical costs associated with INTRABEAM were factored in.
l Both studies were based in the USA and adopted a societal perspective and are, therefore, not
generalisable to the UK NHS.
l The time horizon was 10 years in one study106 and not clearly stated in the other study108 (but assumed
to be 10 years based on the estimation of mean utility), which is inappropriate as the risk of local
recurrence continues over a lifetime.
l Alvarado et al.106 used a standard 33 fractions of WB-EBRT in their model, which is more than the
current standard UK practice of 15 fractions and will lead to an overestimation of WB-EBRT costs.
The number of fractions of WB-EBRT was not reported by Shah et al.108
l The quality of utility data used in both the studies is questionable. The source study119 was a
publication dated 1998, and more recent data would have been appropriate, such as those identified
in Chapter 5, Southampton Health Technology Assessments Centre’s systematic review of health-related
quality-of-life studies.
Quality of life
l The systematic review on HRQoL studies was conducted with an aim to identify utility data for the
SHTAC’s independent model. Nine studies were identified, which were diverse with respect to their
aims, interventions, comparators, study designs and methodologies. When assessing the studies on
the basis of their relevance to the NICE reference case, only three met all of the criteria (details in
Appendix 8).126,128,132
l The studies provide a source of EQ-5D data for five of the seven health states identified a priori as
being potentially relevant for the SHTAC’s independent model. EQ-5D data were not identified for the
health states WLE+ INTRABEAM or WLE+ INTABEAM+WB-EBRT.
Manufacturer’s submission
l The MS evaluated the cost-effectiveness of INTRABEAM in early breast cancer patients when compared
with radiotherapy usually given in the UK over 3–6 weeks as WB-EBRT. The total costs, QALYs gained
and cost-effectiveness associated with the intervention and comparator under consideration in the
appraisal were reported. A multistate Markov model consisting of four health states was constructed.
The analysis was conducted for a time period of 20 years with an annual cycle length. The perspective
was that of the NHS and benefits and costs were discounted at 3.5%.
l The base-case results indicate that INTABEAM is associated with greater QALYs and lower costs than
WB-EBRT. One-way sensitivity analyses and scenario analyses were not conducted. PSA found that at
the £20,000 and £30,000 WTP thresholds, INTRABEAM has the highest probability of being cost-effective,
at 100% for both thresholds.
l Limited information on the model structure and input parameters is provided in the MS and the AG
has raised a number of concerns regarding the methods used; as a consequence the results of the MS
model should be viewed with caution.
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Southampton Health Technology Assessments Centre’s model
l INTRABEAM is less expensive but less effective than WB-EBRT. The base-case ICER for replacing
WB-EBRT with INTRABEAM is £1596 saved per QALY lost. INTRABEAM is, therefore, not cost-effective
compared with WB-EBRT at the WTP threshold of £20,000 per QALY.
l At the £20,000 WTP threshold WB-EBRT has a greater probability than INTRABEAM of being
cost-effective, at 61.3%. WB-EBRT also has the highest probability of being cost-effective (61.4%) at a
WTP of £30,000 per QALY.
l The base-case result is subject to a degree of uncertainty. For four model parameters, the difference in
their upper and lower values causes a switch in the treatment option, which is considered cost-effective
at a WTP of £20,000 per QALY. Model outcomes are particularly sensitive to the probability of any
other recurrence.
l Alternative model health state utility values examined in scenario analysis do not substantively change
the base-case findings. Other scenario analyses show that INTRABEAM is dominated by WB-EBRT if it is
assumed to serve a smaller catchment population than the base case, and that INTRABEAM dominates
WB-EBRT if trial-observed mortality data are used for the first five model cycles.
Strengths and limitations of the assessment
This assessment has the following strengths:
l The systematic reviews and economic evaluation have been carried out independently of any vested
interest and the results are presented in a consistent and transparent manner.
l The systematic reviews have been undertaken following established methodology and principles for
conducting a systematic review. The methods used were set out in a research protocol, which defined
the research question in line with the NICE scope, and set out the inclusion and quality assessment
criteria, data extraction process and the other methods to be employed during the evidence synthesis.
l An advisory group has informed the review from its initiation. The research protocol was informed by
comments received from the advisory group and the advisory group also commented on a draft of the
final report.
l A de novo economic model has been developed following recognised guidelines and the model
structure and data inputs are clearly presented in this report. The main results have been summarised
and presented. This should facilitate replication and testing of our model assumptions.
l The economic model is based on data identified from systematic searches for clinical effectiveness,
cost-effectiveness and QoL evidence.
l The QoL/health state utility weights used in the economic model are taken from studies using the
EQ-5D and valued using the UK general population tariff.
l A transparent approach was taken to costing the use of INTRABEAM per procedure by considering all
elements of the cost base.
l The model is validated against external data.
In contrast, this assessment also has certain limitations:
l Only one RCT has been published that met the inclusion criteria for the review.
l The length of follow-up in the published reports of the included trial may be inadequate.
l The economic model is based on estimates of efficacy from the included trial, which may have
inadequate follow-up.
l The systematic review of QoL did not find EQ-5D values to populate all of the model health states.
l The economic model does not include any costs for the ‘any other recurrence’ health state in the base
case owing to limitations in the evidence base.
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Uncertainties
l The TARGIT-A trial was a non-inferiority RCT with ITT results presented. An extension to the CONSORT
statement77 for non-inferiority trials states that there would be greater confidence in the results of a
non-inferiority trial if both ITT and non-ITT (per-protocol) results were presented and shown to be
consistent with one another. As no per-protocol analysis was presented it is not known whether or not
the results of such an analysis would confirm the findings of the ITT analysis.
l In the WB-EBRT arm of the TARGIT-A trial, centres were allowed to stipulate local policy for the delivery
of WB-EBRT and, therefore, there would have been some differences between WB-EBRT delivered at
different centres, for example, in dose delivered or quality control. The impact of these differences is
unknown however it seems unlikely that variations in WB-EBRT as delivered in non-UK TARGIT-A trial
centres and the standard UK radiotherapy schedule (40 Gy in 15 fractions over 3 weeks11) would have
an impact on results. Evidence from the UK-based START-B trial163 which was recruiting patients with
operable early invasive breast cancer at a similar time to TARGIT-A compared a radiotherapy schedule
of 50 Gy in 25 fractions over 5 weeks with 40 Gy in 15 fractions over 3 weeks. After a median
follow-up of 6 years, START-B showed that 5-year local-regional relapse from a 40 Gy in a 15-fraction
schedule (2.2%, 95% CI 1.3% to 3.1%) were as least as favourable as the 50 Gy in a 25-fraction
schedule (3.3%, 95% CI 2.2% to 4.5%). A potentially more important consideration is the possibility
of variable quality control of WB-EBRT between centres. The TARGIT-A trial protocol69 voiced the
expectation that all trial investigators would be working to local or national standards conforming to
international guidelines for quality assurance and thus no trial-specific quality control measures were
put in place.
l Some key estimates of clinical efficacy used in the economic model have wide CIs. Base-case results are
therefore subject to a degree of uncertainty, which stems from uncertainty in the evidence base. For a
few parameters [probability of any other recurrence assumed for WB-EBRT and INTRABEAM, the beta
coefficient for the time to local recurrence (INTRABEAM) and the probability of death from breast
cancer (INTRABEAM)] the cost-effectiveness findings are reversed when values at the upper and lower
bounds of the appropriate CI are considered.
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Chapter 8 Conclusions
Implications for service provision
There are only eight INTRABEAM devices currently available in the NHS. Therefore, there would be a need
for significant investment in INTRABEAM equipment and in staff training for surgeons and physicists if
this technology were to be available across the NHS. As indicated in Chapter 6, there is likely to be an
impact on theatre capacity. If the use of INTRABEAM reduces the number of operations that can be
completed in a given time, this could increase waiting list times, especially for centres that already find it
difficult to meet waiting time targets.
Suggested research priorities
The evidence base for the use of INTRABEAM for the adjuvant treatment of early-stage breast cancer is
limited to one RCT, the TARGIT-A trial, which has reported on outcomes after a median follow-up of
2 years and 5 months. The population enrolled in the trial has a low risk of local recurrence and of
mortality and, therefore, there is scope for uncertainty about whether or not the results observed to date
will hold over the longer term. To increase confidence in the results, longer-term follow-up data from
the TARGIT-A trial are required. Future analyses should report the numbers experiencing each type of
recurrence within the ‘any other recurrence’ category. ‘Any other recurrence’ included regional recurrence,
contralateral breast recurrence and distance recurrence which have very different prognoses and contribute
to the slightly higher breast cancer mortality associated with INTRABEAM. The economic model is very
sensitive to this.
To address the effectiveness of INTRABEAM in a wider range of patients, analysis from other trials and
analysis of registry data will be needed when sufficient data with an appropriate length of follow-up have
been accrued [ongoing currently: one RCT (TARGIT-B),100,101 one prospective single-arm study (TARGIT-E)102
and three registry database studies,103–105 see Chapter 4, Ongoing studies].
Further HRQoL data are desirable. A very limited quantity has been published from the TARGIT-A trial and
it is not clear whether or not HRQoL outcome data will be available for the whole trial population in
the future.
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Appendix 1 Search dates and example MEDLINE
search strategies for clinical effectiveness,
cost-effectiveness and health-related quality of life
Databases searched for the systematic reviews of clinical effectiveness, cost-effectiveness and HRQoL arepresented below. Searches were updated in March 2014.
Database searched (host)
Clinical effectiveness
searches
Cost effectiveness and
QoL searches
Cochrane Central, Cochrane CDSR, Cochrane DARE,
Cochrane HTA, and Cochrane Methods (The
Cochrane Library)
All available years to
19 March 2014
Cochrane Central, Cochrane DARE, Cochrane
Economic Evaluations, and Cochrane Methods
(The Cochrane Library)
All available years to
18 March 2014 (QoL) and to
19 March 2014 (cost)
CRD databases: DARE, HTA and NHS EED (CRD) All available years to
19 March 2014
All available years to
18 March 2014 (both)
CPCI – Science (Web of Science) All available years to
19 March 2014
All available years to
18 March 2014 (both)
Cost-effectiveness analysis registry
(Tufts Medical Center)
Searched to 19 March 2014 (cost)
EMBASE (via Ovid) All available years to
19 March 2014
All available years to
18 March 2014 (both)
MEDLINE(R) (via Ovid) All available years to
19 March 2014
All available years to
18 March 2014 (both)
MEDLINE(R) In-Process & Other Non-Indexed
Citations (via Ovid)
Searched to 19 March 2014 Searched to 18 March 2014 (both)
SCIE (Web of Science) 1995 to 19 March 2014 1970 to 18 March 2014 (both)
ScienceDirect.com Searched 19 March 2014 (cost)
BIOSIS Previews (Web of Science) 1995 to 19 March 2014 All available years to
18 March 2014 (both)
Zetoc (via Mimas) Searched to 19 March 2014 (cost)
Searched for ongoing trials (all searched on 25 March 2014)
NIHR Clinical Research Network (NIHR CRN Portfolio, formally UKCRN website)
Controlled-trials.com
ClinicalTrials.gov
WHO ICTRP
American Society of Clinical Oncology (ASCO)
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Example search strategies
Clinical effectiveness
1. exp Breast Neoplasms/
2. Carcinoma, Intraductal, Noninfiltrating/
3. (“ductal carcinoma* in situ” or DCIS).tw.
4. (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal* or infiltrat* or intraductal* or lobular or medullary or malignan*.tw.
5. (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma*
or dcis or ductal* or infiltrat* or intraductal* or lobular or medullary or malignan*)).tw.
6. exp “Neoplasms, Ductal, Lobular, and Medullary”/
7. (breast or mammar*).tw.
8. 6 and 7
9. or/1-5,8
10. intrabeam*.af.
11. Radiosurgery/ or radiosurg*.tw.
12. Radiotherapy, Adjuvant/
13. (radiother* or irradiat* or radiat* or xray or “x-ray”).tw.
14. or/12-13
15. “during surg*”.tw.
16. “radio* guided surg*”.tw.
17. (intraoperativ* or “intra operativ”).tw.
18. (“single dose” or “single fraction*”).tw.
19. or/15-18
20. 14 and 19
21. IORT.tw.
22. (intraoperativ* adj5 radiotherap*).tw.
23. TARGIT*.tw.
24. “tumo?r bed”.tw.
25. (boost* or target*).tw.
26. 13 and 24 and 25
27. 9 and (10 or 11 or 20 or 21 or 22 or 23 or 26)
28. Randomized Controlled Trials as Topic/
29. randomized controlled trial.pt.
30. controlled clinical trial.pt.
31. Controlled Clinical Trial/
32. placebos/
33. random allocation/
34. Double-Blind Method/
35. Single-Blind Method/
36. (random* adj2 allocat*).tw.
37. placebo*.tw.
38. ((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).tw.
39. crossover studies/
40. (crossover* or (cross adj over*)).tw.
41. Research Design/
42. ((random* or control*) adj5 (trial* or stud*)).tw.
43. Clinical Trials as Topic/
44. random*.ab.
45. or/28-44
46. 27 and 45
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Cost-effectiveness
1. exp Breast Neoplasms/
2. Carcinoma, Intraductal, Noninfiltrating/
3. (“ductal carcinoma* in situ” or DCIS).tw.
4. (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal* or infiltrat* or intraductal* or lobular or medullary or malignan*)).tw.
5. (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma*
or dcis or ductal* or infiltrat* or intraductal* or lobular or medullary or malignan*)).tw.
6. exp “Neoplasms, Ductal, Lobular, and Medullary”/
7. (breast or mammar*).tw.
8. 6 and 7
9. or/1-5,8
10. intrabeam*.af.
11. Radiosurgery/ or radiosurg*.tw.
12. Radiotherapy, Adjuvant/
13. (radiother* or irradiat* or radiat* or xray or “x-ray”).tw.
14. or/12-13
15. “during surg*”.tw.
16. “radio* guided surg*”.tw.
17. (intraoperativ* or “intra operativ”).tw.
18. (“single dose” or “single fraction*”).tw.
19. or/15-18
20. 14 and 19
21. IORT.tw.
22. (intraoperativ* adj5 radiotherap*).tw.
23. TARGIT*.tw.
24. “tumo?r bed”.tw.
25. (boost* or target*).tw.
26. 13 and 24 and 25
27. 9 and (10 or 11 or 20 or 21 or 22 or 23 or 26)
28. exp economics/
29. exp economics hospital/
30. exp economics pharmaceutical/
31. exp economics nursing/
32. exp economics medical/
33. exp “Costs and Cost Analysis”/
34. Cost Benefit Analysis/
35. exp models economic/
36. exp fees/ and charges/
37. exp budgets/
38. (economic* or cost or costs or costly or costing or price or prices or pricing
or pharmacoeconomic*).tw.
39. (value adj1 money).tw.
40. budget$.tw.
41. or/28-40
42. ((energy or oxygen) adj cost).tw.
43. (metabolic adj cost).tw.
44. ((energy or oxygen) adj expenditure).tw.
45. or/42-44
46. 41 not 45
47. (letter or editorial or comment or historical article).pt.
48. 46 not 47
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49. 27 and 48
Lines 50–54 added to strategy on 25/09/2013. Nothing extra found as a consequence.
50. accelerated partial breast irradiation.mp. 430
51. APBI.tw. 266
52. 50 or 51
53. 48 and 52
54. 53 not 49
Health-related quality of life
1. exp Breast Neoplasms/
2. (breast* adj3 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal* or infiltrat* or intraductal* or lobular or medullary or malignan*)).tw.
3. (mammar* adj3 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma*
or dcis or ductal* or infiltrat* or intraductal* or lobular or medullary or malignan*)).tw.
4. or/1-3
5. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirstysix or
shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,ab.
6. (euroqol or euro qol or eq5d or eq 5d).ti,ab.
7. (hui or hui1 or hui2 or hui3).ti,ab.
8. (health adj3 utilit$ ind$).mp.
9. “EORTC QLQ-BR23”.tw.
10. “FACT-B”.tw.
11. “Functional Assessment of Cancer Therapy Breast”.tw.
12. “BCQ”.tw.
13. “breast cancer chemotherapy questionnaire”.tw.
14. or/5-13
15. 4 and 14
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Appendix 2 Excluded clinical effectiveness studies
with rationale
Excluded study
Primary reason for
exclusion (comment)
Andersen KG, Gartner R, Kroman N, Flyger H, Kehlet H. Persistent pain after targeted
intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer:
a randomized trial. Breast J 2012;21:46–9
Outcome (substudy)
Andersen KG, Gartner R, Kroman N, Flyger H, Kehlet H. Persistent pain after targeted
intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer –
a randomized trial. Eur J Cancer 2011;47:S388
Abstracta
TARGIT-B: An international randomised controlled trial to compare targeted
intra-operative radiotherapy boost with conventional external beam radiotherapy boost
after lumpectomy for breast cancer in women with a high risk of local recurrence.
URL: www.nets.nihr.ac.uk/projects/hta/1010407 (accessed 25 March 2014)
Ongoing (no data yet)
Baum M, Joseph DJ, Tobias JS, Wenz FK, Keshtgar MR, Alvarado M, et al. Safety and
efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first
report of a randomized controlled trial at 10-years maximum follow-up. J Clin Oncol
2010;28(Suppl. Abstract LBA517):18
Abstracta
Baum M, Vaidya JS, Tobias JS, Keshtgar M, Williams NR, Wenz F, et al. Targit (targeted
intra-operative radiotherapy for early stage breast cancer): Results from the targit a
randomized controlled trial. Eur J Cancer Supplement 2010;8:19
Abstracta
Drago S, Ciabattoni A, Piccirillo R, Bellotti A, Cresti R, Ciccone V, et al. Intraoperative
radiation boost in early breast cancer: initial results of a randomized trial. Breast Cancer
Res Treat 2004;88:S172
Intervention (abstract)
Engel D, Schnitzer A, Brade J, Blank E, Wenz F, Suetterlin M, et al. Are mammographic
changes in the tumor bed more pronounced after intraoperative radiotherapy for breast
cancer? Subgroup analysis from a randomized trial (TARGIT-A). Breast J 2013;19:92–5
Outcomesa
HAYES Inc. Intraoperative Radiation Therapy (IORT) for breast cancer. CRD Database
Structured abstract. URL: www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?
AccessionNumber=32012000152&UserID=0 (accessed 25 September 2013)
Design
Holmes DR, Baum M, Joseph D. The TARGIT trial: targeted intraoperative radiation
therapy versus conventional postoperative whole-breast radiotherapy after
breast-conserving surgery for the management of early-stage invasive breast cancer
(a trial update). Am J Surg 2007;194:507–10
Abstracta
Joseph DJ. Targit. Radiother Oncol 2012;103:S4 Abstracta
Keshtgar M, Vaidya J, Tobias J, Williams N, Baum M. TARGIT (Targeted intra-operative
radiotherapy for early stage breast cancer): early results from the multi-centre
randomized controlled trial. Eur J Surg Oncol 2010;36:1098
Abstracta
Keshtgar M, Williams N, Corica T, Saunders C, Joseph D, Bulsara M. Cosmetic outcome
after targit compared with external beam radiotherapy for early breast cancer. Radiother
Oncol 2011;99:S251
Abstracta
Keshtgar M, Williams N, Corica T, Saunders C, Joseph D, Bulsara M. Cosmetic outcome
one, two, three and four years after intra-operative radiotherapy compared with external
beam radiotherapy for early breast cancer: an objective assessment of patients from a
randomised controlled trial. Breast 2011;20:S63
Abstracta
Keshtgar M, Williams N, Corica T, Saunders C, Joseph D. Better cosmetic outcome after
intraoperative radiotherapy compared with external beam radiotherapy for early breast
cancer: objective assessment of patients from a randomized controlled trial. Ann Surg
Oncol 2010;17:S178
Abstracta
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Excluded study
Primary reason for
exclusion (comment)
Keshtgar M, Williams N, Corica T, Saunders C, Joseph D. Cosmetic outcome one,
two and three years after intra-operative radiotherapy compared with external beam
radiotherapy for early breast cancer: An objective assessment of patients from a
randomised controlled trial. Eur J Surg Oncol 2010;36:1105
Abstracta
Keshtgar M, Williams N, Corica T, Saunders C, Joseph D. Significantly better cosmetic
outcome after intraoperative radiotherapy compared with external beam radiotherapy for
early breast cancer: objective assessment of patients from a randomized controlled trial.
Ann Surg Oncol 2011;18:S171
Abstracta
Keshtgar M, Williams NR, Corica T, Bulsara M, Saunders C, Flyger H, et al. An objective
assessment of cosmetic outcome after intraoperative radiotherapy or external beam
radiotherapy for early breast cancer in patients from a randomized controlled trial.
Eur J Cancer 2013;49:S450
Abstracta
Keshtgar M, Williams NR, Corica T, Hedges R, Saunders C, Joseph D. Early evidence of
better cosmetic outcome after intra-operative radiotherapy compared with external beam
radiotherapy for early breast cancer: Objective assessment of patients from a randomised
controlled trial. Ann Surg Oncol 2010;17:S13
Abstracta
Keshtgar M, Williams NR, Corica T, Saunders C, Bulsara M, Joseph D. Improved cosmetic
outcome after TARGIT compared with external beam radiotherapy for early breast cancer.
Eur J Cancer 2012;48:S186–7
Abstracta
Keshtgar MR, Williams NR, Bulsara M, Saunders C, Flyger H, Cardoso JS, et al. Objective
assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast
cancer: results from a randomised controlled trial. Breast Cancer Res Treat
2013;140:519–25
Outcome (substudy)a
Keshtgar MR, Williams NR, Corica T, Bulsara M, Saunders C, Flyger H, et al. Cosmetic
outcome after intraoperative radiotherapy or external beam radiotherapy for early breast
cancer: an objective assessment of patients from a randomized controlled trial. J Clin
Oncol 2013;31:(Suppl.; abstract 1110)
Abstracta
Keshtgar MR, Williams NR, Corica T, Bulsara M, Saunders C, Flyger H, et al. Cosmetic
outcome after intraoperative radiotherapy or external beam radiotherapy for early breast
cancer: an objective assessment of patients from a randomized controlled trial. J Clin
Oncol 2013;15:1110
Abstracta
Keshtgar MR, Williams NR, Corica T, Saunders C, Bulsara M, Joseph D. Cosmetic outcome
one, two, three, and four years after intra-operative radiotherapy compared with external
beam radiotherapy for treatment of early breast cancer: An objective assessment of
patients from a randomized controlled trial. Int J Radiat Oncol Biol Physics 2011;81:S225
Abstracta
Keshtgar MR, Williams NR, Corica T, Saunders C, Joseph DJ, Bulsara M. Cosmetic outcome
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Methodological comments
l Allocation to treatment groups: described in detail in the paper reporting initial results.64 Randomisation
schedules were generated centrally by computer and kept securely in two centres (Perth for Australian
centres, London for all other centres). Requests for randomisation were made (before lumpectomy65)
via telephone or fax to one of the two centres where patient eligibility was checked. Treatment was
allocated from a pre-printed randomisation schedule available to authorised staff only. Patients were
randomly assigned in a 1 : 1 ratio with blocks stratified by centre and by timing of delivery of TARGeted
Intraoperative radioTherapy (TARGIT) therapy. The 2010 paper reporting initial results64 states that
timing of delivery of TARGIT therapy had three strata: pre-pathology entry, post-pathology entry/
TARGIT as a second procedure, and history of previous contralateral breast cancer. The 2014 paper65
describes and reports results for only two strata: pre-pathology and post pathology and states that the
post-pathology stratum was added via a protocol amendment in 2004. This was because the option to
provide IORT as a second procedure (by reopening the wound) was requested by some centres
planning to join the trial. The post-pathology stratum had a completely separate randomisation table.
Post-pathology patients had to be randomised within 30 days of lumpectomy.65
l Blinding: no. The paper reporting initial results64 states that neither patients, investigators nor teams
were masked to treatment (but given the nature of the treatments, this would not have been possible).
Individual centres were not blinded to their own patients. States that confidential unblinded reports for
the Data Monitoring Committee and blinded reports for the International Steering Committee (ISC)
were produced by the trial statistician, but also states that unblinded analyses were performed
according to a pre-specified statistical analysis plan. Hence, it is unclear whether or not the ISC reports
were also unblinded. For ascertainment of cause of death, available data were reviewed by an
independent senior clinician who was masked to randomisation.65
l Comparability of treatment groups: p-values are presented65 indicating no statistically significant differences
in baseline characteristics between the groups. States that there was no significant difference between
pre-pathology and post-pathology strata in the timing of delivery of WB-EBRT (p= 0.58).65
l Method of data analysis: all randomised patients were included in an ITT analysis. Patients who had
undergone a mastectomy were not included in the analysis of local recurrence.65 The separate analysis
of the pre-pathology and post-pathology strata was planned.65 A formal analysis for deaths from
cardiovascular causes and deaths from other cancers was pre-specified.65 Exploratory analyses
(presumably not pre-specified) were conducted for regional recurrence, locoregional recurrence, distant
recurrence, any other recurrence, and all recurrence.65
¢ In the 2010 paper reporting initial results:64 for the analysis of local recurrence, patients who
underwent mastectomy as their definitive surgery and those who died or withdrew consent for
further follow-up were censored on that date. All other recurrences in the conserved breast, but
not axilla, were analysed and Kaplan–Meier curves were plotted to account for time to event and
censoring of the data and included all patients. Analysis of the annual hazards of local recurrence
was restricted to 4 years as < 20% patients had follow-up beyond this point. SAS System version
9.2 for Windows XP (SAS Institute Inc., Cary, NC, USA) and STATA version 11.0 were used for data
compilation and analysis. Pearson chi-squared and log-rank tests were used to obtain p-values.
Analysis was done in accordance with CONSORT guidelines.
¢ In the 2014 paper:65 the non-inferiority statistic was analysed by calculating the difference in
binomial proportions of local recurrences in the conserved breast between the two randomised
groups (TARGIT vs. WB-EBRT). To assess stability over time, this statistic was also calculated for the
mature cohort (n= 2232) reported in 201064 and for the earliest cohort (excluding the last 4 years
of enrolment; n= 1222) who had a median follow-up of 5 years. Established methods were used
to calculate the z-value and pnon-inferiority for the whole cohort and the two pre-specified strata
(pre-pathology and post pathology). Overall mortality was also reported for the whole cohort, the
mature cohort and the earliest cohort. If a patient had at least 5 years of follow-up, or if they were
seen within the year before database lock, they were deemed to have adequate follow-up. Patients
were censored when last seen or withdrawn from the trial. SAS System version 9.3 (SAS Institute
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Inc., Cary, NC, USA), Microsoft Excel 2011 (Microsoft Corporation, Redmond, WA, USA), STATA
version 12.0 (StataCorp LP, College Station, TX, USA) and IBM SPSS version 20.0 (IBM Corporation,
Armonk, NY, USA) were used for data compilation, validation and analysis. A log-rank test was
used to compare the difference between survival function and to obtain p-values (significance
levels set at p< 0.01 for local recurrence and p< 0.05 for survival).
l Sample size/power calculation: described in detail in the paper reporting initial results.64 The pre-defined
non-inferiority margin was an absolute difference of 2.5% in the primary endpoint between groups. To test
for non-inferiority with a background recurrence rate of 6% and an absolute non-inferiority margin of
2.5%, a total sample size of 2232 patients was calculated for 80% power at a 5% significance level.
Randomisation continued after the initial analysis in 2010 to allow accrual in subprotocols and the trial was
closed after the planned 1200 additional patients (1219 accrued) had been accrued.65
l Attrition/drop-out:
¢ 2010 paper64 TARGIT 17/1113 (1.5%) (4 withdrawn, 13 unknown); WB-EBRT 28/1119 (2.5%)
(11 withdrawn, 17 unknown). Received allocated treatment:64 TARGIT 996/1113, WB-EBRT
1025/1119.
¢ 2014 paper:65 TARGIT 9/1721 withdrawn; 141 did not receive allocated treatment (78 received WB-EBRT,
42 had mastectomy, 21 received neither TARGIT nor WB-EBRT), 1571/1721 (91%) received allocated
treatment [239/1571 (15.2%) received TARGIT+WB-EBRT; 1332/1571 (84.8%) received TARGIT alone).
WB-EBRT 27/1730 withdrawn, 113 did not receive allocated treatment (12 received TARGIT, 14 received
TARGIT+WB-EBRT, 34 had mastectomy, 53 received neither TARGIT nor WB-EBRT], 1590/1730 (92%)
received allocated treatment.
¢ States that 93.7% (3234/3451) of patients were seen in year before data lock or had at least
5 years of follow-up.
General comments
l Generalisability: women with early breast cancer (although definition of ‘early’ is vague); international
study with 6 out of 33 centres in the UK. Unsure whether or not population is typical of those with
early breast cancer; also unclear how similar the WB-EBRT treatment is to standard WB-EBRT in the UK.
l Outcome measures: outcomes reported are appropriate. Outcomes reported in linked publications,
but are from only one or two participating centres, not for the whole trial population.
l Intercentre variability: teams at each centre were trained and audited by a member of the trial ISC.64
Observation of the baseline stratification data64 shows differences between centres in the number of
patients entering the trial according to the three timings of delivery strata, particularly pre pathology
and post pathology. Seven centres had patients in all three strata, 10 centres had patients in two strata
(pre-pathology and post pathology, n= 3; pre pathology and contralateral, n= 6; post pathology and
contralateral, n= 1), and 11 centres had patients in one stratum only (pre pathology, n= 8; post
pathology, n= 3).64 Centres were allowed to restrict the inclusion criteria beyond the core protocol
(e.g. age, tumour size, grade, node) and to stipulate local policy for the delivery of WB-EBRT. Results
are not presented by treatment centre nor any comment made in the text so intercentre variability in
outcomes is unknown.
l Conflict of interests: appear the same for both the 201064 and 201465 papers. Lead author received a
research grant from Photoelectron Corp and Carl Zeiss and also honoraria; one author receives monthly
consultancy fees from Carl Zeiss; one author has received a research grant and two authors have
received honoraria from Carl Zeiss; Carl Zeiss sponsors most of the travel and accommodation costs for
meetings/conferences relating to TARGIT. Only three authors’ travel/accommodation had not been
sponsored by Carl Zeiss.
l Other: pivotal trial for TARGIT (INTRABEAM). Registered with ClinicalTrials.gov number NCT00983684.
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Cochrane criteria for
assessment of risk of bias
in RCTs56 Judgementa Support for judgement
Selection bias
Random sequence generation Low risk Computer-generated randomisation schedules
Allocation concealment Low risk Central allocation
Performance bias
Blinding of participants
and personnel
Low risk Neither patients nor investigators were blinded. However, outcomes
were unlikely to be influenced by lack of blinding
Detection bias
Blinding of outcome assessment Low risk Some investigators and teams were not blinded and it is not clear
whether or not all the analyses were performed unblinded. However,
most outcomes were objective measures and hence unlikely to be
influenced by lack of blinding
Attrition bias
Incomplete outcome
data addressed
Low risk Low proportion of withdrawals and participants not receiving
allocated treatment (reasons similar between groups). Analyses by ITT
Reporting bias
Selective reporting Low risk The protocol is available online (www.hta.ac.uk/project/1981.asp) and
specifies all outcomes including relapse-free survival and overall
survival (as a secondary outcome)
Other bias
Other sources of bias Low risk None evident
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Reviewer 1: DH,
date: 5 November 2013
Reviewer 2: JP,
date: 19 November 2013
Version: 3, (Reviewer JC replaces
DH 8 April 2014)
Linked study reference Participants Outcome measures
Substudy of TARGIT A trial:64,65
Welzel et al., 201363
Aim of substudy: to assess
radiation-related QoL
parameters in a sample of
patients within the TARGIT RCT
Number of centres contributing
data: one
Location of centres contributing
data: Mannheim, Germany
n= 15264
Other: cross-sectional analysis
using retrospective QoL
questionnaires
Recruitment dates: June 2002
to February 2009 (consented
during TARGIT trial).
Questionnaires sent out 8 to
94 months following treatment
Number of randomised participants: n= 123
eligible (aim was to assess the first 123 women
accrued to TARGIT trial at this centre), n= 88
received questionnaires (ITT), n= 87 included in
as-treated analysis
TARGIT, n= 46 [further split into IORT (n= 30)
and IORT with WB-EBRT boost (n= 16) original
allocation]; ITT, (n= 41 as-treated); WB-EBRT,
n= 42 ITT, (n= 46 as-treated)
Doses:
IORT: 20Gy at applicator surface during
surgery
IORT-WB-EBRT: additional boost of 46Gy
in 23 fractions or 50Gy in 25 fractions
WB-EBRT: 56Gy in 28 fractions (no
additional boost)
Additional inclusion criteria (beyond those of
TARGIT):
Patients had to be randomised in the TARGIT
trial between 2002 and 2009 to qualify
Additional exclusion criteria (beyond those of
TARGIT):
None reported
Outcomes: radiation-related QoL
measures
Method of assessing outcomes:
Two validated questionnaires of
the EORTC: QLQ-C30, version 3,
for global health status, role
functioning and general pain;
QLQ-BR23 for breast symptoms and
arm symptoms. The time frame for
these questions was the situation in the
last week
Length of follow-up: mean
32.1 months (median 25 months,
range 9–94 months)
Results
QoL outcome, ITT analysis
TARGIT (N= 46; IORT n= 30,
IORT+WB-EBRT n= 16) WB-EBRT (n= 42)
Na Mean (SD) Na Mean (SD) p-value
Global health statusb 46 61.6 (21.7) 40 54.8 (19.9) 0.183
Restrictions in daily activitiesb 46 72.8 (32.3) 41 61.8 (29.2) 0.055
General painc 46 29.3 (32.8) 42 42.5 (33.0) 0.048
Breast symptomsc 45 17.0 (20.8) 42 18.1 (20.2) 0.629
Arm symptomsc 45 24.4 (26.7) 40 31.1 (27.9) 0.279
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QoL outcome, as-treated
analysis, mean (SD) IORT (n= 25)
IORT+WB-EBRT
(n= 16)
WB-EBRT
(n= 46) p-value
Global health statusb 63.6 (24.2) 60.9 (19.9) 52.4 (22.1) > 0.01
Restrictions in daily activitiesb 78.7 (35.2) NR 60.5 (29.5) 0.007e
General painc,d 21.3 (95% CI NRh
to 54.4)
43.7 (95% CI
11.6 to 75.9)
40.9 (95% CI
8.6 to 73.2)
0.007,e
0.018f
Breast symptomsc,d 7.2 (95% CI NRh
to 20.9)
29.7 (95% CI
6.8 to 52.5)
19.0 (95% CI
NRh to 39.2)
0.001,e
<0.001,f
0.021g
Arm symptomsc,d 15.2 (95% CI NRh
to 37.2)
32.6 (95% CI
6.8 to 58.4)
32.8 (95% CI
4.2 to 61.5)
0.009,e
0.011f
Frequency of moderate and
severe breast/arm
symptoms,i as-treated
analysis, % moderate/
% severe IORT (n= 25)
IORT+WB-EBRT
(n= 16)
WB-EBRT
(n= 46) p-value
Pain in area of affected breast 4%/0 25%/13% 11%/4% > 0.01
Swelling in area of affected
breast
0/0 7%/7% 4%/2%
Oversensitivity in area of
affected breast
4%/0 20%/7% 9%/7%
Skin problems on or in area of
affected breast
4%/4% 13%/6% 9%/4%
Pain in arm or shoulder 8%/8% 33%/20% 18%/23% > 0.01
Swelling in arm or hand 8%/4% 6%/6% 9%/7%
Difficulty in raising or moving
arm sideways
20%/0 13%/7% 24%/12% > 0.01
NR, not reported.
a Number of valid assessments.
b Higher scores are equal to good functioning/good QoL.
c Higher scores are equal to severe symptoms/worse QoL.
d Figures estimated from graph (see figure 4) by reviewer using Engauge digitising software.
e IORT vs. WB-EBRT.
f IORT vs. IORT-WB-EBRT.
g WB-EBRT vs. iort-WB-EBRT.
h Lower CI not specified on bar chart.
i Reported by patients. Most commonly reported symptoms were moderate or severe pain in the arm or shoulder,
difficulty in raising/moving arm sideways and pain in area of affected breast. States there were no significant differences
between treatment groups (p> 0.01) but unclear whether or not this relates to the three most common symptoms or all
the symptoms.
All scores were linearly transformed to a 0–100 point scale. Univariate regression analysis revealed no influence of follow-up
duration on self-reported pain, breast and arm symptoms. Between-group differences in the Hospital Anxiety and
Depression Scale, Functional Assessment of Cancer Therapy – Fatigue, Rosenberg Self-Esteem Scale and Body Image Scale
scores were not observed (p> 0.01) (no data reported). Paper also reported the percentage of variance explained by multiple
linear regression modelling in a bar chart. Having 2 or more medical comorbidities was associated with worse global health
status, more restrictions in other daily activities, i.e. worse role functioning and more general pain symptoms (p= 0.004 to
0.043) (data not extracted). Breast and arm symptoms were independently predicted by tumour size > 2 cm (p= 0.003 and
0.002) (data not extracted).
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Methodological comments
l Comparability of substudy population to main TARGIT-A trial population: narratively reports that,
compared with patients in the whole TARGIT-A trial, patients in this substudy had largely similar
demographic and clinical characteristics. On observation of the data, the reviewer would agree on the
whole (but not all characteristics are presented in the substudy), although a lower proportion of the
subsample had tumour size 0–1 cm and a greater proportion had tumour size 1–2 cm compared with
the whole TARGIT-A population for both treatment arms.
l Comparability of substudy treatment groups: demographic and clinical characteristics were similar
between groups. p-values were reported and there were no statistical differences although presume
this was for comparison of the three groups (i.e. IORT arm was split into IORT alone and IORT+
WB-EBRT boost) and not IORT as a whole versus WB-EBRT.
l Method of data analysis: reports all analyses were performed on an ITT and as-treated basis. The level of
statistical significance was 0.01 (0.05/5) to reduce type-1 error in multiple comparisons. Chi-squared
tests (or Fisher’s exact tests), Kruskal–Wallis one-way analysis of variance (ANOVA), and post hoc
Mann–Whitney U-tests (or univariate ANOVA and post hoc Scheffe tests) were used to compare
treatment groups. Independent effects of demographic and clinical factors on QoL were tested using
univariate linear regression analysis. Variables with a p-value < 0.05 were further analysed with multiple
linear regression analysis (stepwise forward method). The results from TARGIT-A patients were presented
throughout as three groups with the IORT group split into IORT and IORT with WB-EBRT boost.
l Attrition/drop-out: the main trial publication64 indicates that there were 152 participants at the
Mannheim centre (for recruitment 24 March 2000 to 25 June 2012). This linked substudy aimed to
assess the first 123 patients recruited from this centre (recruited June 2002 to February 2009), with
88 patients consenting (88/152= 58%). Data are reported for the ITT (n= 88) and as-treated (n= 87)
populations. Five patients did not receive IORT (four received WB-EBRT instead and one patient refused
WB-EBRT). It is not possible to assess whether or not there are any other missing data as no ‘n’ is
reported for tables or figures; however, none are apparent to the reviewer.
l Other: the paper includes an additional two non-randomised control groups of WB-EBRT patients (from
the same centre) treated with (1) IORT as a tumour bed boost+WB-EBRT (outside of TARGIT-A trial) or
(2) WB-EBRT+WB-EBRT boost. These groups served as control groups for some analyses but are not
reported on here.
General comments
l Generalisability: this substudy reports on only 46 IORT and 42 WB-EBRT group participants from the
TARGIT-A trial representing only about 2.5% of the total trial population of 3451 randomised
participants (1721 TARGIT, 1730 WB-EBRT).65 It is not clear how generalisable the results are to the
remainder of the TARGIT-A trial population or to UK breast cancer patients.
l Outcome measures: questionnaire response rate was 96–99%. The five functioning and symptom scales of
the QLQ-C30 and QLQ-BR23 questionnaires were preselected during the design of the study based on a
pilot study and relevance for radiation-related QoL in breast cancer. Other subscales and items of the
questionnaires were not presented. In addition, states that four other QoL scales were used: the Hospital
Anxiety and Depression Scale, the Functional Assessment of Cancer Therapy – Fatigue subscale, the
Rosenberg Self-Esteem Scale and the Body Image Scale to control for differences that may inherently exist
between treatment groups. Scores for each questionnaire were summed for each scale. However, the
paper only narratively comments on differences between groups for these scales (no data).
l On observation of the data, ITT and as-treated QoL outcomes seem similar for the WB-EBRT group, but
are difficult to judge for the IORT group because of the way data are presented; for ITT results, IORT
and IORT+WB-EBRT are presented as a single group whereas for as-treated results, IORT alone and
IORT+WB-EBRT are reported separately.
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Partial quality assessment
A complete risk of bias assessment has been conducted for the main TARGIT-A trial.64 Only the criteria that
could potentially differ in the substudy are reported here.
Cochrane criteria for
assessment of risk of bias
in RCTs56 Judgementa Support for judgement
Performance bias
Blinding of participants and
personnel in the HRQoL substudy
High risk As part of the TARGIT-A trial, neither patients nor investigators were
blinded and the outcome could potentially be influenced by the lack
of blinding
Detection bias
Blinding of outcome assessment Unclear risk No information provided regarding blinding (or lack of) for the
assessment of QoL measures
Attrition bias
Incomplete outcome data
addressed
Low risk Reason for loss of one patient given
Other bias
Other sources of bias Unclear risk Retrospective questionnaire with no baseline QoL measurement
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Appendix 4 Southampton Health Technology
Assessments Centre’s critique of manufacturer’s
submission
Southampton Health Technology Assessments Centre’s peer
review of clinical effectiveness data presented in Carl Zeiss
UK’s submission for the INTRABEAM Photon Radiotherapy
System for early breast cancer Multiple Technology Appraisal
Comprehensiveness of ascertainment of published studies
Clinical effectiveness
The MS contains a narrative summary of the key RCT and other studies (non-randomised) with the results
of each study presented separately. One table is presented in the executive summary detailing nine studies
reporting on cosmesis and toxicity. Tables of patient and tumour characteristics are presented separately
for each included study in Appendix 1. There is no formal systematic review of clinical effectiveness
evidence although a systematic literature search is described.
l Were databases and dates of searches specified?
¢ Yes, pages 6 and 7 report that three databases were searched up to December 2013, with
literature included only from 2007 onwards.
l Were search strategies supplied?
¢ Yes.
l Was enough detail provided to be reproducible?
¢ Yes.
l Did they search/report on ongoing studies?
¢ No searches for ongoing studies are reported.
l Did they search for conference proceedings?
¢ Unclear – conference proceedings may have been included in the three databases searched but this
is not specifically stated. Information is included from some conference posters.
l How many of the data are commercial in confidence/academic in confidence?
¢ No data are commercial in confidence /academic in confidence.
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Searches identified
l Note the number of studies.
¢ The MS does not state how many citations were identified by the search. The MS does not describe
the processes or criteria (other than ‘related to the subject to be evaluated’) for selecting included
studies. The MS does not state how many studies overall have been included in the submission.
The reviewer has identified 26 studies, of which six are described as poster abstracts.
l Note what study types.
¢ The MS does not consistently identify the study types for the studies included in the review. Only
one RCT is included, the majority of the remaining 25 citations appear to be cohort studies.
l Did these meet our inclusion criteria?
¢ The included RCT meets our inclusion criteria as do the studies reporting on subgroups of TARGIT-A
participants. The remaining studies included in the MS did not meet our inclusion criteria, chiefly on
the grounds of study design.
l Were any studies identified that we have not included?
¢ No.
l Any key details/issues?
¢ No.
Clinical analysis
l Any major differences in evidence reported?
¢ The MS discusses evidence from four articles that are all based on the key TARGIT-A trial and which
are also included in the SHTAC’s systematic review. The MS has not included evidence from the
initial TARGIT-A trial publication from 201064 stating that this is because more recent data are
available and the 2010 results are expected to be included in the most recent (2014) publication.65
The SHTAC’s systematic review does include evidence on early complications from the 2010 TARGIT-A
trial publication as these are not reported by the more recent 2014 trial paper. The MS also does not
include a study published by Sperk et al.67 reporting on long-term toxicity following treatment either
with the INTRABEAM (n= 54) device or WB-EBRT (n= 55) at one trial centre in Mannheim, Germany.
The MS does, however, include a cohort study79 that reports on post-operative complications within
the first week following surgery among 208 patients treated with INTRABEAM at a centre in
Mannheim, Germany, who were participating in the TARGIT-A trial. Tuschy et al.79 is excluded from the
SHTAC’s systematic review because it is likely that the data reported are either partially or wholly
contained within the early complications reported by the initial TARGIT-A trial publication64 and, in
addition, Tuschy et al.79 report no comparable data for the WB-EBRT group.
¢ The MS also discusses evidence from n= 22 studies (six only reported as conference abstracts) that
did not meet the inclusion criteria of the SHTAC’s review.
¢ The MS provides a narrative summary for each individual study that has been included. Individual
tables of baseline patient characteristics for 13 of the included studies are provided in an appendix.
Aside from one table for eight of the nine studies listed in section 1.2, ‘Literature related to side
effects and cosmetic outcome after IORT as a single treatment’, the MS does not provide summary
tables for the included studies. There is no quality assessment of the included studies.
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l Are their conclusions similar to ours?
¢ In the MS section ‘Interpretation of clinical evidence’ subsections a, b, and c, the focus is on the
TARGIT-A trial data and, consequently, with only one included trial there is no evidence to draw
together and interpret. Therefore, for the outcomes of recurrence and overall survival the MS and
the SHTAC’s systematic review that report on the same data as published in the 2014 TARGIT-A
trial publication.65
¢ In some of the remaining subsections of the MS ‘Interpretation of clinical evidence’, the MS discusses
evidence for outcomes that are also included in the SHTAC’s systematic review (e.g. subsection
d: Cosmetic outcome and toxicities, subsection f: Quality of life) drawing not only on evidence from the
TARGIT-A trial but also on evidence from included cohort studies that support the data from the
TARGIT-A trial. Where the SHTAC’s review reports a small amount of additional information on early
complications reported by the initial TARGIT-A trial publication64 this does not impact on the overall
conclusions. Other subsections of the MS ‘Interpretation of clinical evidence’ draw on cohort or other
non-RCT studies to provide information to support other hypotheses that are not included within the
SHTAC’s systematic review (e.g. subsection e: Side effects and impacts on critical organs are less in
IORT than EBRT, subsection g: IORT can be administered to patients where EBRT is not advised,
subsection i: Low risk of inducing secondary cancer).
l Any indirect comparisons and if so, was this appropriate and what were key results?
¢ There is no indirect comparison.
l Any extra adverse event information?
¢ None that meets the inclusion criteria for the SHTAC’s systematic review.
Interpretation
l Does their interpretation of the clinical data match their analyses?
¢ As already noted above, with only one included trial there is no evidence to draw together
and interpret.
Questions
l Any areas of uncertainty/discrepancy compared with the SHTAC’s review?
¢ None related to the key TARGIT-A trial. Other evidence presented by the MS does not meet the
inclusion criteria for the SHTAC’s systematic review.
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Southampton Health Technology Assessments Centre’s critique
of economic evaluation presented in Carl Zeiss UK’s submission
for the INTRABEAM Photon Radiotherapy system for early
breast cancer Multiple Technology Appraisal
Study characteristics
Reference
Carl Zeiss, UK, 2014.
Health technology
INTRABEAM Photon Radiotherapy System.
1.2 Interventions and comparators
What interventions/strategies were included?
INTRABEAM versus Whole-breast WB-EBRT (WB-EBRT).
Was a no treatment/supportive care strategy included?
No.
Describe interventions/strategies
New Innovative TARGeted Intra Operative Radio Therapy (IORT) using the INTRABEAM radiotherapy system.
Conventional therapy consisting of WB-EBRT.
1.3 Research question
What are the stated objectives of the evaluation?
To determine the cost-effectiveness of INTRABEAM in early breast cancer patients when compared with
radiotherapy usually given in the UK over 3–6 weeks as WB-EBRT.
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1.4 Study type Cost-effectiveness/cost–utility/cost–benefit analysis?
Cost–utility analysis.
1.5 Study population
What definition was used for [condition]? What are the characteristics of the baseline cohort for
the evaluation?
The baseline cohort included patients aged 55 years who were disease free after WLE. The economic model
was based on the results of the pre-pathology stratum of the trial with 2298 patients (this was because the
outcome in patients in whom IORT was given only after the final pathology showed much less favourable
results than in the patients who received IORT during lumpectomy).
1.6 Institutional setting: where is/are the intervention(s) being evaluated
usually provided?
Not reported.
1.7 Country/currency
Has a country setting been provided for the evaluation? What currency are costs expressed in and does the
publication give the base year to which those costs relate?
UK; £. Price year for cost of INTRABEAM was unknown as based on expert opinion; price year of WB-EBRT was
2012–13; the price year of post IORT local recurrence and post WB-EBRT local recurrence was of 2013–14;
and that of annual disease-free follow-up care was 2013. The cost was calculated to 2013 price using The
Campbell and Cochrane Economics Methods Group – Evidence for Policy and Practice Information and
Coordinating Centre Cost Converter.
1.8 Funding source
Carl Zeiss, UK.
1.9 Analytical perspective
What is the perspective adopted for the evaluation (health service, health and personal social services, third
party payer, societal (i.e. including costs borne by individuals and lost productivity)]?
NHS health-care payer’s perspective
The MS notes that travel/parking/accommodation expenses for WB-EBRT patients were not included in the WB-EBRT
costs (it was stated that these expenses might range from £50 to £100 per patient per fraction delivered).
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Effectiveness
Were the effectiveness data derived from a single study, a review/synthesis of previous studies or expert
opinion? Give the definition of treatment effect used in the evaluation. Give the size of the treatment
effect used in the evaluation.
Data for effectiveness were derived from a single study by Vaidya et al.65 The source study reported 5-year
cumulative risk which were converted to annual probabilities to populate the model by the manufacturer.
Parameters Probabilities
Local recurrence after IORT 0.004
Local recurrence after WB-EBRT 0.002
Breast cancer death after IORT 0.007
Non-breast cancer death after IORT 0.003
Breast cancer death after WB-EBRT 0.005
Non-breast cancer death after WB-EBRT 0.009
Intervention costs
Were the cost data derived from a single (observational) study, a review/synthesis of previous studies
expert opinion? Were the methods for deriving these data adequately described (give sources if using
data from other published studies)? List the direct intervention costs and other direct costs used in the
evaluation – include resource estimates (and sources for these estimates, if appropriate) as well as sources
for unit costs used.
Cost data were obtained from the following sources: expert opinion, Reference Costs 2012–13,136 tariff
information 2013–14,137 and the study by Wolowacz et al.138 The methods of deriving costs were not
adequately described.
The following costs were used in the model:
Costs Prices Source
Costs of INTRABEAM £2165 Expert opinion
Costs of WB-EBRT £7521 HRG code SC29Z (Reference Cost 2012–13)
Cost of treating post IORT LR (salvage lumpectomy) £1558 HRG code JA09H (Tariff Information 2013–14)
Cost of treating post WB-EBRT LR (salvage mastectomy) £6504 HRG code JA16Z (Tariff Information 2013–14)
Annual disease-free follow-up care £892 Wolowacz et al.138
Indirect Costs (costs owing to lost productivity, unpaid inputs to patient care)
Were indirect costs included?
Not included.
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Health state valuations/utilities (if study uses quality-of-life adjustments
to outcomes)
Were the utility data derived from a single (observational) study, a review/synthesis of previous studies
expert opinion. Were the methods for deriving these data adequately described (give sources if using data
from other published studies)?
The utility data were derived from a single study by Hayman et al.135 The method of deriving these values was
not reported.
List the utility values used in the evaluation?
Health state Utilities
Utility value in disease free patients 0.92
Utility value in salvage lumpectomy patients 0.87
Utility value in salvage mastectomy patients 0.82
Modelling
If a model was used, describe the type of model used (e.g. Markov state transition model, discrete event
simulation). Was this a newly developed model or was it adapted from a previously reported model? If an
adaptation, give the source of the original. What was the purpose of the model (i.e. why was a model
required in this evaluation)? What are the main components of the model (e.g. health states within a
Markov model)? Are sources for assumptions over model structure (e.g. allowable transitions) reported –
list them if reported.
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A multistate Markov model was developed, over a time-horizon of 20 years. It was not reported if the model
was newly developed or adapted from a previously reported model.
The purpose of the model was to assess the cost-effectiveness of INTRABEAM compared with WB-EBRT. The
model consisted of four health states as shown in the figure:
Disease free
Local
recurrence
Mastectomy/
lumpectomy
Non-breast
cancer
death
Breast
cancer
death
No description was provided on patient progression through the health states. The model assumptions were:
l After local recurrence, IORT patients would have salvage lumpectomy.
l After local recurrence, WB-EBRT patients would have salvage mastectomy.
l Death rate in disease free patients was equal to general population.
l Average 23 fractions of WB-EBRT per patient delivered based on 15–30 fractions in the clinical practice.
l All patients were given IORT concurrent with initial lumpectomy (pre-pathology stratum of TARGIT-A trial).
Extract transition probabilities for [natural history/disease progression] model
and show sources (or refer to table in text)
Data for transitional probabilities were extracted from Vaidya et al.65
Transitions Annual probability 95% CIa
Local recurrence after IORT 0.0042 0.0022 to 0.0085
Local recurrence after WB-EBRT 0.0022 0.0010 to 0.0051
Breast cancer death after IORT 0.0067 0.0038 to 0.0119
Non-breast cancer death after IORT 0.0026 0.0014 to 0.0057
Breast cancer death after WB-EBRT 0.0055 0.0030 to 0.0094
Non-breast cancer death after WB-EBRT 0.0090 0.0057 to 0.0142
a Rounded to four decimal places.
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What is the model time horizon?
20 years.
What, if any, discount rates have been applied in the model? Same rate for costs
and outcomes?
Costs and outcomes were discounted at 3.5%.
Results/analysis
What measure(s) of benefit were reported in the evaluation?
Cost per QALY.
Provide a summary of the clinical outcome/benefits estimated for each intervention/
strategy assessed in the evaluation
Strategies Total QALYs (discounted)
IORT 13.230
WB-EBRT 13.223
Provide a summary of the costs estimated for each intervention/strategy assessed in
the evaluation
Strategies Total costs (discounted)
IORT £14,461
WB-EBRT £20,926
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Synthesis of costs and benefits: are the costs and outcomes reported together
(e.g. as cost-effectiveness ratios)? If so, provide a summary of the results
vs. WB-EBRT
Incremental costs (discounted) Incremental QALYs (discounted) ICER
IORT –£6465 0.007 Dominates
Give results of any statistical analysis of the results of the evaluation
None.
Was any sensitivity analysis performed? If yes, what type(s) [i.e. deterministic
(one-way, two-way etc.) or probabilistic]?
Probabilistic sensitivity analyses (ran for 1000 simulations).
What scenarios were tested in the sensitivity analysis? How do these relate to structural
uncertainty (testing assumptions over model structure such as relationships between
health states), methodological uncertainty (such as choices of discount rate or inclusion
of indirect costs) or parameter uncertainty (assumptions over values of parameters in the
model, such as costs, quality of life or disease progression rates)?
No scenario analysis was conducted.
Give a summary of the results of the sensitivity analysis, did they differ substantially
from the base-case analysis. If so, what were the suggested causes?
None; it was only reported that probabilistic results were similar to the base case results however no one-way
sensitivity analysis was conducted.
Conclusions/Implications
Give a brief summary of the author’s conclusions from their analysis.
The authors concluded that INTRABEAM was a cost-effective strategy to treat early-stage breast cancer patients
in the UK.
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What are the implications of the evaluation for practice?
The MS stated that INTRABEAM could save valuable NHS resources in comparison with the current practice of
WB-EBRT.
SHTAC’s commentary
Selection of comparators:
Number of fractions (23) for the WB-EBRT arm was not relevant to UK practice.
Validity of estimate of measure of benefit:
The manufacturer’s model assessed health benefit in terms of QALYs which was a valid measure of health in
the UK NHS setting. Standard gamble was used to estimate utilities in the source study which was a 1997
publication;135 the reported values were not obtained from general population. In addition, no details were
provided regarding whether or not a systematic search was conducted to identify utilities for the model.
Validity of estimate of costs:
The validity of the costs estimates remained questionable. The cost of INTRABEAM per patient was obtained
from expert opinion. The manufacturer provided the cost compositions of INTRABEAM; however, it was not
transparent in explaining the assumed cost per patient. In addition, cost of WB-EBRT was obtained from
inappropriate HRG code: the code used in the model for WB-EBRT was for ‘other radiotherapy treatment’. On
the contrary, the HRG code required for the purpose of this analysis was ‘external beam radiotherapy delivered
by linear accelerator’ which required the weighted average of SC22Z and SC23Z (for delivery) and a weighed
average SC45Z, SC46Z, SC47Z and SC48Z (for planning). Costs were only varied by ± 10% in PSA. There were
also inconsistencies in the price years of the reported costs: cost of WB-EBRT was expressed in 2012–13; costs
of treating post IORT local recurrence and post WB-EBRT local recurrence were in 2013–14; and cost of annual
disease follow-up was in 2013.
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Critical appraisal checklist of economic evaluation (questions in this checklist based on Philips et al.58)
Item number Item MS
1 Is there a clear statement of the decision problem? Yes
2 Is the comparator routinely used in UK NHS? Uncleara
3 Is the patient group in the study similar to those of interest in UK NHS? Unclearb
4 Is the health care system comparable to UK? Yes
5 Is the setting comparable to the UK? Yes
6 Is the perspective of the model clearly stated? Yes
7 Is the study type appropriate? Yes
8 Is the modelling methodology appropriate? Unclearc
9 Is the model structure described and does it reflect the disease process? Yesd
10 Are assumptions about model structure listed and justified? No
11 Are the data inputs for the model described and justified? No
12 Is the effectiveness of the intervention established based on a systematic review? Noe
13 Are health benefits measured in QALYs? Yes
14 Are health benefits measured using a standardised and validated generic instrument? Yesf
15 Are the resource costs described and justified? No
16 Have the costs and outcomes been discounted? Yes
17 Has uncertainty been assessed? Unclearg
18 Has the model been validated? No
a Different number of fractions used in the model (23) than in the UK practice, which is to include 15 fractions. However,
in the TARGIT trial, centres were allowed to use the number of fractions that were normal for them, but it is not clear
from the publication what this number was in all cases. This might be an average of the fractions delivered in the study,
but no details were provided.
b Although the MS reported that the analysis was based on UK population, no baseline characteristics of the included
patient population were provided.
c Very limited details were provided around the modelling methodology.
d A simplified model structure of four health states was included; an additional health state for ‘any other recurrence’
would have been more appropriate.
e However, only one RCT was identified by the AG systematic review.
f The source study by Hayman et al.135 used standard gamble technique to estimate utilities.
g Only PSA was conducted, not DSA or scenario analyses.
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Appendix 5 Excluded cost-effectiveness studies
with rationale
Excluded study Reasons for exclusion
Xoft Axxent eBx electronic brachytherapy system (iCAD Inc.)
for early-stage breast cancer. 2012
Not full economic evaluation, inappropriate
intervention and comparator
Alvarado M, Ozanne E, Mohan A, Esserman L. Cost-effectiveness
of intraoperative radiation therapy for breast conservation. Journal
of Clinical Oncology Conference: ASCO Annual Meeting 2011
Chicago, IL United States Conference Start: 20110603
Conference End: 20110607 Conference Publication 2011;29(Suppl. 1)
Abstract
BlueCross BlueShield Association. Accelerated partial breast
irradiation as sole radiotherapy after breast-conserving surgery for
early stage breast cancer. 2007
Not full economic evaluation, inappropriate
population of interest, intervention and comparator
BlueCross BlueShield Association. Accelerated radiotherapy after
breast-conserving surgery for early stage breast cancer. 2012
Not full economic evaluation
Santos M, Guerra JLL, Gordillo MJO, Fondevilla A, Calvo F,
Samblas J, et al. Cost-effectiveness analysis of four validated
techniques of accelerated partial breast irradiation for the
treatment of early-stage breast cancer: Spanish public health
system standard estimations. Value in Health 2012;15:A354
Abstract, inappropriate intervention
Sher DJ, Wittenberg E, Suh WW, Taghian AG, Punglia RS.
Partial-breast irradiation versus whole-breast irradiation for
early-stage breast cancer: a cost-effectiveness analysis. Int J Radiat
Oncol Biol Phys 2009;74:440–6
Inappropriate intervention
Xie X, Dendukuri N, McGregor M. Single-dose intraoperative
radiotherapy using Intrabeam® for early-stage breast cancer:
a health technology assessment. 2012
Not full economic evaluation
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Appendix 6 Cost-effectiveness data extraction
tables
Study Alvarado, 2013;106 Esserman, 2014107
Research question The study analysed, from a societal perspective, the cost-effectiveness of two radiation strategies
for early-stage invasive breast cancer: single-dose IORT and the standard 6-week course of
WB-EBRT
Country/setting The model was based on the protocol of the international TARGIT-A trial; the economic
evaluation is US based
Funding source Not stated
Analysis type Cost–utility analysis
Study type A Markov decision-analytic model based on the TARGIT-A trial was developed consisting of
six health states:
l Disease-free status post BCS
l Recurrence in women initially with WB-EBRT had salvage mastectomy followed by
immediate reconstruction
l Recurrence in women who received IORT had the option of salvage lumpectomy followed
by WB-EBRT
l Metastases
l Death due to other causes
l Death due to metastatic breast cancer
Perspective Societal
Time horizon 10-year period with annual cycle length
Model assumptions l All women were assumed to have had BCS followed by either IORT or 6-week WB-EBRT
l 14.1% of women with IORT received an additional 5 weeks (28 fractions) of WB-EBRT
l Recurrence in women who initially had WB-EBRT could only be treated with salvage
mastectomy followed by immediate reconstruction
l Recurrence in patients who received IORT had the option of salvage lumpectomy followed
by WB-EBRT
l Death resulting from breast cancer was only possible for women with metastatic
breast cancer
l The utilities of IORT and IORT followed by 5-week WB-EBRT were equal to that of 6-week
WB-EBRT
l LRRs were assumed to progress linearly over 10 years
l For women treated with IORT followed by WB-EBRT, it was assumed that they incurred the
same LRR as those who had IORT alone
Discounting (rate) Yes at 3% for both costs and effectiveness
Costing year,
currency
2011, US$
Population Trial name: TARGIT-A
Definition of condition: women with early breast cancer who were aged ≥ 55 years old
Characteristics of baseline cohort/risk factors: early-stage was defined as stage I-IIA, ER-positive
(ER+) breast cancer
Intervention(s),
comparator(s)
Intervention: single-dose IORT INTRABEAM
Comparator: 6-week course of WB-EBRT with a standard 33 fractions
Intervention effect Data for the 4-year LRRs from the TARGIT-A trial were transformed to annual transitional
probabilities which were then estimated over a 10-year period. At 4 years, the Kaplan–Meier
estimate of local recurrence in the conserved breast was estimated to be 1.2% (95% CI 0.53 to
2.71) in the INTRABEAM arm and 0.95% (95% CI 0.39 to 2.31) in the WB-EBRT arm
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Study Alvarado, 2013;106 Esserman, 2014107
Health state utilities Utility values associated with the health states were attained via standard gamble preferences,
when feasible.119 Published literature was used to populate the remaining values (reference
provided)119
Health state utilities Base-case value Range values
IORT 0.92 0.87–0.97
3-week WB-EBRT 0.92 0.87–0.97
6-week WB-EBRT 0.92 0.87–0.97
IORT followed by 5-week WB-EBRT 0.92 0.87–0.97
Salvage mastectomy 0.82 0.77–0.87
Salvage mastectomy and WB-EBRT 0.87 0.82–0.92
Metastatic breast cancer 0.70 0.60–0.80
Death 0.00 –
Details on the measurement technique and valuation approach were not provided
Intervention cost l IORT: $5547
l 6-week WB-EBRT: $10,464
l IORT followed by 5-week WB-EBRT: $13,640
l 3-week WB-EBRT: $6640
Sources:
Medicare Physician Fee Schedule. US Department of Health and Human Services; 2010.
www.cms.gov/apps/physician-fee-schedule/overview.aspx
Outpatient Prospective Payment System (OPPS). US Department of Health and Human
Services; 2010
Indirect costs l Indirect costs (6-week WB-EBRT): $1467
l Indirect costs (IORT followed by 5-week WB-EBRT): $1244
l Indirect costs (3-week WB-EBRT): $667
The above figures were derived from the same sources:
l Highlights of Women’s Earnings in 2010. In Labor USDo, editor, US Bureau of Labor
Statistics; 2011
l CPI Inflation Calculator. US Bureau of Labor Statistics; 2011 http://data.bls.gov/cgi-bin/cpicalc.pl
l IRS announces 2011 standard mileage rates: internal revenue service; 2010
l Gasoline and Diesel Fuel Update. US Energy Information Administration; 2011.
www.eia.gov/oog/info/gdu/gasdiesel.asp
Results
Discounted/undiscounted IORT 3-week WB-EBRT 6-week WB-EBRT
Costs $28,879 $29,789 $34,070
Life-years 8.38240 8.38152 8.38257
QALY 7.66020 7.64618 7.65994
ICER Dominated Dominated
CPI, Consumer Price Index; IRS, Internal Revenue Service.
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Study Alvarado, 2013;106 Esserman, 2014107
Sensitivity analysis
The model conducted a series of one-way and two-way sensitivity analyses. A scenario analysis of 3-week accelerated
WB-EBRT schedule of 16 fractions was also conducted
Parameter/scenario Value ICER ($/QALY)
Utility of IORT 0.97 Dominated
0.87 12,820
Utility of 6-week WB-EBRT 0.97 14,965
0.87 Dominated
Utility of IORT followed by 5-week WB-EBRT 0.97 Dominated
0.87 91,517
Utility of salvage lumpectomy after IORT 0.92 Dominated
0.82 2,284,464
LRR of IORT (10 year) 6.0% 746,158
1.5% Dominated
LRR of 6 week WB-EBRT (10 year) 3.6% Dominated
1.2% 2.7 million
Proportion of women who receive IORT followed by 5-week WB-EBRT 28.2% 267 million
7.1% Dominated
Rate of MBC after salvage lumpectomy or mastectomy (10-year rates) 40.0% 21 million
10% Dominated
Author’s conclusions Alvarado et al.106 concluded that IORT was a better strategy as it was less costly and provided
more QALYs compared with WB-ERT. Esserman et al.107 concluded that the result of TARGIT-A
trial was not expected to change
Reviewer’s comments Overall, the analysis was well conducted. The results of the analysis were in line with the study
conclusions. However, the model did not incorporate any PSA. Further, only two sets of two-way
sensitivity analyses were conducted. Hence, the robustness of the cost-effectiveness results
remains questionable
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Quality assessment checklist for economic evaluations
Item Yes/no/unclear
1. Is the decision problem (including interventions compared and patient group) relevant to the UK? Yesa
2. Is the setting comparable to the UK? No
3. Is the analytical and modelling methodology appropriate? Yes
4. Are all the relevant costs and consequences for each alternative identified? Yes
5. Are the data inputs for the model described and justified? Yes
6. Are health outcomes measured in QALYs? Yes
7. Is the time horizon considered appropriate? Nob
8. Are costs and outcomes discounted? Yes
9. Is an incremental analysis performed? Yes
10. Is uncertainty assessed? Yesc
a The number of fractions of WB-EBRT (comparator) was not relevant to UK practice as the study used the assumption of
using WB-EBRT with a standard 33 fractions whereas the current standard UK practice is 15 fractions.
b A lifetime horizon would have been appropriate as the risk of local recurrence continues over a lifetime.
c PSA was not conducted.
Critical appraisal checklist for economic evaluations
(based on Drummond et al.57)
Study Shah, 2014108
Research question The study analysed the cost-efficacy of IORT compared with WB-EBRT and APBI
for early-stage breast cancer
Country/setting The analysis was based on data from two phase III trials: TARGIT-A trial and the
ELIOT trial; the economic evaluation was US based
Funding source Not stated
Analysis type Cost–utility analysis, cost minimisation analysis
Study type The study used local recurrence data from two trials: TARGIT-A and ELIOT
For the cost-effectiveness analyses, reimbursement models were calculated in
four ways:
l Reimbursement only (professional and facility)
l Reimbursement incorporating additional medical costs (e.g. increased
operative time with IORT, fraction of IORT patients requiring
additional radiation)
l Reimbursement requiring non-medical costs
l Reimbursement incorporating costs associated with recurrences
The ICER analysis provided the increased reimbursement required to use
WB-EBRT or APBI compared with IORT per percentage point of improvement
in local recurrence
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Study Shah, 2014108
Perspective Societal
Time horizon Not clearly stated; it is assumed that the time horizon was for 10 years based
on the estimation of mean utility by technique
Model assumptions The model assumptions based on Suh et al.123 were as follows:
l It was assumed that an average round trip travel was 40 miles to the
radiation centre (at a cost of 36 cents per mile)
l The time involved was assumed to be 2 hours per treatment, which
included travel time. Of the 2 hours, 30 minutes was assumed to be spent
on receiving treatment (at a cost of $14.78 per hour)
l Patients who received treatment twice daily were assumed to return to
work during the interfraction interval
The study reported that all assumptions and methodology adopted were based
on and consistent with previously published articles, discussed elsewhere125
Discounting (rate) Not stated
Costing year, currency US $ (price year not stated)
Population TARGIT-A trial: women with early-stage ductal breast cancer who were
≥ 45 years old
ELIOT trial: women with unicentric cancer less than 2.5 cm who were
> 45 years old
Intervention(s), comparator(s) Intervention: IORT (INTRABEAM in TARGIT-A trial) or electron intraoperative
radiotherapy (in ELIOT trial). The latter is not eligible for inclusion in this review
Comparator(s): WB-EBRT 3D-CRT; APBI 3D-CRT; APBI IMRT; APBI SL; APBI ML;
APBI interstitial
Intervention effect LRRs for both the INTRABEAM and WB-EBRT arms (3.3% for IORT vs. 1.3% for
WB-EBRT) were obtained from the TARGIT trial
Data from the ELIOT trial was not extracted as the intervention is not eligible
Health state utilities The utility values for the outcome states (shown below) were based on the
study by Hayman et al.119
Health state utilities Base-case value
No recurrence 0.92
Local recurrence 0.779
Other recurrence 0.685
Intervention cost Reimbursement costs were reported
Reimbursement type IORT WB-EBRT
Total reimbursement $3094 $11,726
Reimbursement including additional
medical costsa
$8003–8706 $11,726
Reimbursement including medical and
non-medical costsa
$8192–8971 $12,985
Reimbursement including medical,
non-medical, and recurrence costs (TARGIT)a
$9399–10,179 $13,743
a Range based on differences in WB-EBRT rates (15–21%).
Data for APBI not extracted as it is not relevant for the purpose of this review
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Study Shah, 2014108
Indirect costs Non-medical costs including travel costs were estimated to be $44.96 and $89.92
per day for once-daily and twice-daily schedules of treatment, respectively
Results The results for QALY, ICER and costs per QALY are extracted based on the
TARGIT-A trial as ELIOT trial was not relevant for the purpose of this review.
These are:
l QALY: INTRABEAM 9.04; WB-EBRT 9.08
l When all associated costs are incorporated, using the LRRs (3.3% for
INTRABEAM vs. 1.3% for WB-EBRT), the ICERs for local recurrence ranges
from $1782 to $2172 for WB-EBRT based on difference in whole-breast
irradiation rates (15%–21%)
l The costs per QALY for WB-EBRT compared with IORT range from $89,234/
QALY to $108,735/QALY depending on the difference in whole-breast
irradiation rates
Sensitivity analysis Not reported
Author’s conclusions The authors concluded IORT to be a potential cost-effective strategy in the
treatment of women with early-stage breast cancer. But, depending on cost per
QALT analysis, the authors stated WBI and APBI to be more cost-effective
strategies in delivering radiation therapy, despite IORT having reduced
reimbursement rates
Reviewer’s comments Limited information surrounding the model structure was presented in the
study. Time horizon for the model was not clearly stated. Although the
techniques adopted to estimate costs associated with non-medical, follow-up,
local recurrence or other recurrence (including salvage mastectomy) were
mentioned, the costs were not reported, except for non-medical costs.
Sensitivity analysis was not conducted
Quality assessment checklist for economic evaluations
Item Yes/no/unclear
1. Is the decision problem (including interventions compared and patient group) relevant to the UK? Yesa
2. Is the setting comparable to the UK? No
3. Is the analytical and modelling methodology appropriate? Yesb
4. Are all the relevant costs and consequences for each alternative identified? Yesc
5. Are the data inputs for the model described and justified? Yes
6. Are health outcomes measured in QALYs? Yes
7. Is the time horizon considered appropriate? Uncleard
8. Are costs and outcomes discounted? No
9. Is an incremental analysis performed? No
10. Is uncertainty assessed? No
a Details on the number of fractions used in the WB-EBRT (comparator) arm was not presented.
b Details surrounding the modelling methodology not presented but references provided and checked.
c Details not presented but references provided and checked.
d It is assumed that the time horizon was for 10 years based on the estimation of mean utility by technique; a lifetime
horizon would have been appropriate as the risk of recurrence continues over a lifetime.
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Appendix 7 Excluded quality-of-life studies
with rationale
Excluded study Primary reason for exclusion
Bao T, Cai L, Snyder C, Betts K, Tarpinian K, Gould J, et al. Patient-reported outcomes
in women with breast cancer enrolled in a dual-centre, double-blind, randomised
controlled trial assessing the effect of acupuncture in reducing aromatase
inhibitor-induced musculoskeletal symptoms. Cancer 2014;120:381–9
Not EQ-5D
Bonnetain F, Conroy T, Velten M, Jolly D, Mercier M, Causeret S, et al. Impact of
response shift in longitudinal postoperative quality of life (QoL) analysis among breast
cancer (BC) patients: a randomised multicenter cohort study. J Clin Oncol 2010;
Conference (var.pagings):15
Abstract
Brown DS, Trogdon J, Ekwueme DU, Chamiec-Case L, Tangka FK, Guy GP et al.
Preference-based estimates of the health utility impacts of breast cancer in women ages
18–44 in the United States. Value Health 2012; Conference(var.pagings):4
Abstract
Chandwani KD, Thornton B, Perkins GH, Arun B, Raghuram NV, Nagendra HR et al.
Yoga improves quality of life and benefit finding in women undergoing radiotherapy for
breast cancer. J Soc Integrative Oncol 2010;8:43–55
Not EQ-5D
Chang J, Couture FA, Young SD, Lau CY, Lee MK. Weekly administration of epoetin
alfa improves cognition and quality of life in patients with breast cancer receiving
chemotherapy. Supportive Cancer Therapy 2004;2:52–8
No relevant information on
health states
Cheung YB, Lee CF, Luo N, Ng R, Wong NS, Yap YS, et al. Comparison of the
measurement properties between the 5-level euroqol group’s 5-dimension (EQ-5D-5l)
questionnaire and the functional assessment of cancer therapy-breast (FACT-B) in Asian
breast cancer patients. Value Health 2012;15:A605
Abstract
Cheville AL, Almoza M, Courmier JN, Basford JR. A prospective cohort study defining
utilities using time trade-offs and the euroqol-5D to assess the impact of cancer-related
lymphedema. Cancer 2010;116:3722–31
Inappropriate participants
Conner-Spady B, Cumming C, Nabholtz JM, Jacobs P, Stewart D. Responsiveness of the
EuroQol in breast cancer patients undergoing high dose chemotherapy. Qual Life Res
2001;10:479–86
No relevant information on
health states
Coyle D, Grunfeld E, Coyle K, Julian JA, Pond GR, Folkes A, et al. Cost-effectiveness of a
survivorship care plan for breast cancer survivors. J Clin Oncol 2011;
Conference(var.pagings):15
Abstract
Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D
patient preferences. European J Health Econ 2010;11:427–34
Not primary research
Dabakuyo TS, Guillemin F, Conroy T, Velten M, Jolly D, Mercier M, et al. Response shift
effects on measuring post-operative quality of life among breast cancer patients:
a multicenter cohort study. Qual Life Res 2013;22:1–11
Not EQ-5D
de KM, Dirksen CD, Kessels AG, van der Weijden T, van de Velde CJ, Roukema JA, et al.
Cost-effectiveness of a short stay admission programme for breast cancer surgery.
Acta Oncol 2010;49:338–46
No relevant information on
health states
Dolbeault S, Cayrou S, Bredart A, Viala AL, Desclaux B, Saltel P, et al. The effectiveness
of a psycho-educational group after early-stage breast cancer treatment: results of a
randomised French study. Psycho-Oncology 2009;18:647–56
Not EQ-5D
Domeyer PJ, Sergentanis TN, Zagouri F, Zografos GC. Health-related quality of life in
vacuum-assisted breast biopsy: short-term effects, long-term effects and predictors.
Health Qual Life Outcomes 2010;8:11
Inappropriate participants
Fang P, Tan KS, Troxel AB, Rengan R, Freedman G, Lin LL. High body mass index is
associated with worse quality of life in breast cancer patients receiving radiotherapy.
Breast Cancer Res Treat 2013;141:125–33
Not EQ-5D
DOI: 10.3310/hta19690 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 69
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Picot et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
151
Excluded study Primary reason for exclusion
Fang P, Tan K, Troxel A, Rengan R, Freedman G, Lin L. High BMI associated with worse
quality of life in breast cancer patients receiving radiation therapy. Int J Radiat Oncol Biol
Physics 2013;87(Suppl. 1):S607
No relevant information on
health states
Farkkila N, Roine R, Jahkola T, Sintonen H, Hanninen J, Taari K, et al. Health state
utilities in breast cancer. Value Health 2011; Conference (var.pagings):7
Abstract
Haines TP, Sinnamon P, Wetzig NG, Lehman M, Walpole E, Pratt T, et al.Multimodal
exercise improves quality of life of women being treated for breast cancer, but at what cost?
Randomised trial with economic evaluation. Breast Cancer Res Treat 2010;124:163–75
No relevant information on
health states
Hayran M, Cakir B, Cilingiroglu N, Erman M, Kilickap S, Ozisik YY, et al. Validation and
clinical evaluation of different quality of life (QoL) scales in patients (pts) with breast
cancer (BC) in Turkey. J Clin Oncol 2011; Conference (var.pagings):15
Abstract
Jansen SJ, Otten W, van de Velde CJ, Nortier JW, Stiggelbout AM. The impact of the
perception of treatment choice on satisfaction with treatment, experienced
chemotherapy burden and current quality of life. Br J Cancer 2004;91:56–61
No relevant information on
health states
Jeruss JS, Hunt KK, Xing Y, Krishnamurthy S, Meric-Bernstam F, Cantor SB, et al.
Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with
breast cancer cost-effective? Cancer 2006;107:2328–36
Not primary research
Katharina WA, Schumacher A. Social connotations of breast cancer-work in progress.
Psycho-Oncology 2013;22:222
Abstract
Kimman ML, Dirksen CD, Falger P, Voogd A, Kessels A, Gijsen B, et al. Results of an
RCT investigating the cost-effectiveness of four follow-up strategies after breast cancer.
Eur J Cancer, Supplement 2009; Conference (var.pagings):2–3
Abstract
Kimman ML, Dirksen CD, Lambin P, Boersma LJ. Responsiveness of the EQ-5D in primary
breast cancer survivors. EJC Suppl 2008;6:73–4
Abstract
Kimman ML, Dirksen CD, Voogd AC, Falger P, Gijsen BC, Thuring M, et al. Economic
evaluation of four follow-up strategies after curative treatment for breast cancer: results
of an RCT. Eur J Cancer 2011;47:1175–85
Inappropriate participants
Lee CF, Luo N, Ng R, Wong NS, Yap YS, Lo SK, et al. Comparison of the measurement
properties between a short and generic instrument, the 5-level EuroQoL Group’s
5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument,
the Functional Assessment of Cancer Therapy-Breast (FACT-B), in Asian breast cancer
patients. Qual Life Res 2013;22:1745–51
Inappropriate participants
Lee CF, Ng R, Luo N, Wong NS, Yap YS, Lo SK, et al. The English and Chinese versions
of the five-level EuroQoL Group’s five-dimension questionnaire (EQ-5D) were valid and
reliable and provided comparable scores in Asian breast cancer patients. Supportive Care
Cancer 2013;21:201–9
Inappropriate participants
Lee J-A, Kim S-Y, Kim Y, Oh J, Kim H-J, Jo D-Y, et al. Comparison of health-related
quality of life between cancer survivors treated in designated cancer centres and the
general public in Korea. Japanese J Clin Oncol 2014;44:141–52
No relevant information on
health states
Lovrics PJ, Cornacchi SD, Barnabi F, Whelan T, Goldsmith CH. The feasibility and
responsiveness of the health utilities index in patients with early-stage breast cancer:
a prospective longitudinal study. Qual Life Res 2008;17:333–45
Not EQ-5D
Matalqah LM, Radaideh KM, Yusoff ZM, Awaisu A. Health-related quality of life using
EQ-5D among breast cancer survivors in comparison with age-matched peers from the
general population in the state of Penang, Malaysia. J Public Health 2011;19:475–80
Inappropriate participants
Milne RJ, Heaton-Brown KH, Hansen P, Thomas D, Harvey V, Cubitt A. Quality-of-life
valuations of advanced breast cancer by New Zealand women. Pharmacoeconomics
2006;24:281–92
Inappropriate participants
Moro-Valdezate D, Peiro S, Buch-Villa E, Caballero-Garate A, Morales-Monsalve MD,
Martinez-Agullo A, et al. Evolution of Health-Related Quality of Life in Breast Cancer
Patients during the First Year of Follow-Up. J Breast Cancer 2013;16:104–11
No relevant information on
health states
Ng R, Lee CF, Wong NS, Yap YS, Lo SK, Wong C, et al. Measurement properties and
equivalence of the English and Chinese versions of the new 5-level EQ-5D in Asian
breast cancer patients. Eur J Cancer 2011; Conference(var.pagings):S235
Abstract
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Excluded study Primary reason for exclusion
Oh S, Heflin L, Meyerowitz BE, Desmond KA, Rowland JH, Ganz PA. Quality of life of
breast cancer survivors after a recurrence: a follow-up study. Breast Cancer Res Treat
2004;87:45–57
Not EQ-5D
Peasgood T, Ward SE, Brazier J. Health state utility values in breast cancer: a review
and metaanalysis. Value Health 2010; Conference(var.pagings):7
Not primary research
Polsky D, Keating NL, Weeks JC, Schulman KA. Patient choice of breast cancer
treatment: impact on health state preferences. Med Care 2002;40:1068–79
Not EQ-5D
Polsky D, Mandelblatt JS, Weeks JC, Venditti L, Hwang YT, Glick HA, et al. Economic
evaluation of breast cancer treatment: considering the value of patient choice. J Clin
Oncol 2003;21:1139–46
Not EQ-5D
Postma EL, Koffijberg H, Verkooijen HM, Witkamp AJ, van den Bosch MA, van HR.
Cost-effectiveness of radioguided occult lesion localisation (ROLL) versus wire-guided
localisation (WGL) in breast conserving surgery for nonpalpable breast cancer: results
from a randomised controlled multicenter trial. Ann Surg Oncol 2013;20:2219–26
No relevant information on
health states
Rand KL, Otte JL, Flockhart D, Hayes D, Storniolo AM, Stearns V et al. Modelling hot
flushes and quality of life in breast cancer survivors. Climacteric 2011;14:171–80
No relevant information on
health states
Shimozuma K, Shiroiwa T, Fukuda T, Mori M, Ohashi Y, Watanabe T. Comparison of
Eq-5D Score Between Treatment with 4 Cycles of Anthracycline Followed by 4 Cycles of
Taxane and 8 Cycles of Taxane for Node Positive Breast Cancer Patients After Surgery:
N-Sas Bc 02 Trial. Value Health 2010;13:A274
Abstract
Shiroiwa T, Fukuda T, Shimozuma K, Kuranami M, Suemasu K, Ohashi Y, et al.
Comparison of EQ-5D scores among anthracycline-containing regimens followed by
taxane and taxane-only regimens for node-positive breast cancer patients after surgery:
the N-SAS BC 02 trial. Value Health 2011;14:746–751
No relevant information on
health states
Slovacek L, Slovackova B, Slanska I, Petera J, Priester P, Filip S, et al. Depression
symptoms and health-related quality of life among patients with metastatic breast cancer
in programme of palliative cancer care. Neoplasma 2009;56:467–72
No relevant information on
health states
Slovacek L, Slovackova B, Slanska I, Petera J, Priester P. Quality of life and depression
among metastatic breast cancer patients. Med Oncol 2010;27:958–9
Abstract
Sun Y, Kang E, Heo C, Kim D, Hwang Y, Yom C, et al. Comparison of Quality of Life
According to the Surgical Techniques Among Breast Cancer Survivors. Breast
2013;22(Suppl. 1):S117–18
Abstract
Sura K, Tan K, Freedman GM, Troxel AB, Lin LL. Factors affecting breast cancer
patient quality of life in association with radiation. Int J Rad Oncol Biol Phys 2013;
87(Suppl. 1):S115–16
Abstract
Takei H, Ohsumi S, Shimozuma K, Ohashi Y, Fujiki Y, Suemasu K, et al. Health-related
quality-of-life and psychological distress of breast cancer patients after surgery
during phase III randomised trial comparing tamoxifen, exemestane, and anastrozole:
N-SAS BC 04. Breast Cancer Res Treat 2006;100(Suppl. 1):S189–90
Not EQ-5D
Teckle P, Peacock S, McTaggart-Cowan H, van der Hoek K, Chia S, Melosky B, et al. The ability
of cancer-specific and generic preference-based instruments to discriminate across clinical and
self-reported measures of cancer severities. Health Qual Life Outcomes 2011;9:106
Inappropriate participants
Velthuis MJ, May AM, Koppejan-Rensenbrink RA, Gijsen BC, van BE, de Wit GA, et al.
Physical Activity during Cancer Treatment (PACT) Study: design of a randomised clinical
trial. BMC Cancer 2010;10:272
Not EQ-5D
Verkooijen HM, Buskens E, Peeters PH, Borel Rinkes IH, de Koning HJ, van Vroonhoven TJ,
et al. Diagnosing non-palpable breast disease: short-term impact on quality of life of
large-core needle biopsy versus open breast biopsy. Surg Oncol 2002;10:177–81
Inappropriate participants
von Meyenfeldt MF, de KM, Kessels AGH, van der Weijden T, Bell AVRJ, Roukema JA,
et al. Economic evaluation of a short stay admission programme for breast cancer
surgery in four hospitals in the Netherlands. Eur J Cancer, Supplement 2010;
Conference(var.pagings):3
Abstract
Wilking N, Bernow M, Kossler I, Wilking U, Jonsson B. Health related quality of life
(HRQoL) in Swedish relapse free breast cancer patients. A study of EQ5D and TTO in a
patient advocacy population. Cancer Res 2009; 69:780S–1S
Abstract
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Excluded study Primary reason for exclusion
Wu Y, Segreti A, Cella D, DiLeo A, Amonkar M, Koehler M, et al. Lapatinib plus
paclitaxel versus paclitaxel alone for first line metastatic breast cancer (MBC) in ErbB(2+)
patients – quality of Life (QOL) results. EJC Suppl 2008;6:171
Abstract
Yaqata H, Iwase T, Ohtsu H, Komoike Y, Saji S, Takei H, et al. Baseline assessment of
patient-reported outcomes (PROs) for breast cancer patients after 5-years of endocrine
treatment in a randomised clinical trial: NSAS-BC 05. Breast 2011;20(Suppl. 1):S68
Abstract
Zhou X, Cella D, Cameron D, Amonkar MM, Segreti A, Stein S, et al. Lapatinib plus
capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer:
quality-of-life assessment. Breast Cancer Res Treat 2009;117:577–89
No relevant information on
health states
Zhou X, Segreti A, Cella D, Cameron D, Geyer C, Amonkar M, et al. Lapatinib plus
capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) –
quality of Life (QOL) assessment. EJC Supplements 2008;6:216–17
Abstract
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Appendix 8 Data extraction forms for
health-related quality-of-life studies
(presented in order of health states)
Reference
Turnbull, 2010.126
Study characteristics
Research question
What are the stated objectives of the study?
To determine the potential benefits to the patient and to the NHS of the addition of MRI to the routine
techniques employed for locoregional staging of primary breast cancer.
Describe the type of study and study design.
Randomised controlled trial.
Was the sample from i) the general population, ii) patients with the disease of interest, iii) individuals with
knowledge of the disease, iv) other?
Are inclusion/exclusion criteria clearly described? Do these exclude any individuals that may be relevant
(e.g. > 80 years)?
Women with biopsy-proven primary breast cancer, who were scheduled for WLE following triple assessment
(clinical, radiological and pathological).
Yes, the inclusion and exclusion criteria were clearly described; the study included patients aged 18 years
or above.
What are the characteristics of the baseline cohort for the evaluation?
Age MRI scan No MRI scan
Mean (years) (SD) 56.38 (9.67) 56.59 (10.09)
Median (years) (range) 57 (27–86) 57 (58–85)
Note
Clinical details based on ITT population.
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Age (as randomised) MRI scan No MRI scan
< 50 years, n (%) 187 (22.9) 187 (23.2)
≥ 50 years, n (%) 629 (77.1) 620 (76.8)
Note
Clinical details based on ITT population.
Sex Female 100%
Race (if appropriate) Not reported
Indication/disease Primary breast cancer
Other characteristics
(sample size)
n= 1625 (MRI scan: n= 817; no MRI scan: 808)
Variablesa Category MRI scan No MRI scan
Menopausal status, n (%) Pre-menopausal 232 (28.4) 234 (29.0)
Post menopausal 574 (70.3) 565 (70.0)
Missing 10 (1.2) 8 (1.0)
HRT use, n (%) Currently 63 (7.7) 46 (5.7)
Previously 232 (28.4) 231 (28.6)
Never 514 (63.0) 528 (65.4)
Missing 7 (0.9) 2 (0.2)
Pre-operative neoadjuvant therapy,
n (%)
Yes 6 (0.7) 11 (1.4)
No 808 (99.0) 792 (98.1)
Missing data 2 (0.2) 4 (0.5)
In situ disease. Carcinoma in situ
present, n (%)
Yes 586 (71.8) 568 (70.4)
No 191 (23.4) 193 (23.9)
Missing data 39 (4.8) 46 (5.7)
Grade, n (%) I 177 (23.8) 179 (24.8)
II 358 (48.2) 331 (45.8)
III 200 (26.9) 205 (28.4)
Missing 8 (1.1) 8 (1.1)
HRT, hormone replacement therapy.
a Information has been brought together from more than one place. n= 1625 is number
randomised; however, the variables are for those analysed (n= 1623).
Note
Other characteristics were reported but not data extracted.
QoL instrument EQ-5D
Utility values,
(yes/no)
Yes
Treatment effect,
if reported
Yes, reoperation rates
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Country/setting
What is the country and setting for the evaluation?
UK, RCT.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
QoL data were collected as part of the RCT.
Results
Summarise the results.
EQ-5D scores MRI scan: mean (SE), 95% CI No MRI scan: mean (SE), 95% CI
Baseline 0.8567 (0.0065), 0.8435 to 0.8699 0.8601 (0.0063), 0.8475 to 0.8728
8 weeks post randomisation 0.7791 (0.0078), 0.7634 to 0.7948 0.7728 (0.0079), 0.7569 to 0.7887
6 months post initial surgery 0.8040 (0.0094), 0.7844 to 0.8237 0.7935 (0.0078), 0.7781 to 0.8089
12 months post initial surgery 0.8101 (0.0069), 0.7965 to 0.8236 0.8112 (0.0072), 0.7970 to 0.8253
Note
Rounded to 4 decimal places.
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? (Was a valid preference-based instrument used to describe health states, such as
EQ-5D? Was the valuation of health states from the UK general population?)
Yes. EQ-5D was used to assess health states; the valuation of health states were from the UK population.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
l The authors concluded that overall the two arms of the trial had similar QoL scores which decreased slightly
between baseline and 8 weeks post randomisation but recovered between 6 and 12 months post
initial surgery.
l The authors reported that 12 months after initial surgery, there was no statistically significant difference in
HRQoL as measured by EQ-5D between the two arms of the trial once baseline HRQoL and other covariates
were controlled for. The nominal values of the point estimates of the mean changes between baseline and
12 months were also very similar.
What are the implications of the study for the model?
The utility values were derived from EQ-5D estimates based on UK population; therefore, the EQ-5D estimates
reported for the no MRI arm could be used to inform the SHTAC’s model as this arm of the trial represented
current UK treatment option for primary breast cancer. Specifically, the EQ-5D estimates in the baseline and
12 months post initial surgery for the cohort in no MRI arm could be used in the SHTAC’s model.
Criteria for assessment of study relevance to the National
Institute for Health and Care Excellence’s reference case
(adapted from Papaioannou et al.62)
Relevance questions Requirement for NICE
Do the population characteristics (e.g. age, sex, comorbidities, diagnosis, severity of disease) in
the study match those described in the decision problem of the review and those modelled?
Yes
Was a generic preference-based instrument (preferably EQ-5D) used to describe the
health states?
Yes
Was the change in HRQoL taken directly from the patient population? Yes
Was the valuation of changes in patients’ HRQL undertaken from the general
(UK) population?
Yes
Was the technique used to value the health states a choice-based method (such as TTO)? Yes
Reference
Freedman, 2010.127
Study characteristics
Research question
What are the stated objectives of the study?
To use the EQ-5D instrument to evaluate the long-term health states of women with early-stage breast cancer
treated by BCS and radiation.
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Describe the type of study and study design.
Single cohort study.
Was the sample from i) the general population, ii) patients with the disease of interest, iii) individuals with
knowledge of the disease, iv) other?
Are inclusion/exclusion criteria clearly described? Do these exclude any individuals that may be relevant
(e.g. > 80 years)?
Women with early breast cancer treated with BCS and radiation with or without systemic therapy.
Yes, the inclusion and exclusion criteria were clearly described and do not exclude any individuals that may be
relevant (the study excluded male breast cancer, T3-T4 disease, stage IV disease, mastectomy, or patients
treated without radiation).
What are the characteristics of the baseline cohort for the evaluation?
Age (years) 18–44: 13%
45–64: 57%
> 64: 30%
Sex Female, 100%
Race (if appropriate) Not reported
Indication/disease Early-stage breast cancer, American Joint Committee on Cancer stages 0, I,
or II breast cancer
Other characteristics (sample size) n= 1050
Tumour stage, n (%)
Tis 192 (18%)
T1 714 (68%)
T2 141 (13%)
Nodal stage, n (%)
N0 644 (61%)
N1–3 positive 174 (17%)
N4+ positive 38 (4%)
NX 194 (18%)
QoL instrument EQ-5D
Utility values, (yes/no) Yes, presented in a figure over time and in text
Treatment effect, if reported Not reported
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Country/setting
What is the country and setting for the evaluation?
USA, hospital outpatient clinic.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Single study.
Results
Summarise the results.
l Mean descriptive index:
Time points EQ-5D score (95% CI)
5 years 0.89 (0.87 to 0.91)
10 years 0.9 (0.86 to 0.94)
15 years 0.9 (0.83 to 1.00)
l Mean scores by age:
Time points
Age groups
18–44 years 45–64 years > 64 years
5 years 0.95 0.9 0.88
10 years 0.96 0.93 0.76
l No significant differences in health states between patients by age.
l States no significant differences in mean index score by the use of adjuvant systemic therapy when
compared with those treated by chemotherapy only, tamoxifen only, both or neither (p> 0.05); no data
were reported.
l States no apparent difference in mean score by use of IMRT versus conventional radiation although very few
patients treated with IMRT had follow-up greater than 3 years. No data were reported.
l States no significant differences between patients with and without a recurrence, although the number of
questionnaires from patients with recurrence was small (n= 94) compared with those without recurrence
(n= 2,386). No data were reported.
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Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? (Was a valid preference-based instrument used to describe health states, such as
EQ-5D? Was the valuation of health states from the UK general population?).
Yes. EQ-5D was used to assess health states. However, the valuation of health states were not from the UK
general population – the study was US based.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The authors concluded that patients reported high EQ-5D value, which was steady for up to 15 years following
treatment with BCS and radiation. In addition, it was also observed that there was good level of statistical
correlation between patient-reported outcomes by either descriptive system or VAS.
What are the implications of the study for the model?
The study is not UK based; therefore, the reported EQ-5D values could be used to inform the model for testing
uncertainty or model validity. However, if no UK-based study is found, the mean EQ-5D score reported for
WLE+WB-EBRT health state could be fed into the model. Data on mean index scores are reported for the
entire cohort of patients (i.e. women treated with BCS and radiation) but report no significant difference
between subgroups (e.g. the use of adjuvant systemic therapy, use of IMRT, recurrence, although the number
of questionnaires from patients with recurrences was very small compared with those without recurrence).
DOI: 10.3310/hta19690 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 69
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Picot et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
161
Criteria for assessment of study relevance to the National
Institute for Health and Care Excellence’s reference case
(adapted from Papaioannou et al.62)
Relevance questions Requirement for NICE
Do the population characteristics (e.g. age, sex, comorbidities, diagnosis, severity of disease)
in the study match those described in the decision problem of the review and
those modelled?
Yes
Was a generic preference-based instrument (preferably EQ-5D) used to describe the
health states?
Yes
Was the change in HRQoL taken directly from the patient population? Yes
Was the valuation of changes in patients’ HRQL undertaken from the general
(UK) population?
No
Was the technique used to value the health states a choice-based method (such as TTO)? Yes
Reference
Prescott, 2007.128
Study characteristics
Research question
What are the stated objectives of the study?
To assess whether or not omission of post-operative radiotherapy in women with ‘low-risk’ axillary node-negative
breast cancer (T0–2) treated by BCS and endocrine therapy improves QoL and is more cost-effective.
Describe the type of study and study design.
Randomised controlled trial. A non-randomised cohort was also recruited in order to complete a comprehensive
cohort study.
Was the sample from i) the general population, ii) patients with the disease of interest, iii) individuals with
knowledge of the disease, iv) other?
Are inclusion/exclusion criteria clearly described? Do these exclude any individuals that may be relevant
(e.g. > 80 years)?
Breast cancer patients undergoing BCS and endocrine therapy with complete excision on
histological assessment
The inclusion and exclusion criteria were reported. The study did not include patients aged below 65 years.
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What are the characteristics of the baseline cohort for the evaluation?
Age Randomised (n= 255)
Radiotherapy (n= 127)
No radiotherapy
(n= 128)
Mean age (years) at surgery (SD) 72.3 (5.0) 72.8 (5.2)
Sex Female 100%
Race (if appropriate) Not reported
Indication/disease Breast cancer patients with ‘low risk’, axillary node negative
Other characteristics
(sample size)
n= 255 (randomised patients); 253 patients were evaluable; EQ-5D data were available for
203 patients
QoL instrument EQ-5D
Utility values, (yes/no) Yes
Treatment effect,
if reported
Not reported
Country/setting
What is the country and setting for the evaluation?
UK, RCT.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Yes, a RCT and a cohort study.
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Results
Summarise the results.
EQ-5D
Radiotherapy: n (n= 102),
mean (95% CI)
No radiotherapy: n (n= 101),
mean (95% CI)
Baseline 0.77 (0.73 to 0.80) 0.74 (0.70 to 0.77)
3.5 months 0.78 (0.74 to 0.81) 0.76 (0.73 to 0.79)
9 months 0.76 (0.71 to 0.81) 0.72 (0.68 to 0.76)
15 months 0.74 (0.70 to 0.78) 0.73 (0.69 to 0.77)
Unadjusted QALYs 0.95 (0.90 to 0.99) 0.92 (0.88 to 0.95)
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? (Was a valid preference-based instrument used to describe health states, such as
EQ-5D? Was the valuation of health states from the UK general population?)
Yes. EQ-5D was used to assess health status; the study was UK based.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The authors concluded that patients in the radiotherapy arm had higher utility values at the baseline compared
with those in the no radiotherapy arm. However, it was observed that the difference in adjusted QALYs for the
two arms was too small to be statistically significant at the 5% level.
What are the implications of the study for the model?
As this is a UK-based study, the model inputs on utilities could be used to inform SHTAC’s cost-effectiveness
model in development. In particular, this study could be used to populate the health state ‘Wide local excision
followed by WB-EBRT’ with the value of 0.74 (95% CI 0.70 to 0.78).
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Criteria for assessment of study relevance to the National
Institute for Health and Care Excellence’s reference case
(adapted from Papaioannou et al.62)
Relevance questions Requirement for NICE
Do the population characteristics (e.g. age, sex, co-morbidities, diagnosis, severity of disease)
in the study match those described in the decision problem of the review and those modelled?
Yes
Was a generic preference-based instrument (preferably EQ-5D) used to describe the
health states?
Yes
Was the change in HRQoL taken directly from the patient population? Yes
Was the valuation of changes in patients’ HRQL undertaken from the general
(UK) population?
Yes
Was the technique used to value the health states a choice-based method (such as TTO)? Yes
Reference
Serra, 2012.129
Study characteristics
Research question
What are the stated objectives of the study?
To evaluate the impact of guided imagery (a stress reduction technique) on patients undergoing radiation
therapy for breast cancer.
Describe the type of study and study design.
Single cohort study.
Was the sample from i) the general population, ii) patients with the disease of interest, iii) individuals with
knowledge of the disease, iv) other?
Are inclusion/exclusion criteria clearly described? Do these exclude any individuals that may be relevant
(e.g. > 80 years)?
Women receiving radiation therapy for breast cancer.
Yes, inclusion/exclusion criteria were reported.
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What are the characteristics of the baseline cohort for the evaluation?
Age (years) Mean age (range): 57 (28–77)
Sex Female 100%
Race (if appropriate) Not reported
Indication/disease Women undergoing radiation therapy for breast cancer
Other characteristics (sample size) N= 66
Characteristics n
Stage
0 18
I 24
II 11
III 9
Local recurrences 4
Adjuvant therapy
Chemotherapy and hormones 13
Chemotherapy only 9
Hormones only 28
None 16
QoL instrument EQ-5D
Utility values, (yes/no) Yes
Treatment effect, if reported Not reported
Country/setting
What is the country and setting for the evaluation?
USA.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Single study.
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Results
Summarise the results.
l Health status was evaluated at two time points: prior to start of guided therapy (time 1) and at the end of
radiation therapy (time 2).
l EQ-5D index at time 1: 0.88 (n= 64), time 2= 0.86 (n= 54).
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? (Was a valid preference-based instrument used to describe health states, such as
EQ-5D? Was the valuation of health states from the UK general population?)
Yes. EQ-5D questionnaire was used; the study was US based.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
l Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The authors concluded that EQ-5D results indicated an increase in pain ratings attributed to the radiation-
induced skin reactions which was also associated with a reduction in anxiety and depression. This reduction
further reinforced the use of guided imagery.
What are the implications of the study for the model?
As the study was US based, the value of 0.86 (after radiation therapy) could be used to inform the health state
of ‘wide local excision +WB-EBRT’ within the cost-effectiveness model, should there be no available UK-based
data. However, patients also received guided imagery and there was no control arm in the study. It is therefore
unclear what impact guided imagery had.
In other case, this value could be used in conducting sensitivity analysis.
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Criteria for assessment of study relevance to the National
Institute for Health and Care Excellence’s reference case
(adapted from Papaioannou et al.62)
Relevance questions Requirement for NICE
Do the population characteristics (e.g. age, sex, comorbidities, diagnosis, severity of disease) in
the study match those described in the decision problem of the review and those modelled?
Yes
Was a generic preference-based instrument (preferably EQ-5D) used to describe the
health states?
Yes
Was the change in HRQoL taken directly from the patient population? Yes
Was the valuation of changes in patients’ HRQL undertaken from the general (UK) population? ?
Was the technique used to value the health states a choice-based method (such as TTO)? Yes
?, unclear.
Reference
Conner-Spady, 2005.130
Study Characteristics
Research question
What are the stated objectives of the study?
To examine changes in HRQoL in breast cancer patients with poor prognosis (stage II/III) receiving HDC
treatment with autologous blood stem cell transplantation during long-term follow-up.
Describe the type of study and study design.
Prospective 2-year longitudinal study.
Was the sample from i) the general population, ii) patients with the disease of interest, iii) individuals with
knowledge of the disease, iv) other?
Are inclusion/exclusion criteria clearly described? Do these exclude any individuals that may be relevant
(e.g. > 80 years)?
Patients with breast cancer with poor prognosis (stage II/III).
Yes. Inclusion/exclusion criteria were described clearly; consecutive patients aged between 18 and 65 years.
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What are the characteristics of the baseline cohort for the evaluation?
Age (years) Mean age (range, SD): 44.7 (21–62, 8.5)
Age distribution n %
21–35 years 6 11.5
36–50 years 32 61.5
51–62 years 14 26.9
Sex Not reported specifically
Race (if appropriate) Not reported
Indication/disease Breast cancer patients with poor prognosis (stage II/III) who are at high risk
of relapse
Other characteristics
(sample size)
N= 52
Variables Category n Per cent
Marital status Single 8 15.4
Married/Partner 40 76.9
Divorced 2 3.8
Widowed 2 3.8
Years of education Grade 12 or less 18 35.3
More than Grade 12 33 64.7
Stage of cancer II 18 34.6
III 34 65.4
Type of surgery Modified radical mastectomy 22 42.3
Total mastectomy 19 36.5
Segmental 11 21.2
Nodal status 10 or more 39 75.0
Tamoxifen Yes 5 10.0
Menopausal status Pre 37 71.2
Post 15 28.8
QoL instrument EQ-5D
Utility values, (yes/no) Yes
Treatment effect, if reported Not reported
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Country/setting
What is the country and setting for the evaluation?
Canada; Phase II trial.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
A prospective longitudinal study.
Results
Summarise the results.
l Mean QoL scores across different time-points.
Time points EQ-5D scores (SD)
T1: pre-induction 0.78 (0.18)
T2: day 1, third cycle of FAC 0.75 (0.18)
T3: 3 weeks post HDC 0.61 (0.29)
T4: 6 months or 8 weeks post HDC 0.79 (0.19)
T5: 12 months 0.84 (0.19)
T6: 18 months 0.84 (0.13)
T7: 24 months 0.89 (0.13)
BAN, British Approved Name; FAC, fluorouracil, Adriamycin (doxorubicin; BAN)
l HRQoL decreased significantly from T1 to T3 but at T4, i.e. 8 weeks post HDC, it returned to baseline levels.
Although in the short term there was a negative effect of treatment on HRQoL, it rebounded quickly.
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? (Was a valid preference-based instrument used to describe health states, such as
EQ-5D? Was the valuation of health states from the UK general population?)
Yes, EQ-5D questionnaire was used.
The valuation of health states was from a set of Canadian breast cancer patients group.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The authors concluded that EQ 5D data indicated a decline in HRQoL following the administration of HDC but
returned to baseline levels post HDC.
What are the implications of the study for the model?
The study did not report utility values for the health states that are relevant for the SHTAC’s cost-effectiveness
model in development. However, as the patients included in the study had all undergone mastectomy/surgery,
the utility value reported by EQ-5D at the end of 2 years (i.e. at time-point T7) valued at 0.89 could be used to
represent the utility value for ‘mastectomy & reconstruction’ health state in the SHTAC’s cost-effectiveness model.
Criteria for assessment of study relevance to the National
Institute for Health and Care Excellence’s reference case
(adapted from Papaioannou et al.62)
Relevance questions Requirement for NICE
Do the population characteristics (e.g. age, sex, comorbidities, diagnosis, severity of disease) in
the study match those described in the decision problem of the review and those modelled?
No
Was a generic preference-based instrument (preferably EQ-5D) used to describe the
health states?
Yes
Was the change in HRQoL taken directly from the patient population? Yes
Was the valuation of changes in patients’ HRQL undertaken from the general
(UK) population?
Yesa
Was the technique used to value the health states a choice-based method (such as TTO)? Yes
a Health states were converted to EQ-5D index using standardised weights derived from time-trade off measurements
based on UK population.
Reference
Robertson, 2012.131
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Study characteristics
Research question
What are the stated objectives of the study?
To present an audit of all IBRs during the period 2005–8 performed by breast surgeons, including
post-operative HRQoL.
Describe the type of study and study design.
Retrospective descriptive study.
Was the sample from i) the general population, ii) patients with the disease of interest, iii) individuals with
knowledge of the disease, iv) other?
Are inclusion/exclusion criteria clearly described? Do these exclude any individuals that may be relevant
(e.g. > 80 years)?
Consecutive patients recruited between 2005 and 2008 who had undergone IBRs.
Inclusion and exclusion criteria were reported.
What are the characteristics of the baseline cohort for the evaluation?
Age (years) Mean age at IBR: 50
Sex Female 100%
Race (if appropriate) Not reported
Indication/disease IBR patients with implants
Other characteristics
(sample size)
Sample size: 223 patients
Indication
for IBR
Mastectomy as
first treatment
Completion
mastectomy IBTR Total
% (n) % (n) % (n) % (n)
Patients 62.8 (140) 27.3 (61) 9.9 (22) 100 (223)
IBTR, ipsilateral breast tumour recurrence.
QoL instrument EQ-5D
Utility values, (yes/no) Yes
Treatment effect,
if reported
Not reported
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Country/setting
What is the country and setting for the evaluation?
Sweden.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Single study.
Results
Summarise the results.
l The calculated EQ-5D index for the patient population was 0.83.
l EQ-5D questionnaire for patients’ current state of health at median of 4 years post operatively.
Dimension
Severity level of problem
MissingNo problem Moderate Severe
% (n) % (n) % (n) n
Mobility 86.6 (142) 6.7 (11) 0 (0) 11
Self-care 92.7 (152) 0.6 (1) 0 (0) 11
Usual activities 78 (128) 13.4 (22) 1.8 (3) 11
Pain/discomfort 52.4 (86) 37.8 (62) 1.8 (3) 13
Anxiety/depression 53.7 (88) 37.8 (62) 1.8 (3) 11
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? (Was a valid preference-based instrument used to describe health states, such as
EQ-5D? Was the valuation of health states from the UK general population?)
Yes. EQ-5D was used to assess health status of the patients.
The valuation of health states was not from the UK general population; the study was based on
Swedish population.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The authors stated that although the rate of irradiated patients was high, patient-reported outcomes related to
aesthetics of the breast reconstruction and items in day-to-day life were satisfactory. Furthermore, they
observed that, compared with norm data, there was a high frequency of moderate problems associated with
pain/discomfort and anxiety/depression at a median of 4 years following surgery, even though the general state
of health was highly rated.
What are the implications of the study for the model?
The estimated EQ-5D score of 0.83 could be populated for the ‘mastectomy and reconstruction’ health state
within the SHTAC’s cost-effectiveness model in development.
Criteria for assessment of study relevance to the National
Institute for Health and Care Excellence’s reference case
(adapted from Papaioannou et al.62)
Relevance questions Requirement for NICE
Do the population characteristics (e.g. age, sex, comorbidities, diagnosis, severity of disease) in
the study match those described in the decision problem of the review and those modelled?
Yes
Was a generic preference-based instrument (preferably EQ-5D) used to describe the health states? Yes
Was the change in HRQoL taken directly from the patient population? Yes
Was the valuation of changes in patients’ HRQL undertaken from the general (UK) population? No
Was the technique used to value the health states a choice-based method (such as TTO)? Yes
Reference
Lidgren, 2007.132
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Study characteristics
Research question
What are the stated objectives of the study?
To describe the HRQoL in different breast cancer disease states using preference-based measures.
Describe the type of study and study design.
Cross-sectional observational study.
Was the sample from i) the general population, ii) patients with the disease of interest, iii) individuals with
knowledge of the disease, iv) other?
Are inclusion/exclusion criteria clearly described? Do these exclude any individuals that may be relevant
(e.g. > 80 years)?
Women with a previous diagnosis of breast cancer.
The inclusion criteria are reported, but exclusion criteria are not.
What are the characteristics of the baseline cohort for the evaluation?
Age (years) Mean age (range): 57 (28–93)
Age distribution Frequency Percentage
< 50 years 91 26
50–64 years 178 52
≥ 65 years 76 22
Total 345 100
Sex Female, 100%
Race (if appropriate) Not reported
Indication/disease Women with a previous diagnosis of breast cancer
Other characteristics (sample size) n= 361; n= 345 after exclusions
QoL instrument EQ-5D
Utility values, (yes/no) Yes
Treatment effect, if reported Not reported
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Country/setting
What is the country and setting for the evaluation?
Sweden, breast cancer outpatient clinic.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
A cross-sectional observational study.
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Results
Summarise the results.
State n % Mean EQ-5D score 95% CI
State P (patients in their first year after a
primary breast cancer)
72 21 0.696a 0.634 to 0.747
State R (patients in their first year after
a recurrence)
21 6 0.779 0.700 to 0.849
State S (patients who had not had a primary
breast cancer diagnosis or a recurrence during
the previous year)
177 53 0.779 0.745 to 0.811
State M (patients with metastatic disease) 65 19 0.685a 0.620 to 0.735
a Significant difference compared with second and following years after primary breast cancer/recurrence
(p< 0.005).
The main driver behind the reduction in HRQoL was pain and discomfort as well as anxiety and depression.
EQ-5D dimensions (no problems, moderate problems and severe problems) were reported but no data
were extracted.
State n Mean EQ-5D score 95% CI
Patients in state P receiving adjuvant chemotherapy 23 0.620 0.509 to 0.697
Patients in state P receiving hormone therapy 17 0.744 0.573 to 0.841
Patients in state R receiving adjuvant chemotherapy 7 0.767 0.573 to 0.841
Patients in state R receiving adjuvant hormone therapy 4 0.816 0.729 to 0.963
Patients in state S receiving adjuvant hormone therapy 79 0.824 0.785 to 0.857
Patients in state M receiving hormone therapy 16 0.648 0.513 to 0.765
Patients in state M receiving chemotherapy 38 0.692 0.611 to 0.746
Metastatic patients who had at least one new distant
recurrences more than 1 month after their first
distant recurrence
10 0.661 0.454 to 0.812
Metastatic patients who did not have a new distant
recurrences more than 1 month after their first
distant recurrence
55 0.690 0.630 to 0.753
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? (Was a valid preference-based instrument used to describe health states, such as
EQ-5D? Was the valuation of health states from the UK general population?)
Yes. EQ-5D data were presented clearly. The valuation was based on Swedish patients.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The authors found that there was an association between breast cancer and decline in HRQoL. This relationship
was most evident in patients with metastatic disease.
What are the implications of the study for the model?
l If UK-based data are not available: the utility value of 0.685 as derived for the patients with metastases
could be used to inform the SHTAC’s cost-effectiveness model for the health state of distant recurrence,
although the data are derived from Swedish patients. In addition, the value of 0.779 could be used to
populate the utility value for health state ‘disease free after local recurrence’.
l If UK-based data are available: the above values could be used for conducting sensitivity analysis.
Criteria for assessment of study relevance to the National
Institute for Health and Care Excellence’s reference case
(adapted from Papaioannou et al.62)
Relevance questions Requirement for NICE
Do the population characteristics (e.g. age, sex, comorbidities, diagnosis,
severity of disease) in the study match those described in the decision
problem of the review and those modelled?
Yes
Was a generic preference-based instrument (preferably EQ-5D) used to
describe the health states?
Yes
Was the change in HRQoL taken directly from the patient population? Yes
Was the valuation of changes in patients’ HRQL undertaken from the general
(UK) population?
Yes; the study used UK EQ-5D index tariff
Was the technique used to value the health states a choice-based method
(such as TTO)?
Yes
Reference
Sherrill, 2008.133
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Study characteristics
Research question
What are the stated objectives of the study?
To examine whether or not patients receiving combination therapy of lapatinib+ capecitabine would
experience, on average, more time in a better health state compared with patients on capecitabine alone.
Describe the type of study and study design.
Randomised controlled trial; Q-TWiST analysis.
Was the sample from i) the general population, ii) patients with the disease of interest, iii) individuals with
knowledge of the disease, iv) other?
Are inclusion/exclusion criteria clearly described? Do these exclude any individuals that may be relevant
(e.g. > 80 years)?
Advanced or metastatic HER-2+ breast cancer patients who had progressive disease following prior therapy
which included an anthracycline, a taxane and trastuzumab.
Inclusion and exclusion criteria were reported elsewhere (references provided).151,164
What are the characteristics of the baseline cohort for the evaluation?
Age Not reported
Sex Female, 100%
Race (if appropriate) Not reported
Indication/disease Advanced or metastatic HER-2+ breast cancer who had progressive disease
following prior therapy
Other characteristics
(sample size)
N= 399
Lapatinib+ capecitabine arm Capecitabine arm
n 198 201
Patients characteristics
Prior therapy Anthracycline 97%
Taxane 97%
Trastuzumab 97%
Patients with metastatic disease 96%
Patients with visceral lesions 78%
Patients with visceral at three or more sites 49%
QoL instrument EQ-5D
Utility values, (yes/no) Yes
Treatment effect, if reported Not reported
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Country/setting
What is the country and setting for the evaluation?
UK and the USA; Phase III RCT.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Single study; patient-reported utility weights were derived from the EQ-5D using published algorithms.165
Results
Summarise the results.
Average utility values by health state, based on EQ-5D scores.
Health state ITT population Lapatinib plus capecitabine Capecitabine monotherapy
Toxicity:a Grade 3/4 0.60 (n= 27) 0.59 (n= 17)
TWiST 0.66 (n= 168) 0.66 (n= 157)
Relapseb 0.41 (n= 50) 0.44 (n= 67)
a Toxicity included all days spent with grade 3/4 adverse events after randomisation and prior to
disease progression.
b Relapse includes period till death or end of follow-up.
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? (Was a valid preference-based instrument used to describe health states, such as
EQ-5D? Was the valuation of health states from the UK general population?).
Yes, EQ-5D questionnaire was used.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The authors concluded that Q-TWiST was greater in patients receiving the combination of lapatinib and
capecitabine compared with those receiving capecitabine alone. Although the full impact of the combination
therapy could not be assessed owing to the early closure to accrual and subsequent crossover, the authors
envisaged that the average 7 weeks improvement underestimated the overall benefits.
What are the implications of the study for the model.
The utility value for the ‘relapse’ health state could be used to inform the ‘distant recurrence’ health state in
the cost-effectiveness model.
Criteria for assessment of study relevance to the National
Institute for Health and Care Excellence’s reference case
(adapted from Papaioannou et al.62)
Relevance questions Requirement for NICE
Do the population characteristics (e.g. age, sex, comorbidities, diagnosis, severity of disease) in
the study match those described in the decision problem of the review and those modelled?
Yes (for one of the health
states of the model)
Was a generic preference-based instrument (preferably EQ-5D) used to describe the
health states?
Yes
Was the change in HRQoL taken directly from the patient population? Yes
Was the valuation of changes in patients’ HRQL undertaken from the general (UK) population? Unclear
Was the technique used to value the health states a choice-based method (such as TTO)? No
Reference
Hildebrandt, 2014.134
Study characteristics
Research question
What are the stated objectives of the study?
To investigate health utilities as cardinal values of the individual’s preferences for specific health-related
outcomes in women treated in Germany in the fields of gynaecological oncology and mastology in order to
provide local data from Germany.
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Describe the type of study and study design.
Cross-sectional survey from May 2009 to December 2009.
Was the sample from i) the general population, ii) patients with the disease of interest, iii) individuals with
knowledge of the disease , iv) other?
Are inclusion/exclusion criteria clearly described? Do these exclude any individuals that may be relevant
(e.g. aged > 80 years)?
The sample included patients (both men and women) who were affected by breast, cervical, endometrium,
ovarian and other gynaecological cancer as well as healthy individuals.
Limited information was provided; relevant individuals do not appear to be excluded.
What are the characteristics of the baseline cohort for the evaluation?
Age (years) All patients with disease
Median age (years) 59.07
Range (years) 20.12–83.33
Sex Female, 99.4%; male, 0.6%
Race (if appropriate) Not reported
Indication/disease Patients with breast, ovarian, endometrial, cervical and other
gynaecological cancer.
Other characteristics
(sample size)
Number taking part in the survey: n= 655 (including 63 healthy controls)
Number with disease: n= 592
Number of patients with breast cancer: n= 497 (including three men)
QoL instrument EQ-5D
Utility values, (yes/no) Yes
Treatment effect, if reported Not reported
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Country/setting
What is the country and setting for the evaluation?
Germany; surgical and conservative oncological wards, specialist outpatient department for breast diseases and
outpatient gynaecological oncology department.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Single study.
Results
Summarise the results
Breast cancer n Minimum Maximum Median
Overall 442 0.063 1.000 0.887
Primary disease 312 0.262 1.000 0.887
Metastatic disease 80 0.063 1.000 0.887
Recurrent disease 21 0.175 1.000 0.887
Both 29 0.788 1.000 0.887
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? (Was a valid preference-based instrument used to describe health states, such as
EQ-5D? Was the valuation of health states from the UK general population?).
EQ-5D valuation from German population.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
Patients with breast cancer who had primary disease had the highest estimates of QoL as measured by EQ-5D
VAS and these declined in case the disease was already advanced. However, this difference was not evident
from the EQ-5D health index in patients with primary, metastatic, recurrent, or both which had a consistent
median value of 0.8870.
What are the implications of the study for the model?
The study could be used as a reference point for assuming similar utility values for ‘recurrence’ and ‘metastatic’
possible health states within the independent model.
Criteria for assessment of study relevance to the National
Institute for Health and Care Excellence’s reference case
(adapted from Papaioannou et al.62)
Relevance questions Requirement for NICE
Do the population characteristics (e.g. age, sex, comorbidities, diagnosis, severity of disease) in
the study match those described in the decision problem of the review and those modelled?
Yes
Was a generic preference-based instrument (preferably EQ-5D) used to describe the
health states?
Yes
Was the change in HRQoL taken directly from the patient population? Yes
Was the valuation of changes in patients’ HRQL undertaken from the general
(UK) population?
No
Was the technique used to value the health states a choice-based method (such as TTO)? Yes
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Appendix 10 Complete set of results from
deterministic sensitivity analysis, intraoperative
radiation therapy compared with whole-breast
external beam radiotherapy
W illingness to pay has been set to £20,000 per QALY.
Variable description Low value High value
Low value
incremental
NMB (£)
High value
incremental
NMB (£)
Range
(£)
5-year probability of any other recurrence
INTRABEAM
0.029 0.071 5781 –9171 14,952
5-year probability of any other recurrence
WB-EBRT
0.028 0.071 –8760 5977 14,737
Beta coefficient for INTRABEAM arm time to local
recurrence (log-normal)
–0.815 0.307 –4512 118 4630
5-year probability of death from breast cancer
WB-EBRT
0.014 0.045 –4150 –346 3804
5-year probability of death from breast cancer
INTRABEAM
0.016 0.055 1051 –2518 3569
Constant (time to local recurrence) (log-normal) 3.553 6.383 –3367 –836 2531
Discount rate for utilities (%) 0 6 –3192 –1042 2150
Number of WB-EBRT deliveries required to
complete a course of treatment
5 23 –2604 –832 1772
Starting age of model cohort 55 72 –2273 –757 1516
Cost of delivering one-fraction WB-EBRT 71 178 –2211 –877 1334
Proportion of incident cases which are early
breast cancer and suitable for INTRABEAM
0.1 0.5 –2064 –1128 936
Sigma (time to local recurrence) (log-normal) 0.072 0.797 –1110 –2018 908
WB-EBRT planning cost 90 704 –1813 –1303 510
Lifetime of INTRABEAM equipment (years) 5 10 –1973 –1619 354
Population served by one INTRABEAM device 800,004 1,200,000 –1800 –1498 302
Probability of any other recurrence given
local recurrence
0.362 0.471 –1474 –1764 290
Proportion of patients requiring radiation shield 0.25 1 –1463 –1619 156
Cost of 1 hour in operating room 461 688 –1549 –1696 147
Utility recurrence-free subsequent years 0.8 0.83 –1658 –1555 103
Additional time required in theatre while
delivering INTRABEAM
26.4 33 –1540 –1619 79
Discount rate for costs (%) 0 6 –1583 –1658 75
Prop of INTRABEAM who also received WB-EBRT 0.135 0.17 –1583 –1657 74
Utility associated with other recurrence state 0.63 0.74 –1592 –1647 55
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Variable description Low value High value
Low value
incremental
NMB (£)
High value
incremental
NMB (£)
Range
(£)
Cost of staff time in theatre per hour of
delivery time
122 182 –1603 –1636 33
Additional time required in theatre while
planning INTRABEAM
4.8 7.2 –1603 –1635 32
Staff time required in supporting delivery of each
INTRABEAM dose
61 92 –1604 –1635 31
Prop of INTRABEAM patients having mastectomy
at local recurrence
0.618 0.933 –1611 –1625 14
Cost of staff time in theatre per hour of
planning time
203 303 –1614 –1624 10
Cost of WLE 1248 1866 –1614 –1624 10
Cost of independent technical commissioning
and calibration per year
2062 3080 –1615 –1623 8
Cost of mastectomy and reconstruction 6362 9431 –1617 –1621 4
Initial set up costs of INTRABEAM 4847 7239 –1618 –1620 2
Cost of mastectomy alone 2122 2931 –1619 –1621 2
Cost of annual radiation protection refresher
training for theatre staff
745 1113 –1618 –1620 2
Cost of pre-treatment quality control checks 20 31 –1619 –1619 0
Proportion having reconstruction after
mastectomy
0.304 0.318 –1620 –1620 0
Utility recurrence free first year after
WLE+ radiotherapy
0.76 0.79 –1619 –1619 0
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